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Abstract 
Colorectal cancer (CRC) patients survive and stay free of disease for longer 
after surgery if their primary tumours were infiltrated with an increased 
density of T cells. Studies of breast tumours and melanoma have also shown 
that the presence of specialised blood vessels named high endothelial 
venules (HEVs), within tumours are associated with a high density of 
infiltrating T cells and a positive prognosis. It is therefore possible, that 
presence of HEVs within CRC is associated with a high density of infiltrating 
T cells and a good patient outcome.  
To test this hypothesis, primary tumours, resected from sixty-two CRC 
patients were analysed for the presence of HEVs. These were studied with 
respect to the numbers and distribution of intra-tumoural T cells as well as 
tumour stage and patient survival. The results showed that HEV developed 
in response to CRC but were found within the extra-tumoural area and not 
the tumour mass. HEVs were also always present within a concentration of T 
and B cells, namely lymphoid aggregates which resemble ectopic lymphoid 
structures (ELS). These ELS were associated with more advanced disease 
and hence did not necessarily identify patients with a better prognosis.  
 
Recent studies have suggested that the type of T cells infiltrating the 
tumours is a determinant for patient outcome indicating that not all T cells 
confer benefit. IL-17A producing T cells are thought to drive CRC 
development. Moreover, our laboratory has previously shown that detection 
of a CEA (Carcinoembryonic antigen)-specific T cell response by in vitro 
secretion of IFN-γ is associated with tumour recurrence whereas the 
opposite is true for the 5T4 tumour antigen. This study therefore set out to 
determine whether IL-17A producing T cells are present at higher 
frequencies in CRC compared to normal bowel and whether IL-17A-
producing T cells are CEA-specific.   
 
The experiments revealed that IL-17A-producing T cells are present at a 
higher frequency within CRCs, but the prevalence of Th17 responses 
specific for 5T4 was slightly higher than for CEA, implying that IL-17A 
secretion by CEA-specific T cells was not responsible for the tumour 
recurrence. Tumours from CEA-responsive patients were less immunogenic 
than those from CEA non-responsive patients reflecting the aggressiveness 
of the tumour.  
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1. Introduction 
1.1 Colorectal cancer 
1.1.1 Colorectal cancer incidence 
Colorectal cancer (CRC) is one of the most frequently diagnosed cancers in 
the Western world affecting 1.2 million individuals with 1 million new cases 
emerging every year (Jemal et al., 2011). It accounts for 600 000 deaths per 
annum worldwide and in developed countries it is the second and third most 
diagnosed tumour amongst women and men, respectively (Jemal et al., 
2011). Treatment often involves a colectomy, surgically removing the primary 
tumour from the affected colon, but despite such efforts 40 – 50 % of the 
patients still relapse and die after tumour excision.  
1.1.2 Colorectal cancer staging 
Colectomy specimens are histologically analysed and the CRC staged 
according to bowel muscle infiltration of the tumour and spread to adjacent or 
distant lymph nodes (LN). The Dukes’ classification (Dukes’ A to D) 
commonly used in the Great Britain, highly correlates with patient survival 
rate ranging from 90 to 10% according to Dukes’ A or Dukes’ D classification, 
respectively. Even though Dukes’ D was not initially proposed by Dukes’ as a 
disease stage, it is routinely used to indicate tumours that have metastasised 
to distant sites of the body. Dukes’ A tumours have penetrated the mucosa 
and submucosa layers. Dukes’ B1 and B2 have spread into and through the 
muscularis propria of the bowel wall, respectively. Dukes’ C1 is equivalent to 
B1 but the tumour has also spread to the regional LN and C2 is equivalent to 
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B2 but it has spread to the regional and apical LN (a group within the axillary 
LN) whereas Dukes’ D have invaded other parts of the body (Dukes, 1949; 
1932). The TNM classification is also routinely used to determine the extent 
of tumour growth and LN invasion. T refers to the actual tumour size, N 
refers to LN involvement and M is related to the development of distant 
metastasis (Figure 1.1).  
 
 
 
Figure 1.1 Colorectal cancer staging according to Dukes’ or TNM classification. 
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1.1.3 Colorectal cancer aetiology 
Colorectal cancer is usually described as hereditary or sporadic, however the 
latter form accounts for the majority of cases. Risk factors associated with 
the development of CRC encompass older age, male gender, having a 
familiar history of CRC, diabetes, inflammatory bowel disease (IBD), smoking, 
being obese and drinking alcohol in excess. Evidence also supports the 
association with increased red meat consumption (Brenner et al., 2014).  
1.1.3.1 Sporadic colorectal cancer 
The majority of CRC cases (approximately 85%) arise through the adenoma-
carcinoma pathway. This pathway involves the accumulation of a series of 
mutations in oncogenes and tumour suppressor genes, which over many 
years may lead to the development of a tumour (Raskov, 2014). Benign 
tumours that originate from glands and form within epithelial tissue are 
considered adenomas whereas a carcinoma corresponds to a malignant 
tumour with the potential to penetrate nearby tissue. 
1.1.3.1.1 p53 
The main function of the p53 protein is to detect and signal to caretaker 
genes cell damage including DNA damage so that such damage can be 
repaired. p53 stops cell division at the G1 phase so that cell repair can 
proceed. However if the cell damage is too severe p53 is involved in 
promoting apoptosis avoiding further damage and the replication of defective 
cells. Mutations in the p53 gene are detected in approximately 75% of all 
invasive CRC (Raskov, 2014). 
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1.1.3.1.2 Adenomatous polyposis coli 
Mutations in the adenomatous polyposis coli (APC) gene can be detected in 
about 80% of adenomas and carcinomas of the colon. The APC protein is 
involved in communication between colonocytes through cadherins. In order 
for APC to exert its proper function it binds β-catenin, GSK3-β and the 
cytoplasmic domain of cadherin therefore allowing the junctions to function 
adequately. APC is also involved in the wingless/integration1 (Wnt) signalling 
pathway via its interaction with β-catenin. By binding β-catenin in the 
cytoplasm APC prevents β-catenin translocation into the nucleus and Wnt-
pathway activation exacerbating proliferation and interfering with apoptosis 
and differentiation (Raskov, 2014). Mutations within APC lead to the 
formation of a shorter protein which will not bind β-catenin, allowing 
translocation of β-catenin into the nucleus and Wnt-pathway activation. 
1.1.3.1.3 K-ras 
K-ras is a GTPase and is involved in signal transduction upon ligand binding 
to the epithelial growth factor (EGF) receptor. Upon EGF receptor 
engagement K-ras acts downstream to activate genes involved in anti-
apoptosis, proliferation, cell survival, metastasis and angiogenesis. 30% to 
50% of all CRC patients have a mutation in the K-ras protein. Mutations in 
the BRAF protein are also implicated in the development of CRC as this is 
also involved in signalling downstream of K-ras upon EGF receptor activation 
(Raskov, 2014).  
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1.1.3.2 Hereditary forms of Colorectal cancer 
Familial CRC development accounts for approximately 20% of all CRC cases. 
Lynch syndrome and familial adenomatous polyposis (FAP) are the primary 
and secondary, respectively, causes of inherited CRC development (Valle, 
2014).  
1.1.3.2.1 Lynch syndrome 
Lynch syndrome (LS) arises as a consequence of a germline mutation in 
mismatch repair (MMR) genes. As the main function of MMR genes is to 
repair mutations, deletions or other abnormalities, their malfunction results in 
an increased number of mutated genes. Inactivation of MMR proteins such 
as MLH1, MLH2, MLH6 and PMS2 leads to microsatellite instability (MSI) 
and a 80% increased risk of developing CRC (Raskov, 2014; Valle, 2014).  
1.1.3.2.2 Familial adenomatous polyposis 
Familial adenomatous polyposis (FAP) accounts for roughly 0.2% to 1% of 
all the CRC cases worldwide. Even though some forms develop as a 
consequence of de novo mutations, the majority of the cases (80%) are a 
result of an autosomal dominant trait that arises as an outcome of mutations 
within the APC gene. FAP leads to the development of colonic adenomatous 
polyps throughout life which if left untreated leads to the development of 
CRC (Valle, 2014).  
1.1.3.3 Microsatellite instability in CRC    
Up to 15% of all CRCs show high microsatellite instability (MSI-H). Around 
3% of MSI-H CRCs arise due to LS whereas around 12% fall into the 
sporadic CRC category. Microsatellites are unique polymorphic non-coding 
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nucleotide sequences present in every cell in each individual. Microsatellites 
are three to hundred repeats of two to four nucleotides which are unique 
amongst every individual. Deficiency in any of the MMR proteins leads to a 
loss of function making them unable to repair shorter or longer microsatellites 
wrongly created because of replicative errors thus leading to MSI (Boland 
and Goel, 2010; Raskov, 2014). MSI+ CRCs have distinct characteristics 
compared to other CRCs. They show high lymphocytic infiltration, poor 
differentiation, tend to be proximal e.g. right-side of colon; and have a 
mucinous appearance. Usually patients with a MSI+ CRC respond differently 
to therapy and have a better prognosis (Buckowitz et al., 2005). 
1.1.4 Microbiota and the development of colorectal cancer 
Recent evidence suggests that microbial products derived from both 
commensal and pathogens contribute to protection against and/or 
development of CRC. Also, as different microorganisms express different 
pattern associated molecular patterns (PAMPs) they elicit specific pro/anti-
inflammatory responses which may impinge on tumorigenesis. The 
microbiota plays an important role at maintaining gut homeostasis and 
preventing dysbiosis as is observed when Clostridium difficile outgrows the 
gut commensals after antibiotic treatment (Keku et al., 2015). In an 
experiment designed to understand the role of bacteria in the development of 
colon cancer in TGF-β deficient mice, Engle et al., crossed a Tgf-β-/- with 
RAG (recombination-activating gene) 2-/- mice and observed the formation of 
adenocarcinomas. However, equivalent but germ-free (GF) animals were 
absent of any inflammatory bowel lesions or adenocarcinoma. Re-
introduction of the GF animals into the same housing facilities as the mice 
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developing colon cancer led to the development of adenocarcinomas in the 
GF mice. Helicobacter hepaticus was identified as the pathogen present in 
animals developing adenocarcinomas but absent in cancer-free mice (Engle 
et al., 2002).  
Microbiota is closely linked to diet as fat, protein, fibre and carbohydrates 
present in everyday food are broken down and processed by the gut bacteria 
generating by-products which could be harmful and pro-tumorigenic. Gut 
commensals are of extreme importance when it comes to processing 
complex carbohydrates and fibre but the by-products generated during these 
processes may lead to the formation of reactive oxygen species (ROS), and 
secondary bile acids which can aid DNA damage and genetic mutations 
further promoting inflammation and cancer development (Keku et al., 2015). 
Short chain fatty acids (SCFAs) such as acetate, propionate and butyrate are 
generated as a result of carbohydrate and dietary fibre fermentation. 
Butyrate in particular has been associated with protection against CRC as it 
inhibits the growth of tumour cells, promotes apoptosis and maintains a low 
level of inflammation within the gut (Keku et al., 2015).  
Inflammation is closely linked to CRC and the presence of colonic regulatory 
T cells may serve a crucial homeostatic function in limiting excessive 
proliferation and expansion of pro-inflammatory T cells in the gut. Smith et al. 
observed that animals kept in GF conditions have a lower number of CD4+ 
cells expressing Foxp3, a transcription factor characteristic of regulatory T 
cells (Tregs). Addition of propionate, butyrate and acetate to the animals’ 
drinking water augmented the frequency and suppressive capacity of colonic 
Tregs (Smith et al., 2013). This indicates that microbiota and their byproducts 
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are directly linked to the level and function of colonic Tregs and could 
influence colonic inflammation and tumour formation.             
1.2 T cell subsets  
The first and immediate response to the presence of a foreign antigen is 
mounted by the innate immune system. This arm of the immune system 
consists of neutrophils, eosinophils, basophils, dendritic cells (DCs), 
macrophages and natural killer (NK) cells. Such cells recognise the foreign 
antigen in a non-specific manner, engulfing and destroying it by the release 
of toxic chemicals and degradative enzymes. In order to sense foreign 
organisms these cells are equipped with pattern recognition receptors 
(PRRs) which recognise PAMPs, consisting of lipoteichoic acid on the cell 
wall on Gram-positive bacteria, lipopolysaccharide on the outer membrane of 
Gram-negative bacteria, flagellin and double stranded RNA amongst others. 
PRRs detect features usually not present within the mammalian body 
triggering a cascade of events, which often results in pathogen clearance.  
A delayed but more specific response is also subsequently mounted by the 
adaptive immune system. B and T lymphocytes are responsible for such 
responses. B cells can either act as antigen-presenting cells (APCs) after 
antigen capture, ingestion, digestion and presentation on their surface in the 
context of major histocompatibility complex (MHC) or they can also 
recognise the antigen through the B cell receptor leading to plasma cell 
proliferation and antibody secretion. The other lymphocyte of the adaptive 
immune system, the T lymphocyte, expresses a T cell receptor (TCR) on its 
cell surface that recognises peptides bound to MHC molecules. Binding of 
the TCR to its cognate peptide / MHC complex leads to a cascade of 
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reactions depending on the subtype of T cells, cytokine milieu and the co-
stimulatory signals provided. The co-receptors CD4 and CD8 distinguish T 
helper and cytotoxic T cells, respectively. CD4+ T cells or T helper cells boost 
the immune response by macrophage activation, induction of T cell 
proliferation and antibody secretion. The TCR present on CD4+ T cells 
interacts with MHC II/peptide complexes whereas the TCR present on CD8+ 
T cells interact with MHC I / peptide complexes.  
Even though Th1 and Th2 cells are the most well understood helper T cells, 
additional T helper subsets have been recently described such as Th9, Th17, 
Th22, Tregs and follicular T cells (Tfh). Tregs, Th1 and Th17 cells are 
thought to be the subsets most relevant to CRC and will therefore be 
described in detail. 
1.2.1 Th1 cells  
Th1 alongside Th2 cells were the first helper subsets to be described in a 
landmark study from the Coffman group (Mosmann et al., 1986). 
Engagement of TCR on a naive T cell with peptide/MCH II in the presence of 
IL-12, IFN-γ and IFN-α leads to CD4+ T cell activation and differentiation into 
a Th1 phenotype. Relocation of activated Th1 cells from blood to the site of 
infection and secretion of their signature cytokines: IFN-γ, TNF-α, 
lymphotoxin-α (LT-α) and IL-2 can potentiate their effector functions. IL-2 is 
essential for T cell survival and proliferation and helps activate cytotoxic T 
lymphocytes (CTLs) whereas IFN-γ promotes macrophage activation.  
Activation of naïve CD4+ T cells into Th1 cells is highly dependent on IFN-γ 
and IL-12 as these two cytokines activate STAT1 and STAT4, respectively. 
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Activation of both STAT1 and STAT4 is essential for the induction of Tbx21 
(T-box transcription factor) also known as T-bet which binds to the IFN-γ 
promoter inducing its secretion.  
 
Chemokine receptors located on the cell surface can modulate cell 
recruitment based on their specificity and local chemokine environment at 
the inflammatory site. CXCR3 and CCR5 are the main chemokine receptors 
present on classic Th1 cells (Annunziato et al., 2014).  
CXCR3 binds to CXCL9, CXCL10 and CXCL11 allowing migration of Th1 
cells to the site of inflammation and penetration into affected tissues (Groom 
and Luster, 2011). CCR5 binds to CCL3, CCL4 and CCL5 and is expressed 
on memory T cells. CCR5 engagement enhances T cell activation and 
increases proliferation of antigen specific T cells (Barmania and Pepper, 
2013). Therefore expression of chemokine receptors on the surface of T cells 
is important for trafficking and homing to inflammatory sites.  
1.2.2 Th17 cells 
1.2.2.1 Th17 cells development 
Th17 cells are a distinct subset of T helper cells first discovered in mice in 
2005 (Aggarwal et al., 2003; Harrington et al., 2005; Iwakura and Ishigame, 
2006; McKenzie et al., 2006; Park et al., 2005). Their main role is to protect 
against fungal and extracellular bacterial infections, but studies have 
demonstrated that they also play a role in the development of autoimmune 
conditions. The initial cues that inferred the existence of a fourth helper T cell 
subset came from studies carried out on models of autoimmune diseases 
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thought to be mediated by Th1 cells. In a series of in vivo studies in mice, 
Cua and colleagues demonstrated that IL-23 and not IL-12 signalling is 
crucial for the development of experimental autoimmune encephalomyelitis 
(EAE). To demonstrate this, the group took advantage of the shared subunit 
between both cytokines, p40. To determine the importance of each cytokine 
in the development of the disease they used animals either lacking the p19 
subunit, exclusive to IL-23, the p35 subunit, exclusive to IL-12 or the p40 
subunit necessary for the formation of both cytokines. To induce EAE, the 
murine model for multiple sclerosis (MS), animals were immunised with the 
encephalitogenic myelin oligodendrocyte glycoprotein 35-55 (MOG) peptide. 
Unexpectedly, animals resistant to the development of EAE were the ones 
lacking the IL-23 cytokine and not IL-12 (Cua et al., 2003). Injection of the IL-
23 cytokine into the central nervous system of p19-/- and p40-/- restored the 
EAE phenotype (Cua et al., 2003). To further understand why the IL-23 
cytokine was related to the onset of EAE, IL-23 in parallel to IL-12 was 
injected into the peritoneal cavity of mice and mRNA levels assessed. IL-23 
but not IL-12 induced the expression of IL-1β and TNF mRNA in 
macrophages (Cua et al., 2003). Such findings supported the idea of a fourth 
subset of helper T cells with important and distinct effector functions.  
Differentiation and maintenance of human Th17 cells often but not 
exclusively occurs in the constant presence of low levels of TGF-β (Bettelli et 
al., 2006; Y. K. Lee et al., 2009; Veldhoen et al., 2006) in combination with 
IL-21, IL-6 and IL-23 or IL-6 and IL-21. Any combination of these cytokines in 
addition to TCR engagement leads to the initial commitment to a Th17 
phenotype. Further exposure to IL-1β and IL-21 produced by the Th17 cells 
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themselves and IL-6 leads to additional amplification and upregulation of the 
IL-23 receptor (Figure 1.2). Albeit generally accepted as essential, TGF-β 
may not be as important as initially discussed for the development of Th17 
cells. The presence of Th17 cells can still be detected in TGF-β free systems 
and animals still develop EAE (Ghoreschi et al., 2010). It is possible that 
TGF-β plays a role in the initial differentiation of Th17 cells by inhibiting the 
development of other T cell lineages but is not critical for its effector functions. 
Moreover stimulation of activated T cells with IL-1β, IL-6 and IL-23 also drove 
the development of Th17 cells (Ghoreschi et al., 2010; Muranski and Restifo, 
2013). The heterodimeric cytokine IL-23 secreted by APCs and tissue 
resident macrophages becomes active when the p19 subunit comes together 
with the p40 subunit. Engagement of IL-23 with its receptor on the cell 
surface of a pre-committed Th17 cell leads to a final differentiated and stable 
effector phenotype capable of secreting IL-17A, IL-17F, IL-21 and IL-22 
(Bettelli et al., 2006; Veldhoen et al., 2006). The transcription factor retinoic 
acid-related orphan receptor γ thymus (RORγt) regulates IL-17A transcription 
and is required for Th17 differentiation (Ivanov et al., 2006) as IL-17 
production by CD4+ cells from mice lacking rorγt reduced drastically 
compared to wild-type (WT) mice. Another key transcription regulator in the 
differentiation of Th17 is STAT3. By creating a STAT3 knock-out (KO) mouse 
under the control of cre recombinase Yang et al. were able to knock out 
STAT3 in a controlled manner.   
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Figure 1.2 Differentiation and maintenance of human Th17 cells. Initial commitment of a 
naïve T cell into a Th17 cell involves TCR engagement in the presence of cytokines such as 
IL-6, IL-21 and low levels of TGF-β. The role of TGF-β in the initial commitment of naïve T 
cells is still controversial but it is believed that low TGF-β levels inhibit signalling through Th1 
and Th2 – associated transcription factors thus potentiating Th17 cell development. Upon 
initial Th17 commitment, cells amplify in the presence of IL-1β, IL-6 and IL-21 which will lead 
to the upregulation of the IL-23 receptor on the cell surface. IL-23/IL-23R engagement leads 
to further expansion and stabilisation of the Th17 cell phenotype. Effector Th17 cells mainly 
secrete IL-17A but also IL-17F, IL-21 and IL-22. 
 
 
After activation of STAT3-deficient naïve CD4+CD25-CD62LhiCD44lo T cells 
in the presence of a cocktail of Th17 promoting cytokines, RORγt expression 
and secretion of IL-17A were reduced. It was further demonstrated that IL-6 
and STAT3 activation are required for upregulation of IL-23 receptor 
expression of the surface of pre-committed Th17 cells (X. O. Yang et al., 
2007). Other transcription factors involved in Th17 cell differentiation are 
described in Table 1.1. 
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Table 1.1 Transcription factors involved in Th17 cell differentiation. Table created 
based on (Brüstle et al., 2007; Kurebayashi et al., 2013; Malhotra and Kang, 2013; Schraml 
et al., 2009; Tanaka et al., 2014; Veldhoen et al., 2008; F. Zhang et al., 2008). 
 
 
 
CCR6, a chemokine receptor for the CCL20 ligand, that allows T cells to 
home to mucosal tissues and to the skin was found to be expressed on 
memory T cells producing IL-17A in the peripheral blood of healthy donors. 
(Acosta-Rodriguez et al., 2007). RORC mRNA, the human ortholog of mouse 
RORγt, was also highly expressed in activated CCR6+ T cells (Acosta-
Rodriguez et al., 2007). Th17 cells are therefore widely characterised as 
CD4 and CCR6 positive T cells expressing the IL-23 receptor and secreting 
the IL-17A cytokine.  
 
 
Transcription 
factor Function/Effects upon manipulation References
IRF Cooperates with STAT3 in upregulation of RORγt Brüstle et al. 2007
BATF Batf-/- mice produced reduced levels of IL-17A and IL-22 Schraml et al. 2009
AHR
Addition of FICS, a high affinity endogenous AHR ligand, to 
naïve T cells led to high levels of Il17a, Il17f and Il22 mRNA 
expression
Veldhoen et al. 
2008
SMADs
SMAD2 can interact with RORγt and increase production of 
IL-17A whereas SMAD2/SMAD3 collectively bind to Foxp3 
inhibiting RORγt expression. Production of IL-17A is deficient 
in animals lacking SMAD2 
Malhotra and Kang 
2013
c-Maf/ Sox5
C-Maf and Sox5 form a complex which acts downstream of 
STAT3 and upstream of RORγt binding to its promoter and 
mediating activation
Tanaka et al. 2014
Hypoxia-inducible 
factor 1 (HIF-1) 
HIF-1α promotes Th17 differentiation by binding to Foxp3 
and inducing its proteosomal degradation 
Kurebayashi et al. 
2013
Runx1
It binds to rorγt and it enhances it transcriptional activity but it 
forms a complex with RORγt which binds to Il17 increasing 
its transcription 
F. Zhang et al. 
2008
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1.2.2.2 Th17 cells, IL17 and IL-22 in health and disease (excluding 
cancer) 
IL-17A is part of a family of six cytokines, A through F and the IL-17F amino 
acid conformation is 55% similar to IL-17A (Tesmer et al., 2008). The IL-17A 
cytokine is the most well studied cytokine of this family and from now on it 
will be mentioned as IL-17. IL-17 plays an important role in the interplay 
between the innate and adaptive immune systems. It is involved in 
angiogenesis and in recruitment of a multitude of cells necessary for an 
effective immune response. IL-17 has several functions: 1) acts on T cells to 
augment their proliferation, 2) attracts neutrophils to sites of infection, 3) 
promotes the expression of CXC chemokines and G-CSF, 4) recruits and 
enhances survival of macrophages, 5) induces pro-inflammatory cytokines 
such as IL-6, TNF-α and IL-1β, and 6) increases the production of matrix-
metalloproteinases, nitric oxide and the production of prostaglandin E2 
(PGE2) (Bettelli et al., 2008; Tesmer et al., 2008; Torchinsky and Blander, 
2010). 
Even though Th17 cells are now under great scrutiny due to their 
involvement in autoimmune conditions and cancer, their primary role appears 
to be as a defence mechanism against extracellular bacteria and fungi 
against which Th1 and Th2 cells are less effective. These findings are 
relevant to human infections as patients suffering from chronic 
mucocutaneous candidiasis (CMC), a condition characterised by the 
constant infection with Candida albicans (C. albicans), produce extremely 
low levels of IL-17 and IL-22 upon ex vivo stimulation with the yeast (Eyerich 
et al., 2008). Also mutations in the STAT3 gene resulting in the autosomal-
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dominant hyper-IgE syndrome or Job’s syndrome renders patients highly 
vulnerable to both fungal infections with C. albicans but also with 
Staphylococcus aureus (S. aureus). Further studies have shown that upon 
stimulation of patient’s peripheral blood mononuclear cells (PBMCs) with 
both C. albicans and S. aureus these patients lack the ability to generate 
specific Th17 responses against these pathogens (Milner et al., 2008). 
IL-22 produced by Th17 cells or other cells of the innate immune system is 
thought to be important in the defence against bacteria at the epithelial 
barrier level as its receptor (IL-22R) is expressed on epithelial cells namely of 
the human and mouse gastrointestinal tract. Inoculation of IL-22 KO mice 
with Clostridium rodentium, an enteric mouse pathogen, led to weight loss 
and extreme mortality compared to WT mice. IL-22 also upregulates the 
secretion of antimicrobial proteins such as haptoglobin, SAA3, 
lactotransferrin, RegIIIβ, RegIIIγ, S100A8 and S100A9 from/by colonic 
epithelial cells (Zheng et al., 2008).    
1.2.2.2.1 Inflammatory Bowel Disease (IBD) 
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two main types of 
IBD affecting humans. Both are chronic diseases of the intestinal tract and 
can greatly disrupt the affected individuals’ daily life by causing bleeding, 
diarrhoea and abdominal pain. A genome-wide association study performed 
in a cohort of European individuals reported that single nucleotide 
polymorphisms in the il-23r allele was associated with susceptibility to IBD in 
some cases (Duerr et al., 2006; Maddur et al., 2012). UC and CD patients 
show increased infiltration of Th1 and Th17 cells and their associated 
cytokines in the intestinal mucosa and serum (Maddur et al., 2012).  
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1.2.2.3 Th17 cells in the intestine 
The human gastrointestinal tract is a key site of microbial-host interactions 
both during homeostasis and disease as is populated by a vast number of 
microorganisms in what forms the microbiome (Ley et al., 2006). The 
presence of normal flora can directly influence the generation of Th17 cells 
by modulation of IL-23 levels. The levels of microRNA-10a (miRNA-10a), 
known to suppress IL-23, are elevated in GF animals but return to a low level 
upon colonisation with normal flora (Chewning and Weaver, 2014). 
Segmented filamentous bacteria (SFB) are a group of spore-forming bacteria, 
anaerobic and gram-positive which reside in the ileum of mice under 
homeostasis. Secretion of IL-22 and IL-17 is absent in Swiss-Webster GF 
mice but highly abundant after colonisation with SFB. Such colonisation 
induces expression of RORγt specifically in CD4+ T cells demonstrating that 
Th17 differentiation can be induced by SFB. The secretion of both IL-17 and 
IL-22 by CD4+ T cells, barely detected in the small intestinal lamina propria 
infiltrating lymphocytes in GF conditions, increases by approximately 3-fold 
after colonisation with SFB (Ivanov et al., 2009). 
In a follow-up study in 2014 the group elucidated the mechanisms involved in 
the generation of a Th17 effector phenotype in response to SFB. Th17 cells 
were completely absent in mice lacking MHC II even after SFB colonisation. 
Furthermore, specific expression of MHC II on DCs is essential and sufficient 
in order to induce Th17 cell differentiation as mice lacking MHC II expression 
on DCs could not develop a Th17 response even after colonisation with SFB 
(Goto et al., 2014). 
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1.2.2.4 Th17 plasticity 
The helper T cell subsets have historically been considered terminally 
differentiated lineages. However the ability of Tregs and Th17 cells to alter 
their phenotype later on during their maturation stage has challenged such 
perspective as these two lineages appear to possess an aptitude to 
transdifferentiate from one subset of helper T cells into another.  
Lee et al. reported in 2009 the ability of Th17 cells to start secreting IFN-γ in 
the presence of IL-12. Interestingly, secretion of IFN-γ was accompanied by 
the down regulation of RORγt, RORα, ll-17A and Il-17F and upregulation of 
genes associated with a Th1 signature (Y. K. Lee et al., 2009). It 
subsequently become apparent that committed Th17 cells can convert into 
Th1 cells and have therefore been named non-classical Th1 cells. Non-
classical Th1 cells have the ability to secrete IFN-γ but express both RORγt 
and T-bet and the chemokine receptors CCR6 and CXCR3. The origins and 
functions of non-classical Th1 cells are yet to be fully understood. Thus far, 
non-classical Th1 cells are believed to arise from an IFN-γ/IL-17A double-
producing cell. This IFN-γ/IL-17A double-producing cell (Th17/Th1 cell in 
Figure 1.3) differentiates from a mature Th17 cell in the presence of IL-12 
and at this developmental stage it secretes IFN-γ and IL-17 and expresses 
RORγt and T-bet (Bailey et al., 2014). One study has proposed the usage of 
the CD161 marker to distinguish between classical and non-classical Th1 
cells, so in the future it may be possible to distinguish IFN-γ secreting cells 
that originate from Th17 cells (Cosmi et al., 2008). 
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In an extremely informative study Gagliani and colleagues asked if Th17 
cells could experience functional and genetic reprogramming to become a 
distinct T helper subset. The group observed that upon inflammation, T cells 
that had secreted IL-17A at some stage during maturation acquired 
characteristics of Tr1 cells. These Tr1exTh17 cells secreted IL-10, expressed 
low levels of RORγt, and were LAG-3+ and CCR6-. Additionally, pathogenic 
Th17 cells were injected in a RAG-/- mouse in order to monitor the 
development of colitis. Injection of pathogenic Th17 led to the development 
of colitis but injection of pathogenic Th17 cells in combination with Tr1 or 
Tr1exTh17 cells prevented the development of colonic inflammation (Gagliani 
et al., 2015).  
In another study by the Sallusto group, Th17 cells were shown to secrete 
different cytokines depending on the pathogen used to prime the response 
both in vitro and in vivo. Human naïve T cells primed with C. albicans in vitro 
secreted both IL-17 and IFN-γ whereas in contrast naïve T cells primed with 
S. aureus secreted high levels of IL-17 and IL-17 secreting cells could also 
secrete IL-10 upon activation (Zielinski et al., 2012). This finding suggests 
that different microorganisms have the capacity to elicit distinct helper 
responses. Co-secretion of IFN-γ or IL-10 by Th17 cells may have a 
beneficial/harmful effect on disease clearance on addition to the downstream 
effects caused by IL-17A. Th17 cells can also acquire other cell lineages 
phenotypes and have also been shown to acquire Tfh features (Peters et al., 
2011).  
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Figure 1.3 Schematic illustrating the plasticity of Th17 cells. Precursors of Th17 cells 
express the chemokine receptor CCR6 and the transcription factor RORγt. The presence of 
IL-1β and IL-6 within the microenvironment leads to upregulation of the IL-23 receptor, 
maturation of the Th17 phenotype and secretion of IL-17. Maintenance of Th17 cells can be 
achieved by IL-23 signalling. In the presence of IL-12, Th17 cells start secreting IL-17 and 
IFN-γ and CXCR3 is also upregulated on the surface of such cells (Th17/Th1). Continuous 
IL-12 signalling leads to IFN-γ expression alone but both T-bet and RORγt transcription 
factors are expressed resulting in a non-classical Th1 cell. Th17 cells can also adopt a 
regulatory phenotype upon stimulation with a high concentration of TGF-β. Th17 cells can 
either become Treg if they express Foxp3 and secrete TGF-β and IL-10 or Tr1 cells if they 
only secrete IL-10 and express the aryl hydrocarbon receptor. Based on (Bailey et al., 2014; 
Gagliani et al., 2015; Voo et al., 2009). 
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1.2.3 Regulatory T cells (Tregs) 
1.2.3.1 Discovery of Tregs 
Studies performed by Sakaguchi and Mason convincingly showed the 
existence of a distinct T cell population responsible for suppression of auto-
reactive cells (Fowell and Mason, 1993; Powrie and Mason, 1990; Sakaguchi 
et al., 1985). In 1995 Sakaguchi and colleagues showed that CD25 was a 
marker for such suppressive cells in mice. Depletion of CD4+CD25+ cells 
caused a series of autoimmune diseases, which could be prevented if the 
animals were re-inoculated with CD4+CD25+ cells (Sakaguchi et al., 1995). 
CD25 is the α chain of the IL-2 receptor and removal of the thymus in 
recently born mice eliminates the CD4 sub-population constitutively 
expressing CD25, resulting in development of autoimmunity in the 
thymectomised mice. However, injection of these mice with CD4+CD25+ but 
not CD4+CD25- T cells prevents the development of autoimmune disease 
(Asano et al., 1996). Similarly, Read et al. showed that transfer of 
CD45RBhigh cells into immunodeficient mice caused colitis but that this was 
prevented by injection of CD4+CD25+ T cells but not CD4+CD25- T cells from 
the CD45RBlow population (Read et al., 2000).  
 
Studies of scurfy mouse, which present with a pathology caused by 
uncontrolled CD4+ T cell proliferation with exacerbated cytokine production, 
revealed that these animals have a mutation within the Foxp3 gene 
generating a non-functional Foxp3 protein; a member of the 
forkhead/winged-
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non-functional version of the Foxp3 protein results in excessive proliferation 
of CD4+CD8- T cells. (Brunkow et al., 2001).   
 
In 2003, Fontenot and colleagues showed that regulatory CD4+CD25+ 
T cells expressed higher levels (40-fold) of the Foxp3 mRNA in comparison 
with their CD4+CD25- counterparts. The same pattern was observed for the 
Foxp3 protein which was barely present in CD4+CD25- T cells but abundantly 
detected in the CD4+CD25+ T cell fraction. Furthermore, deletion of the 
Foxp3 gene rendered male mice susceptible to an autoimmune syndrome 
similar to the scurfy mice (Fontenot et al. 2003). CD4+CD25+ T cells from 
Foxp3+/+ mice were able to suppress CD4+CD25- T cell proliferation whereas 
CD4+CD25+ T cells from Foxp3-/- mice could not (Fontenot et al. 2003).   
 
 Further studies showed that Foxp3 expression converts naïve CD25- 
T cells into Tregs (Hori et al., 2003). DO11.10 CD4+ T cells (which express a 
TCR recognising an ovalbumin-derived peptide) from a RAG (recombination-
activating gene) KO mouse were used to test the ability of ectopic Foxp3 
expression to induce a regulatory phenotype in an antigen-specific manner. 
Upon infection with a bicistronic retroviral vector expressing Foxp3 and 
stimulation with OVA peptides, transgenic CD4+ T cells could control T cell 
proliferation whereas those stimulated with OVA but not infected with the 
Foxp3 retrovirus could not. The group also demonstrated that the 
CD4+CD25+ subset contained most of the Foxp3+ population (Hori et al., 
2003). 
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The most compelling evidence for the existence of a Treg subset of 
cells in humans comes in the form of a mutation within the Foxp3 gene 
causing a disorder known as IPEX (immunodysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome) (Bennett et al., 2001). 
IPEX manifests in a range of severe autoimmune episodes. Mutations in the 
Foxp3 gene render Foxp3 inactive, which affects Treg development and 
function in a similar fashion to the phenotype seen in scurfy mouse (Bennett 
et al., 2001). By immunohistochemistry and flow cytometry Roncador et al. 
also ascertained that the great majority of cells expressing the Foxp3 protein 
in humans were also CD4+CD25+. Foxp3 expression was detected on almost 
all CD4+CD25hi T cells, in less than half of the CD4+CD25Int T cells and no 
expression was detected in CD4+CD25- T cells (Roncador et al., 2005).  
 
In 2006, the Rudensky group reported the creation of a strain of mice 
in which depletion of Foxp3 could be achieved by injection of the diphtheria 
toxin. In this system, the human diphtheria toxin receptor was expressed only 
in Foxp3+ cells. Injection of the diphtheria toxin caused depletion of Foxp3+ 
Tregs and an autoimmune phenotype similar to Foxp3 deficient animals (Kim 
et al., 2006). 
1.2.3.2 Phenotypic characterisation 
Although not exclusive to Tregs, a number of markers have been associated 
with these cells including CD25, CTLA-4, GITR, LAG-3, CD127, the α chain 
of the IL-7 receptor, and Foxp3 (Corthay, 2009). The downside of such 
markers is the fact that they are also transiently expressed on other subsets 
of T cells during activation. Nonetheless, Foxp3 is still considered to be the 
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hallmark transcription factor marker for Tregs due to its importance for the 
development, maintenance and function of these cells. A combination of 
CD3+, CD4+, CD25+, Foxp3+ and CD127lo/- is generally considered the best 
combination for identification of Tregs in tumours (Santegoets et al., 2016). 
 
1.2.3.3 Origins 
1.2.3.3.1 Thymus-induced Tregs 
Tregs can be divided into thymus (tTregs) and periphery induced Tregs, 
(pTregs). tTregs and pTregs are also referred to as natural and induced 
Tregs, respectively. tTregs are generated at the time of negative and positive 
selection in the thymus. The process of positive selection identifies the 
thymocytes which engage with self MHC complexed with peptides with low 
avidity within the thymic epithelium enabling their survival. T cells which 
interact with self-antigens with high avidity die or become anergic in a 
process of negative selection. Meanwhile tTregs are generated as a result of 
immature thymocytes recognising self MHC:peptide with an intermediate 
avidity just below the strength of interaction necessary for negative selection 
(Reviewed in (Maloy and Powrie, 2001)). tTregs then populate LNs in a 
resting state and upon antigen encounter, upregulate CTLA-4 and Foxp3 
thus increasing their suppressive capacity (Gratz et al., 2013; Maloy and 
Powrie, 2001).  
1.2.3.3.2 Periphery-induced Tregs 
Generation of pTregs follows antigenic stimulation and exposure to 
appropriate cytokines, most notably TGF-β, in the periphery. Type 1 
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regulatory T cells (Tr1) are also peripherally induced (Groux et al., 1997). 
These cells in a similar manner to Foxp3+ Tregs play a role in the 
suppression of effector T cell responses but they do not express Foxp3 and 
secrete high levels of IL-10 (Reviewed in (Pot et al., 2011)).  
1.2.3.4 Treg maintenance and survival 
IL-2 and TGF-β, and costimulation via CD28, are necessary for the survival, 
expansion and suppressive function of Tregs. Experiments performed in 
mice lacking either CD28 or B7-1 or -2 showed a reduced number of both 
tTregs and pTregs. Survival and renewal of pTregs is also dependent on 
CD28 as CD28 blockade hinders the survival and self-renewal of adoptively 
transferred Tregs in vivo (Huynh et al., 2014). ICOS is also important for 
growth, maintenance and expansion of CD4+Foxp3+ T cells (Burmeister et al., 
2008). 
1.2.3.5 Mechanisms of action of Tregs 
T lymphocytes which evaded thymic deletion and are reactive against self-
antigens can be detected in the periphery. The main function of Tregs is to 
control their activation and further expansion promoting self-tolerance and 
preventing autoimmunity. They also control the development of chronic 
inflammatory diseases, keeping the activation of innate and adaptive 
immune cells in check (Hori et al., 2003). Such mechanisms involve either 
contact-dependent interaction with APCs and modulation of their functions; 
scavenging of essential amino acids or the growth factor IL-2; direct targeting 
of effector cells by the secretion of granzyme B, TGF-β, IL-10 and IL-35 
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and/or catabolism of ATP by the ectonucleotidases (Attridge and Walker, 
2014). 
1.2.3.5.1 Contact-dependent Treg suppression 
Suppression by Treg via a contact-dependent fashion can occur either 
directly on conventional effector T cells (Tcons) or indirectly via suppression 
of APCs resulting in their diminished capacity to present antigen or tolerance 
induction. 
Birebent et al. reported that in the presence of an anti-CTLA-4 
blocking antibody Tregs were less able to suppress allogeneic cell activation 
of PBMCs suggesting that CTLA-4 engagement is one of the mechanisms 
used by Tregs to regulate the activity of target cells (Birebent et al., 2004). 
 
Tregs also possess the ability to turn APCs into tolerogenic cells by 
modulation of indoleamine 2,3-dioxygenase (IDO) expression. Engagement 
of CTLA-4 on Tregs with B7.1/2 on DCs leads to upregulation of IDO. IDO 
then mediates the conversion of tryptophan into kynurenine effectively 
starving conventional effector T cells (Tcons) of this essential nutrient. 
Furthermore IDO+ DCs interact with cytotoxic and helper T cells causing cell 
cycle arrest, apoptosis, anergy, and even acquisition of regulatory cell 
functions. IDO+ tumour cells can also modulate CTL, hindering cell activation 
and promoting cell death (Reviewed in (Löb et al., 2009)). The suppressive 
function of Tregs was also diminished by half in mice lacking Granzyme B 
compared to WT animals demonstrating that secretion of Granzyme B is 
another contact-dependent mechanism used by Tregs to regulate effector 
cell functions (Gondek et al., 2005). 
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LAG-3, a surface protein which interacts with MHC class II, is 
expressed on some Tregs and may also contribute to their suppressive 
functions (Workman and Vignali, 2005). 
1.2.3.5.2 Secretion of soluble factors 
Expression of the cytokines TGF-β, IL-10 and IL-35 by Tregs is also 
important for their suppressive functions.. Neutralisation of TGF-β has been 
shown to block the ability of Tregs to inhibit T cell-driven colitis in mice 
(Asseman et al., 1999; Powrie et al., 1996).  
 
Another cytokine important for the Treg suppressive activity is IL-35. 
Collison and colleagues demonstrated that IL-35 is upregulated in 
CD4+CD25+ Treg cells in comparison with CD4+CD25- T effector cells and 
that its expression is exclusive to Foxp3+CD4+ T cells. The group measured 
the suppressive ability of Tregs with or without IL-35 to control effector T cell 
proliferation in vitro and concluded that T cells lacking IL-35 are functionally 
defective (Collison et al., 2007).  
 
1.2.3.5.3 Competition with the target cell 
Contrary to conventional T cells which only upregulate CD25 upon activation, 
the constitutive presence of CD25 on the surface of Tregs allows them to 
more efficiently bind IL-2 thereby reducing the availability of this essential 
growth/survival factor for effector cells resulting in their apoptosis (Barthlott et 
al., 2005; la Rosa et al., 2004; Pandiyan et al., 2007).  
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Tregs also mediate the destruction of essential amino acids by induction of 
essential amino acids consuming enzymes such as arginase, tryptophan 
hydroxylase 1 and L-threonine dehydrogenase, after antigen-specific 
interaction between APCs and Tregs (Cobbold et al., 2009).  
 
1.3 Cancer immunosurveillance and immunoediting 
1.3.1 Initial experiments 
 The “cancer immunosurveillance” hypothesis emerged in the mid 50s 
with Burnet and Thomas’ proposal that lymphocytes would travel around the 
body sensing the presence of newly transformed cells and eliminating them 
(Burnet, 1957). They initially suggested that humans, as long-lived animals 
would be prone to the development of constant mutations leading to the 
formation of dangerous malignancies. Cells of the immune system, namely 
lymphocytes, would prevent this (Burnet, 1964). 
 
 The exciting concept that the immune system plays an active role in 
tumour protection was questioned after the “Stutman experiments” 
demonstrated that there was no difference in the number of tumours 
developing in immunocompetent and immunodeficient mice (Stutman, 1974). 
It was not until later on that the field understood that NK cells and a small 
percentage of functional αβ T cells were still present in the nude mice used 
(Ikehara et al., 1984; Maleckar and Sherman, 1987). The presence of these 
two populations of cells could have played an anti-tumour role thereby 
casting doubt over the interpretation of the findings.  
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 In 1994 a role for IFN-γ in tumour cell specific killing began to emerge 
when Dighe et al. showed that mice that had been given anti-IFN-γ treatment 
as well as those inoculated with IFN-γ-insensitive Meth A cell lines developed 
tumours more promptly (Dighe et al., 1994). The same augmentation of 
tumours was later on observed in mice lacking the IFN-γ α chain and STAT1 
(Kaplan et al., 1998). Tumours also became detectable at an earlier time 
point in p53-/- x IFNγR-/- and p53-/- x Stat1-/- double KO mice. The role of IFN-
γ and perforin in tumour-mediated killing was also assessed with respect to 
cells of the innate immune system, namely NK cells. The number of lung 
metastases drastically increased in BALB/c pfp-/-, BALB/c IFN-γ-/-, B6 pfp-/- 
and B6 IFNγ-/- compared to control animals, with different tumour models 
showing that not only IFN-γ but also perforin greatly contributes to effective 
control of tumour growth (Street et al., 2001). 
 
 However, it was not until the generation of RAG KO mice, in the late 
nineties, that the technology to deplete NKT, T and B cells, leaving non-
lymphocyte compartments intact, became available. Shankaran et al. used 
age matched WT and RAG-/- mice to study the development of 
spontaneously forming and chemically induced tumours (Shankaran et al., 
2001). They observed the formation of more tumours and at an earlier stage 
on RAG-/- compared to WT mice (Shankaran et al., 2001).   
 
Throughout the nineties it became apparent that immunocompromised 
patients such as AIDS patients were more susceptible to tumours of viral 
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origin such as human papilloma virus, human herpesvirus 8 and Epstein-Barr 
virus (reviewed in (Boshoff and Weiss, 2002)). Such observations and the 
fact that the cancer incidence for a combination of malignancies including 
melanoma, colon, kidney and lung cancers amongst others was higher in 
patients immunosuppressed as a result of organ transplantation began to 
support the “cancer immunosurveillance” hypothesis in humans (reviewed in 
(Dunn et al., 2004)). Schreiber et al. since revisited the cancer 
immunosurveillance hypothesis and suggested it being only the first phase of 
what he and his colleagues named the “Three Es of cancer immunoediting” 
which refers to an elimination phase, equilibrium phase and escape phase. 
During the elimination phase both innate and adaptive arms of the immune 
system join forces to detect and destroy new transforming cells.  
 
The equilibrium phase describes the stage when some malignant cells 
have escaped elimination but are still kept under control by lymphocytes and 
the constant presence of IFN-γ and TNF-α. The continuous pressure exerted 
by the immune system leads to considerable cell death but also to the 
selection of cells carrying mutations and adaptations serving to reduce their 
immunogenicity (Dunn et al., 2004). In 2007 an elegant study showed the 
importance of the adaptive immune system in the maintenance of tumour 
dormancy. Mice were injected with methylcholanthrene (MCA) and 200 days 
later mice, which appeared tumour-free, received anti-CD4/-CD8/-IFN-γ 
antibodies. Tumour outgrowth was rapidly observed (Koebel et al., 2007) 
suggesting that T cells were controlling tumour progression.  
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Ultimately, the escape phase occurs when malignant cells evade the 
immune response and start to form a clinically apparent tumour. Many 
mechanisms are involved in immune evasion such as: secretion of TGF-β 
and IL-10, recruitment of immunosuppressive cells such as Tregs, MHC 
down regulation, loss of tumour antigen expression, mutation or loss of 
components of the antigen processing machinery and also the development 
of IFN-γ insensitivity. In a clinical trial where NY-ESO-1 protein was 
administrated with and without the ISCOMATRIX adjuvant, patients that 
relapsed showed down-regulation of NY-ESO-1 and HLA class I expression 
by immunohistochemistry (Nicholaou et al., 2011). The authors suggest that 
the altered tumour phenotype observed after relapse appears as a 
consequence of continuous selective pressure illustrating that immunoediting 
occurs in human tumours. 
 
1.3.2 Tumour infiltrating lymphocytes (TILs) and their role in tumour 
growth control 
The presence of immune cells within human solid tumours has been 
established for years. In 1931 the surgical pathologist MacCarty published 
the first study demonstrating that the highest tumoural infiltrate (breast, colon, 
stomach) of lymphocytes were found in patients with the best post-operative 
survival (MacCarty, 1931). These type of studies have been repeated, in 
often high profile publications, demonstrating the same fundamental point 
(Galon, 2006). 
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1.3.2.1 The presence of TILs in human cancers 
Gooden et al. have compiled a comprehensive review detailing the 
prognostic influence of tumour-infiltrating lymphocytes (TILs) in cancer. In 
this review the authors included 52 studies carried out between 2003 and 
2011. Colorectal and ovarian cancers were the main malignancies 
considered and the lymphocytic prognostic significance was based on the 
presence and density of CD3+, CD4+, CD8+ and Foxp3+ T lymphocytes. 
Overall and/or progression-free survival were associated with infiltration of 
lymphocytes into the tumour mass after a combined analysis of hazard ratios 
and 95% confidence intervals for the 52 studies (Gooden et al., 2011).  
 
Schumacher et al. reported that the presence of CD8+ T cells in the 
stroma of oesophageal carcinomas was highly correlated with both disease-
free and overall survival as compared to peritumoural CD8+ T cells or their 
complete absence. IFN-γ was also measured by PCR and 
immunohistochemistry and its presence surrounding CD8+ T cells indicated a 
possible activation status for these effector cells (Schumacher et al., 2001).  
In a cohort of 186 ovarian cancer patients, Zhang et al. observed the same 
survival pattern. Patients whose tumours contained intratumoural T cells had 
a significantly longer progression-free and overall survival (L. Zhang et al., 
2003).  In hepatocellular carcinoma a longer tumour-free survival was highly 
correlated with a higher prevalence of memory, CD3+ and CD8+ T 
lymphocytes (Cai et al., 2006). Whilst it is widely accepted that a high density 
of CD3+, CD8+ and conventional CD4+ T cells is associated with a favourable 
outcome, elevated levels of CD4+ Foxp3+ T cells is often associated with a 
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negative outcome (Curiel et al., 2004; Geng et al., 2015). It has become 
apparent that even though the presence of lymphocytes within the tumour is 
of clinical relevance, their phenotype and activation status is even more 
important.  
 
1.3.2.2 Tumour cell killing by T helper cells and CTLs 
1.3.2.2.1 Tumour cell killing by T helper cells  
Th1 cells limit tumour growth through production of IFN-γ which activates 
macrophages enabling them to target and kill tumour cells in an antigen 
independent manner (Haabeth et al., 2014). IFN-γ and TNF-α released by 
effector T cells can also directly kill target cells albeit in distinct ways. TNF-α 
promotes cell death by activation of the caspase pathway whereas IFN-γ 
interacts with its receptor on the target cell promoting 1) an increased 
expression of MHC class I and endogenous peptides presentation, 2) 
upregulation of Fas (CD95) on the cell surface and 3) production of oxidative 
species (Barthlott et al., 2005; Pandiyan et al., 2007).  
 
Cytotoxic CD4+ T cells also kill MHC II+ tumour cells via granzyme B 
and perforin secretion and upon signalling through the death receptor Fas 
and TNF-related apoptosis-inducing ligand (TRAIL) (Haabeth et al., 2014).  
Even though CD4+ T cells can kill tumour cells on their own right they play a 
crucial role in promoting activation of CD8+ T cells. Furthermore secretion of 
IFN-γ by Th1 cells promotes upregulation of MHC I on the tumour cell 
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surface facilitating the engagement between the TCR and the MHC complex 
(Kennedy and Celis, 2008).   
 
1.3.2.2.2 Tumour cell killing by CTLs  
Once activated CTLs can target and kill tumour cells in an antigen-specific 
manner. Granule-mediated apoptosis mediated by perforin, granulysin and 
serine proteases or via death receptors/death ligands such as Fas/FasL and 
TRAIL. Upon activation CTLs upregulate TRAIL and Fas Ligands on their 
surface, which bind to their respective receptors on the target tumour cell, 
triggering apoptosis and cell death (Martínez-Lostao et al., 2015). In a similar 
fashion, Fas ligand binding to its receptor on the target cell allows DNA 
damage and/or cellular stress and mitochondrial malfunction can increase 
Fas transcription leading to its upregulation on the cell surface (Waring and 
Müllbacher, 1999).        
1.3.2.3 The presence of Tregs in human cancers 
It has been proposed that an elevated number of Foxp3+ Tregs within the 
tumour positively influences the disease as these cells could suppress an 
effector T cell response against the tumour. In hepatocellular carcinoma 
(HCC) a low Treg count within the solid tumour was correlated with a longer 
overall and disease free survival. The positive benefit of low Tregs numbers 
within the tumour was even greater when CD3 cells were highly abundant 
(Gao et al., 2007).  Interestingly, in an ovarian cancer study by Sato et al. the 
authors reported that even though high numbers of Tregs within the tumour 
epithelium was indeed correlated with a shorter survival than patients with a 
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low frequency of Tregs within the epithelium, this difference lacked 
significance. However, a highly significant difference was observed when the 
ratio of CD8/Treg was calculated and survival measured in high and low 
CD8/Treg ratio groups. This indicates that not only the presence of Tregs 
within the tumour epithelium is important but also their numbers in 
comparison to conventional CD4+ and CD8+ effector T cells (Sato et al., 
2005). Evidence of better tumour clearance has also been reported after 
Treg depletion in a number of mouse models using cell lines or injection of 
carcinogen (Hindley et al., 2012; Teng et al., 2010).  
 
1.4 T cells and CRC development 
1.4.1 Th1 and CTL cells in CRC development 
Initial studies on the presence of TILs in CRC indicated that the existence of 
CD8+ T cells within the tumour mass was associated with a more favourable 
prognosis (Naito et al., 1998). A more favourable outcome has also been 
reported for a low CD4+/CD8+ ratio in a different cohort of CRC patients 
(Diederichsen et al., 2003).   
 
In an extensive study performed by Pagès et al. in 2005 looking at 
959 CRC samples, the absence of metastasis was associated with the 
presence of effector memory T cells. Also, patients that did not show early 
signs of metastasis and remained disease-free had increased levels of 
granulysin, granzyme B, CD8α, T-bet, interferon regulatory factor 1 (IRF-1) 
and IFN-γ when compared with relapsed patients. T cell markers like CD3+, 
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CD4+ and CD8+ were also upregulated in metastasis-free patients. 
Furthermore, patients’ whose tumours were infiltrated by a high density of 
memory T cells survived for longer than patients with a low memory T cell 
infiltration (Pagès et al., 2005). A follow-up study by the same group 
analysed the density of CD3+ and CD8+ T cells alongside granzyme B and 
CD45RO within the centre of the tumour (CT) and the invasive margin (IM). 
High levels of such markers both at the CT and IM were associated with a 
longer disease-free period for three different cohorts of CRC patients. The 
difference was even more striking when both regions (CT and IM) were 
combined for the analysis. In order to understand the role of immune cells in 
disease progression the patients were stratified according to high and low 
levels of CD3 and CD45RO cells at the CT and IM. As expected, patients 
whose tumours had a high density of CD3 and CD45RO at the CT and IM 
remained disease free for significantly longer than patients with a low density 
of such cells. However such observation remained true independently of 
tumour stage or node involvement suggesting that T cell infiltration may be a 
better prognostic factor for disease recurrence than tumour stage (Galon, 
2006). In another study performed in an Italian cohort of CRC patients a 
higher CD3 density by the tumour invasive margin was also associated with 
a beneficial survival in patients whose LN had not become affected by the 
tumour (Laghi et al., 2009). 
 
According to a number of studies it has become widely accepted that 
high densities of TILs are associated with a clinical advantage for CRC 
patients (Chiba et al., 2004; Galon, 2006; Guidoboni et al., 2001; Naito et al., 
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1998; Pagès et al., 2005; Prall, 2004; Ropponen et al., 1997; Zlobec and 
Lugli, 2008). However it has since become evident that not only the quantity 
but also the type of T cells infiltrating the tumour has an impact on patient 
survival. 
 
1.4.2 Tregs and CRC development 
Tregs, have an important role in inflammation control. Thus, if tumours are 
driven by inflammation, Tregs may limit tumour progression through 
suppression of inflammation. It is also the case however, that Tregs control 
antigen specific responses thus their presence in the gut has also been 
linked to a less favourable prognosis. Indeed, evidence exists that supports 
both a positive and negative role for Tregs in the development of this 
malignancy.
 
1.4.2.1 Tregs and promotion of CRC development 
Wolf et al. and our own group have detected the presence of a significantly 
higher amount of CD25hi in the blood of CRC patients compared to healthy 
controls (Clarke et al., 2006; Wolf et al., 2003) and removal of CD25hi cells, 
often resulted in an increased T cell responses against tumour antigens, 
measured in vitro. The same was not observed in healthy controls 
suggesting that Tregs are indeed regulating specific anti-tumour responses 
specifically in CRC patients (Clarke et al., 2006). Later studies have 
confirmed these findings and shown that higher numbers of Tregs are 
present within CRCs compared to normal bowel (Ling et al., 2007; Sellitto et 
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al., 2011). In a detailed study performed by our group, CD4+ T cell responses 
against the tumour antigens 5T4 and carcinoembryonic antigen (CEA) were 
measured before and after removal of the CRC. The study indicated that 
Foxp3 expression levels were elevated in the CRC group compared to 
healthy controls when measured before surgery. This returned to normal 
post-surgery suggesting that the CRCs drive Treg activation. When tumour 
recurrence was assessed in the patient cohort, it was found that a 
significantly higher proportion of 5T4- and CEA-specific T cell responses 
were suppressed by Tregs in the patients that recurred at 12 months 
compared to those who did not (Betts et al., 2012) implying that suppression 
of these responses contributes to disease progression. In further support of 
this hypothesis, Scurr et al. showed that 5T4-specific T cell responses was 
greater in healthy donors than CRC patients and that within the patient 
cohort, responses diminished with disease stage. Conversely, the 
percentage of CD4+ T cells expressing Foxp3+ increased with more 
advanced disease further supporting a role for the detrimental effect of Tregs 
in CRC tumour development by their potent suppression of anti-tumour T cell 
responses (Scurr et al., 2013). 
 
1.4.2.2 Tregs and their role in the prevention of CRC development 
Even though some studies indicate that Foxp3+ Tregs are associated with a 
less favourable prognosis in CRC patients, there is also some evidence 
suggesting a positive role of Tregs in preventing CRC development. In a 
study published in 2009 by Salama and colleagues, a high density of Foxp3+ 
Tregs in the tumour tissue was associated with a significantly better 
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prognosis (Salama et al., 2009). Sinicrope et al. also observed that a lower 
CD3+ to Foxp3+ ratio was associated with a worse disease-free survival even 
though there was no association with clinical outcome when Foxp3+ T cells 
were analysed alone (Sinicrope et al., 2009). In another study by Frey et al. 
high infiltration of Foxp3+ Tregs in MMR-proficient tumours was observed in 
an earlier disease stage and a positive association with survival was 
observed for MMR-proficient but not MMR-deficient tumours infiltrated by a 
high density of Foxp3+ Tregs (Frey et al., 2010). Interestingly, a high 
prevalence of Foxp3+ T cells within the tumour was associated with a better 
disease-specific and overall survival by Kaplan-Meier analysis. However, in 
multivariate analysis the Foxp3+ association with a favourable prognosis was 
no longer observed (Nosho et al., 2010). Lee et al. also reported the same 
finding. They reported an association between CD3, CD45RO, CD25 and 
Foxp3 high expression and prolonged survival. When the aforementioned 
markers were combined, the statistical difference between high and low 
density of cells in relation to overall survival was even more significant (W.-S. 
Lee et al., 2010).  
 
Ladoire and colleagues discussed the paradox of Treg infiltration in 
CRC cancers in a review written in 2011 (Ladoire et al., 2011). They highlight 
the fact that, unlike any site of the human body, the colon is constantly being 
exposed to microorganisms. Therefore even though tumour infiltrating Tregs 
have been associated with a less favourable prognosis because of their 
tumour antigen-specific suppression, their alternative function could be linked 
with inflammation control.  
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In a mouse model using RAG-2 deficient and WT mice Erdman et al. 
showed that inoculation of Helicobacter hepaticus into RAG-2-/- mice led to 
the development of inflammation and carcinomas. In contrast, WT animals 
injected with the same bacterium did not develop tumours or significant 
inflammation. Furthermore, adoptive transfer of CD4+CD45RBloCD25+ cells 
into RAG-2-/- mice before inoculation with H. hepaticus prevented intestinal 
inflammation and cancer development (Erdman et al., 2003).     
 
1.4.3 Th17 cells and CRC development 
Through an extensive analysis of two CRC patient cohorts and a validation 
cohort, the Galon group convincingly showed that it is not only the quantity 
but also the quality of T cells infiltrating the tumour that influences the 
patient’s prognosis. Elevated expression of Th1 genes is associated with a 
longer patient survival whereas early recurrence was observed in patients 
with a low level of expression of Th1-related genes. The complete opposite 
was observed for expression of Th17-associated genes. Surprisingly, when 
Th1 and Th17 genes were analysed in combination, patients whose Th17 
genes were highly expressed suffered an early relapse regardless of a high 
expression of Th1-associated genes. Such a finding implies that the harmful 
effects of Th17 activity outweigh the advantageous effect of Th1 cells. This 
result was confirmed by tissue microarray analyses of tumour centres (TC) 
and invasive margins (IM) (Tosolini et al., 2011). In order to understand the 
role of IL-17A in the development of colitis-associated cancer (CAC), Hyun et 
al., injected azoxymethane and dextran sodium sulphate (DSS) in order to 
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promote inflammation in WT and IL-17A KO mice. Less inflammation 
(including production of the pro-inflammatory cytokines IL-6 and IL-23) was 
observed post-DSS treatment in IL-17A KO compared to WT mice 
correlating with fewer tumours (Hyun et al., 2012). A similar association 
between Th17 activity has been observed in mouse models of sporadic CRC. 
Depletion of the APC gene leads to increased levels of IL-23 p19 and IL-17A 
within the tumour compared to normal tissue in a mouse model. Moreover, 
IL-23-deficient animals, developed less and smaller intestinal tumours than 
IL-23 proficient animals (Grivennikov et al., 2012). Wang and colleagues 
reported in 2014 that the level of Th17 cells in the blood of CRC patients was 
significantly elevated compared to healthy donors and this was even more 
pronounced in advanced stages of disease (K. Wang et al., 2014). At the 
protein level, IL-6 which is closely related to IL-17A secretion was also 
greatly upregulated in CRC patients and even more so in advanced disease 
(Li et al., 2014).  
1.5 Tumour antigens 
Currently there are two terms widely used to describe tumour antigens. 
Tumour-specific antigens (TSA) refer to antigens which are exclusively 
present on the surface of tumour cells and tumour associated antigens (TAA) 
which although expressed on tumour cells are also expressed on normal 
tissue. Tumour antigens can be classified into high or low tumour specificity, 
a classification proposed by Coulie in 2014 (Table 1.2) (Coulie et al., 2014).  
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1.5.1 Classification of tumour antigens 
The ability to extract TILs and create stable CTL clones greatly potentiated 
the discovery of melanoma antigen family A 1 (MAGEA1), the first antigen to 
be described as a tumour antigen (van der Bruggen et al., 1991). 
1.5.1.1 Mutated tumour antigens 
Mutations are thought to be a feature of very immunogenic tumours as these 
create novel epitopes previously unseen by the immune system. Usually this 
occurs as a result of one point mutation which can alter the antigenic 
determinant recognised by the T cells or which allows a completely novel 
peptide to bind to the MHC (reviewed in (Vigneron, 2015)). Cancers that 
originate as a result of a high number of mutations such as lung cancer and 
melanoma resulting from exposure to tobacco and ultraviolet radiation, 
respectively, provide examples of tumour antigens created by mutations 
(Paschen et al., 2004). Mutations can also affect oncogenes thus altering 
their function and greatly enhancing the probability that an affected individual 
will develop cancer. Antigens exclusive to the tumour cells, created by 
mutations are attractive candidates for targeted immunotherapy as these are 
not expressed on any normal cell of the body. Besides, T cells primed by 
these tumour-specific novel antigens (neo-antigens) may elicit a stronger 
response than tumour-associated antigens due to a lack of negative 
selection in the thymus. However, the majority of these neo-antigens, even 
those which are presented by MHC molecules, fail to be recognised by T 
cells. They are also tumour and patient-specific thus laborious to identify and 
not applicable as target antigens for large-scale cancer treatment.    
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1.5.1.2 Cancer-testis/cancer-germline tumour antigens 
Cancer-testis or cancer-germline antigens become expressed as a result of 
promoter demethylation which activates the expression of cancer-
germline/cancer-testis genes. This only occurs in either tumour or germline 
cells, such as spermatocytes, spermatogonia or trophoblasts but because 
such cells do not express HLA molecules on their surface, even though they 
express the protein, it cannot be processed and presented in the context of 
MHC which would allow recognition by T cells (reviewed in (Coulie et al., 
2014).  
 
1.5.1.3 Tissue-specific/ differentiation tumour antigens 
Differentiation antigens possess low tumour specificity and include antigens 
present on the tumour cells and the cells where the tumour originated from 
e.g. melanoma and melanocytes (Coulie et al., 2014) 
1.5.1.4 Overexpressed tumour antigens 
Overexpressed antigens are another type of low specificity antigen. Such 
antigens are expressed on some normal cells but their abundance on the 
surface of tumour cells is much higher (Coulie et al., 2014).  
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Table 1.2 Human tumour antigens with high and low tumour specificity. High specificity 
antigens are classified into mutated, cancer-germline and viral antigens (not represented 
here). These are not present on normal cells. Low specificity tumour antigens are classified 
into differentiation and overexpressed antigens and are expressed at some level on normal 
cells. CDK-4, cyclin-dependent kinase 4. CASP8, caspase 8. 5T4, trophoblast glycoprotein. 
SSX-2, synovial sarcoma, x breakpoint 2. Gp100, glycoprotein 100. Mart-1, melanoma 
antigen recognised by T cells 1. HER2, human epidermal growth factor receptor 2. WT, 
Wilms Tumour 1. hTERT, human telomerase reverse transcriptase. CEA, carcinoembryonic 
antigen. Table created based on (Bright et al., 2015; Coulie et al., 2014; Tagliamonte et al., 
2015).       
 
Mutated antigens Cancer-germline antigens Differentiation antigens Overexpressed antigens
CDK-4 5T4 gp100 HER2
Mum-1 NY-ESO-1 Mart-1 (Melan-A) WT1
β-catenin SSX-2 Tyrosinase hTERT
CASP8 Livin
Survivin 
CEA
High specificity Low specificity
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1.5.2 Tumour antigens in colorectal cancer 
Cancer testis or cancer-germline antigens may be ideal targeting candidates 
in an immunotherapy approach as these are only highly expressed on 
tumour tissue and immune-privileged sites. However the challenge lies in the 
fact that even though colorectal malignancies may express such antigens 
they may be poorly immunogenic or not expressed at a high enough quantity 
to mount a robust immune response. Our own laboratory has focussed on 
examining T cell responses to two antigens expressed by CRC, namely CEA 
and 5T4. 
 
1.5.2.1 Detection of Th1 responses specific to tumour antigens in CRC 
patients  
In an unusual approach Bremers and colleagues detected T cell reactivity 
measured by IFN-γ secretion after incubation of CRC patient’s PBMCs with 
autologous tumour lysate. (Bremers et al., 2000). Tumour antigen reactive T 
cells were also detected in the blood of a cohort of 49 CRC patients. 9, 7 and 
6 patients out of 49 contained T cells in their blood reactive to Ep-CAM, her-
2/neu and CEA, respectively. CRC patients also showed a higher rate of T 
cell specificity against tumour antigens if they had metastatic disease and did 
not receive chemotherapy (Nagorsen et al., 2003).  
 
In the first study set to evaluate the detection of spontaneous T cell 
responses specific to tumour antigens and CRC patients’ prognosis, 
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Nagorsen et al. did not observe any difference in survival between 
responders and non-responders. Furthermore, the two-year survival went up 
in patients that did not develop a response to the tumour antigens measured, 
namely Ep-CAM, her-2/neu and CEA (Nagorsen et al., 2005). These initial 
studies successfully demonstrated that T cells specific to tumour antigens 
existed in the blood of CRC patients and could secrete IFN-γ. 
 
1.5.2.2 CEA 
The majority of CRCs overexpress CEA but the protein can also be detected 
at low levels on the surface of healthy mucosa (Davidson et al., 1989). CEA 
is a 180 kDa glycoprotein and due to its glycosylphosphatidylinositol linkage 
it can be easily shed into circulation (Bos et al., 2008). CEA has been shown 
to be involved in cell adhesion when expressed by the tumour cells by in vitro 
studies and it has also been associated with metastasis (Hammarström, 
1999; Kass et al., 1999).  
 
1.5.2.2.1 CEA-specific responses detected in the blood of cancer patients 
and healthy donors 
Lung cancer is another epithelial malignancy in which CEA is highly 
expressed. Crosti and colleagues assessed the presence of spontaneous 
CD4+ T cells specific to CEA in the blood of lung cancer patients and 
observed the existence of naturally occurring CD4+ T cells specific to CEA 
(Crosti et al., 2006). CD4+ responses specific to CEA were detected in the 
blood of pancreatic patients and healthy donors but amongst healthy donors 
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the CEA response detected was mainly a Th1 response whereas amongst 
patients the most prevalent CEA specific response detected was of a Th2 
type. Th17 cells specific to CEA were not detected in the blood of pancreatic 
patients (Tassi et al., 2008). 
 
Also, in a study of CEA-responsiveness amongst healthy individuals, 
IL-10-secreting, CEA-specific T cells were observed in 46% of those tested. 
IL-10 production appeared to be important for keeping CEA-specific T cells in 
check, as neutralisation of the cytokine unleashed IFN-γ-secreting CEA-
specific T cells (Pickford et al., 2007).  
 
1.5.2.2.2 CEA-specific T cell responses in CRC patients  
Our group as recently reported an unexpected finding regarding the 
presence of T cells specific to CEA in the blood of CRC patients. The 
detection of a CEA-specific response in the blood of these patients 
significantly correlated with tumour recurrence. Such a finding was not 
observed for T cell responses specific to the 5T4 antigen and if patients that 
responded to the 5T4 antigen were removed from the analysis, the CEA 
responders were even more likely to relapse. Intriguingly, such observation 
held true even after tumour stage stratification (Scurr et al., 2015).  
 
1.5.2.2.3 Expression of CEA in the gastrointestinal tract of a mouse model  
In 2008 the group of Rienk Offringa created a CEA transgenic (CEA-tg) 
mouse in which the pattern of CEA expression is very similar to what is 
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observed in humans. WT animals injected with MC38-CEA cells receiving T 
cells collected from WT animals previously immunised with CEA showed a 
superior survival of more than 80% compared to the 0% increased survival 
when the same cells were adoptively transferred into CEA-tg mice. This 
suggests that animals expressing CEA as a self-antigen develop regulatory 
mechanisms capable of suppressing CEA-specific responses; therefore 
CEA+ tumours can escape tumour growth control. Furthermore, prolonged 
survival of CEA-tg mice injected with anti-IL-10R antibody, MC38-CEA cells 
and cells reactive to CEA from WT animals, was associated with the 
development of colitis. The detection of CEA-specific IFN-γ producing T cells 
correlated with an even more severe inflammation. This strongly suggests 
that the presence of CEA-reactive Th1 cells can be detrimental and cause 
excessive inflammation if CEA is also expressed as an auto-antigen as in 
CEA-tg mice and immunoregulatory mechanisms are absent (Bos et al., 
2008).    
1.5.2.3 5T4-specific T cell responses in CRC patients  
5T4 is an oncofetal protein expressed on trophoblasts. It has been reported 
that there is very little (if any) expression on healthy tissues but the protein is 
abundantly expressed on some adenocarcinomas like ovarian, gastric and 
colorectal where its high expression has been associated with a poorer 
prognosis (Smyth et al., 2006). 5T4 is grouped in the cancer-germline 
category of antigens as it is expressed on embryonic cells but not on healthy 
adult tissues ((Starzynska et al., 1992) and reviewed in (Zhao and Y. Wang, 
2007) . CD8+ T cells specific for the 5T4 antigen were able to kill HLA-A2+ 
malignant pleural mesothelioma cell lines (Al-Taei et al., 2012). Our group 
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has detected 5T4-specific CD4+ T cells responses in the blood of CRC 
patients; a higher frequency of patients developed a response to 5T4 after 
the removal of the tumour (Betts et al., 2012). Interestingly, in a study 
performed by our group in a cohort of CRC patients, 5T4-specific responses 
detected by IFN-γ release decreased with more advanced disease. However 
responses specific to the recall antigen tuberculin purified protein derivative 
(PPD) remained robust suggesting that even though tumour antigen specific 
responses become impaired with tumour development, especially with more 
advanced carcinomas, bacterial responses did not (Scurr et al., 2013). This 
suggests that tumour development potentiates an immunoregulatory 
microenvironment capable of suppressing tumour antigen specific responses. 
 
1.6 Tertiary lymphoid organs (TLOs) and High endothelial 
venules (HEVs) 
One reported feature of the immune response to cancer is the development 
of tertiary lymphoid organs (TLOs). TLOs, with a cellular organisation similar 
to a secondary lymphoid organ (SLO) can also be referred to as ectopic 
lymphoid structures or organs (ELS/ELO). They are defined by the presence 
of distinct B and T cell areas, fibroblastic reticular cells (FRCs) and HEVs 
within the T cell area. Follicular dendritic cells (FDCs) and the activation-
induced cytidine deaminase (AID) enzyme representative of germinal centre 
activity are also present in fully developed TLOs (Neyt et al., 2012). 
Nevertheless, these ectopic structures can still function as a lymphoid organ 
even if they do not fulfil all the aforementioned criteria (Neyt et al., 2012). For 
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a review of TLO development within tissues see (G. W. Jones and S. A. 
Jones, 2016). The term lymphoid aggregates/follicle is often used when not 
all the cells forming a TLO are present or have been definitively identified.  
1.6.1 TLOs 
1.6.1.1 TLOs in chronic inflammation and infection 
De novo formation of TLOs is associated with inflammation. These structures 
have been found in humans post infection with Helicobacter pylori and 
Borrelia burgdorferi, but also in the context of autoimmune conditions such 
as rheumatoid arthritis (RA), primary biliary cirrhosis, Hashimoto’s thyroiditis, 
MS, Myasthenia gravis, systemic lupus erythematosus and also in the 
context of transplant rejection and exposure to environmental stresses 
(Girard and Springer, 1995; Neyt et al., 2012). TLOs in chronic autoimmune 
diseases may act as a site for self-reactive T cell priming, thus contributing to 
the pathology. Lymphoid aggregates, also known as bronchus-associated 
lymphoid tissue (BALT) if in the lung, were detected in the lung of patients 
with RA and Sjögren syndrome, in the vicinity of areas enriched by 
citrullinated proteins. Since citrullinated proteins are thought to drive 
pathogenic T cell responses in these diseases, these observations imply a 
pathogenic role for the induced BALT in activating the pathogenic T cells 
(Rangel-Moreno et al., 2006). 
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1.6.1.1.1 TLOs in inflammatory bowel disease (IBD)  
TLOs also develop in the context of chronic inflammation in the absence of a 
tumour. These structures have been reported to be present in IBD such as 
UC and CD (Nascimbeni et al., 2004). 
1.6.1.1.2 TLOs in lung cancer 
TLOs present in human lung cancer were positive for the presence of 
CD62L+ cells. However no CD62L+ cells could be detected outside of TLOs 
indicating that active recruitment of naïve T cells were occurring within these 
structures but no where else within the tumour. The majority of the cells 
forming these organised structures were CD4+ memory T cells and to a 
lesser extent CD8+ naïve T cells, CD8+ memory T cells and CD4+ naïve T 
cells (de Chaisemartin et al., 2011). HEVs were also detected within these 
organised structures and but were never detected in the absence of 
surrounding cells (de Chaisemartin et al., 2011). This was the first study 
describing the presence of functional TLOs within a tumour. The same group 
had however published a previous study correlating the density of tumour 
induced-BALT with DC-Lamp+ (mature DCs) cells. A high density of DC-
Lamp+ cells was associated with a longer disease-free survival thus implying 
that such ectopic structures could be involved in anti-tumoural immunity 
supporting the maintenance of an anti-tumour response (Dieu-Nosjean et al., 
2008).  
1.6.1.1.3 TLOs in Human Melanoma Metastases 
TLOs have also been observed in metastatic lesions of melanoma but not in 
the primary tumour. Some cells within large follicles were AID+ indicative of 
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immunoglobulin hypermutation and functionality of the structures. Similarly to 
what was described for lung cancers, HEVs were also detected within or in 
close proximity to lymphoid aggregates. HEVs could also be detected within 
primary tumours in association with loose infiltrates of B and T lymphocytes 
but no FDC were present suggesting incomplete lymphoid neogenesis 
(Cipponi et al., 2012).    
1.6.1.1.4 TLOs in Colorectal cancer 
Lymphoid aggregates have been observed in the context of CRC comprising 
B and T cells and a network of FDCs (Bergomas et al., 2012). A more 
detailed study was later performed by Väyrynen et al. who confirmed the 
presence of these structures in CRC further indicating that the strucutres 
were mainly composed of B cell, T cells and macrophages with few FoxP3+ 
Tregs and DCs (Väyrynen et al., 2014). Di Caro et al. also reported the 
presence of organised structures with features similar to TLOs in CRC. 
These aggregates contained HEVs and positively associated with TIL density. 
In patients whose tumour had not spread to LN, the authors reported that a 
high density of TLOs was associated with a more favourable prognosis (Di 
Caro et al., 2014). 
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1.6.2 High endothelial venules 
1.6.2.1 HEVs in secondary lymphoid organs 
HEVs are important components of TLOs. HEVs are specialised blood 
vessels present in the paracortex and interfollicular areas of SLO excluding 
the spleen. They are specialised structures, which allow migration of naïve 
and central memory T lymphocytes along with other immune cells including 
naïve B cells and DCs, from the circulation into the lymphoid organ. Even 
though their role is mainly associated with the recruitment of B and T cells, 
low levels of DCs can also extravasate through HEVs. These specialised 
post-capillary vessels are formed by endothelial cells with a cuboidal and 
plump morphology thus the “high endothelial” name. The basal lamina of 
these vessels is composed by layers of pericytes, fibroblast reticular cells 
and extracellular matrix. Reviewed in (Ager and May, 2015; Girard et al., 
2012). 
 
The luminal surface of HEVs is decorated by peripheral node 
addressins (PNAds), also known as sialomucins. PNAds are a group of 
sialylated, sulphated and fucosylated glycoproteins including endomucin, 
nepmucin, podocalyxin, CD34 and GLYCAM1 only in the mice (Girard et al., 
2012). In order for HEVs to become functional they need to undergo some 
post-translational modification mediated by glycosyltransferases such as 
Fuc-TVII, β3GlcNAcT-3 and GlcNAc6ST-2 (Hiraoka et al., 1999; Malý et al., 
1996; Yeh et al., 2001).  
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O- and N-glycans present on the PNAds are decorated with the 6-
sulpho sialyl Lewis X motifs, a key determinant for L-selectin binding 
expressed on naïve and central memory lymphocytes and also the ligand for 
MECA-79. MECA-79 is the most utilised antibody to identify HEVs. It is 
highly specific and it does not react with other vessels, positively staining 
peripheral, mesenteric and mucosal HEVs present in LNs albeit with different 
patterns/intensity (Streeter et al., 1988). Emigration of lymphocytes through 
HEVs was abrogated in an in vivo system using the MECA-79 blocking 
antibody confirming its specificity (Streeter et al., 1988). 
 
Mucosal addressin cell adhesion molecule 1 (MAdCAM-1) is another 
marker associated with the HEV phenotype but unlike PNAd is mainly 
associated with mucosal and intestinal lamina propria HEVs and its 
expression is mainly observed in a less advanced developmental stage 
(Girard et al., 2012). Mouse HEVs present in Peyer’s patches (PP) and the 
intestinal wall only express MAdCAM-1 but not PNADs. Markers of vascular 
endothelial cells such as CD31 and vascular endothelial-cadherin are also 
present on the endothelial cells of HEVs even though not exclusive to these 
structures. 
 
Chemokines constitutively expressed by HEVs and surrounding cells 
such as CCL21, CXCL12 and CXCL13 also play a crucial role in the 
recruitment of naïve B and T lymphocytes. The high endothelial cells 
themselves secrete CCL21 whereas FRCs and FDCs express CXCL12 and 
13. CCR7 and CXCR4 are both expressed by naïve T cells and B cells also 
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express CXCR5 in addition to the previously mentioned chemokine receptors. 
See Figure 1.4 for an overview of an HEV. Reviewed in (Girard et al., 2012).  
 
1.6.2.2 HEVs in chronic inflammation and infection 
Even though HEVs are mainly present in SLOs in homeostatic conditions, 
their ectopic formation has been reported in both chronic inflammation and 
tumours. The presence of ectopic HEVs has been described in a range of 
inflammatory diseases such as autoimmune thyroiditis, atherosclerosis, 
psoriasis, dermatitis, bronchial asthma, IBD and RA (Aloisi and Pujol-Borrell, 
2006) mainly in association with TLOs.  
 
 
Figure 1.4 Schematic of a High Endothelial Venule. High endothelial venules are formed 
by plump and cuboidal endothelial cells that express peripheral node addressin (PNAds) on 
their luminal surface. PNAds (also known as sialomucins) are post-translational modified 
proteins which have O and N-glycans on their surface decorated with the 6-sulpho sialyl 
Lewis X motifs, a key determinant for L-selectin binding expressed on naïve and central 
memory lymphocytes. Adapted from (Girard et al., 2012). 
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1.6.2.3 HEVs in cancer 
Even though HEVs have been reported in sites of chronic inflammation, 
especially in patients with autoimmune conditions, it was not until 2011 that 
the Girard group described the existence of HEVs in solid tumour (Martinet et 
al., 2011). In this novel study, the group identified HEVs with the same 
phenotypic characteristics of LN HEVs in melanomas, breast, ovary and lung 
cancer but also colon carcinomas. HEV neogenesis may facilitate 
lymphocyte penetration into the tumour site allowing infiltration of naïve and 
effector T cells such as cytotoxic and helper T cells that could specifically 
target tumour antigens (Martinet et al., 2011). Thus, by presenting a major 
gateway for T cell infiltration into the tumour site, investigating the presence 
of HEVs within the tumour could offer more information on patients’ response 
to therapy and survival rate. In the context of cancer, identification of HEVs is 
usually performed by PNAd rather than MAdCAM-1 staining. 
 
1.6.2.3.1 Breast Cancer 
The Girard group not only performed a general analysis on the pattern of 
HEV expression on a number of solid tumours but also performed a more 
detailed analysis on two cohorts of 127 and 147 breast cancer patients. The 
presence of HEVs was strongly associated with B and T cells and further 
analysis based on HEV density showed that genes characteristic of naïve 
and central memory T and B cells such as CCL19, CCL21, CXCL13 and 
CCR7 were greatly upregulated in tissues with a high density of HEVs. Also, 
a high density of HEVs within the tumour positively predicted a longer 
disease and metastasis-free and overall survival (Martinet et al., 2011).     
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1.6.2.3.2 Melanoma 
In 2012 Martinet et al., published a similar study to the above but in 
melanoma patients. Two hundred and twenty five patients were included and 
similarly to what was observed in breast cancer, HEVs associated with 
infiltration of T and B cells but not Foxp3+ cells. Also, the Breslow tumour 
thickness of the lesions, a marker for disease progression, was inversely 
correlated to HEV density (Martinet et al., 2012). The type of HEVs also 
appears to be important in dictating the nature of the infiltrate. Lymphocytes 
accumulate more readily around cuboidal HEVs than flat HEVs suggesting 
that HEV morphology may be closely related to their function (Avram et al., 
2013). HEVs have been observed in primary and metastatic melanoma 
although ELS have only been observed in metastatic lesions (Cipponi et al., 
2012) and HEV-dense melanomas have been associated with a good 
prognosis (Avram et al., 2013).  
1.6.2.3.3 HEVs in other human tumours 
Even though HEVs have been associated with a favourable prognosis in 
some studies Shen et al. did not observe any significant difference in the 
total density of HEVs between metastasis and non-metastasis patients with 
oral and pharyngeal squamous cell carcinoma. Their data support the notion 
that HEVs play a role in the spreading of cancer cells to neck LNs assisting 
in metastasis development (Shen et al., 2014).  
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HEVs have also been detected in seminomas of 24 out of 26 patients. 
Seminoma is the most prevalent form of testicular cancer. HEVs were 
concentrated in lymphocytic rich areas mainly within the T cell zones and the 
number of T cells surrounding them was greater than B cells (Sakai et al., 
2014).  
 
1.6.2.3.4 Development of HEVs in mouse models 
The presence of HEVs has also been detected in carcinogen-induced 
fibrosarcomas in mice. Interestingly, HEV were only observed in the tumours 
after Treg-depletion suggesting a link between T cell activation and 
neogenesis of HEV. Moreover, HEV density correlated with TIL density and 
tumour regression (Hindley et al., 2012). These data indicate that HEV are 
beneficial for enabling tumour-specific T cells to enter and kill tumours. 
 
Concluding comments 
The studies described above indicate that the nature of the T cell 
response and their specificity in combination with ELS development are 
important parameters in determining the effectiveness of the immune 
response to CRC. With this in mind, I set out to test the hypotheses below:
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1.7 Hypotheses and Aims 
Two hypotheses were tested.  
1. Development of HEVs within the tumour epithelium/stroma of CRC 
patients allows the recruitment of naïve and central memory T cells 
potentiating an anti-tumour response which controls tumour growth 
and favours patient outcome.  
 
 This hypothesis was tested according to the following aims: 
1. Characterise the structure, relative location and density 
of HEVs within CRCs 
2. Correlate HEV density with T cell infiltration 
3. Study MSI in tumours with an elevated density of HEVs 
4. Correlate HEVs and TLOs with disease stage and 
patient survival 
 60 
 
2. A high density of antigen-specific Th17 cells within CRC is associated 
with a less favourable prognosis associated with an elevated 
concentration of IL-17A. 
 
This hypothesis was tested according to the following aims: 
 
1. Determine the percentage of Th17 associated 
cytokines and chemokine receptors in the blood, 
healthy colon and tumour of CRC patients 
2. Measure IFN-γ and IL-17A production by CEA and 
5T4-specific responses in a cohort of CRC patients  
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2 Material and Methods 
2.1 Colorectal cancer patients – Cohort nr 1: HEV 
quantification 
Prior to my arrival, a postdoc in the laboratory, Dr Emma Jones had studied 
the phenotype of tumour infiltrating lymphocytes in a cohort of 62 CRC 
patients. These patients received surgery between 1997 and 2008 and 
tumour samples were collected immediately after surgery, fixed in formalin 
and embedded in paraffin. A healthy portion of the bowel was later collected 
from some patients for formalin-fixation and paraffin-embedding.   
Data regarding patient’s age, gender, tumour staging and five-year survival 
are shown in Table 2.1. 
2.2 Staining formalin-fixed paraffin embedded samples from 
CRC patients  
2.2.1 Immunohistochemistry 
A microtome (Surgipath) was used to cut 5µm thick sections which were 
subsequently mounted on glass slides then dried at room temperature for 
approximately one hour before placing in a 60°C oven overnight.  
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Table 2.1 Patient details. Information about the patient's age, gender and tumor location 
was only available for 54, 60 and 53 patients, respectively (n=62). Columns indicate number 
and percentage unless otherwise specified. Alive and Dead indicate survival at five years 
post surgery. SD, standard deviation 
 
 Number Percentage 
Age Mean 69.4; SD 10.7  
Sex   
    Male 30 50 
    Female 30 50 
Tumor location 
    Ascending colon 12 22.6 
    Transverse colon 2 3.8 
    Descending colon 2 3.8 
    Sigmoid colon and rectum 37 69.8 
Dukes' Staging   
    Dukes' A 24 38.7 
           Alive 21 87.5 
           Dead 3 12.5 
    Dukes' C 38 61.3 
           Alive 18 47.4 
           Dead 20 52.6 
Five-year survival 
    Alive 39 62.9 
    Dead 23 37.1 
 63 
Prior to antibody staining, sections were dewaxed in xylene (3 X five 
minutes) and rehydrated in a descending alcohol series consisting of 100% 
ethanol (2 X 3 minutes), 90% ethanol (1 X 3 minutes) and 70% ethanol (1 X 
3 minutes) before placing in running tap water for 5 minutes and finally 
rinsing in distilled water. From this step onwards it was essential to make 
sure the sections did not dry out at any stage. Heat induced epitope retrieval 
(HIER) was routinely performed in order to ensure successful epitope 
unmasking. Approximately 800 mL of a 10 mmol/L Tris, 1 mmol/ EDTA pH9 
solution was microwaved at 900 watts for 5 minutes. The slides were then 
immersed in the hot buffer and microwaved for a further 8 minutes. Sections 
were left to cool down for approximately 20 minutes and then washed 3 
times in phosphate buffered saline (PBS) for a total of 5 minutes. 
Endogenous peroxidase activity was blocked by immersion in 1% hydrogen 
peroxide diluted in methanol (1% H2O2/MeOH) for 10 minutes. Slides were 
then washed 3 times in PBS for a total of 5 minutes. A hydrophobic barrier 
pen (Vector) was used to draw a circle around the tissue section and 
sections were incubated in two/three drops of 2.5% normal horse or goat 
serum (Vector laboratories) for 30 minutes to block non-specific antibody 
binding. A combination of different antibodies was used and is clearly 
specified in each Figure. For antibody clones, species and concentrations 
used see Table 2.2.  
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Table 2.2 Antibodies used in immunohistochemistry with the respective 
concentrations and the antigen retrieval method and buffer applied. 
 
 
The sections were incubated with the primary antibody diluted in 1% bovine 
serum albumin (BSA) in PBS overnight at 4°C in a humid chamber. Slides 
were then washed three times in PBS for a total of 5 minutes in order to 
remove excessive unbound antibody. Sections were then incubated in the 
appropriate species specific ImmPRESS Horse Radish Peroxidase (HRP) 
Polymer detection reagent (Vector laboratories) for 30 minutes in a humid 
chamber at room temperature. Slides were then washed three times in PBS 
for a total of 5 minutes and briefly incubated in Impact DAB (brown), Vector 
SG (grey) or Vector VIP (purple) peroxidase substrates (all Vector 
laboratories). This process was repeated sequentially with different 
antibodies to detect multiple antigens. Sections were subsequently 
dehydrated in an ascending alcohol series consisting of 70% ethanol (1 X 3 
minutes), 90% ethanol (1 X 3 minutes) and 100% ethanol (2 X 3 minutes) 
followed by three xylene washes (5 minutes each) before mounting in 
mounting medium (distyrene, a plasticizer, and xylene; DPX) and glass 
coverslips and drying in a 60°C oven overnight. For every new antibody 
Antigen Antibody Concentration (µg/mL) Species Antigen retrieval method 
CD3 CD3 (DAKO) 2 Rabbit 
Sections were microwaved for 
8 minutes in 10 mmol/L Tris, 1 
mmol/ EDTA buffer, pH9 
CD8 CD8 (DAKO) 2 Mouse 
FoxP3 FoxP3 (eBioscience) 1 Rat 
CD20 CD20 (DAKO) 0.45 Mouse 
MECA-79 MECA-79 (Santa Cruz Biotechnology) 2 Rat 
CD31 CD31 (Abcam) 2 Rabbit 
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tested an isotype control antibody was used in parallel to check for non-
specific staining. Lymph nodes were routinely included as a positive control. 
2.2.1.1 Rorγt and T-bet staining 
Methods for detecting RORγt and T-bet transcription factors in tissue 
sections differed slightly from those described above. For RORγt detection 
10 mmol/L Tris, 1 mmol/EDTA pH9 antigen retrieval buffer was pre-heated 
for 10 minutes before immersing the slides in the hot buffer and microwaving 
for a further 20 minutes. For T-bet detection 10mM citric acid /0.05% Tween 
20, pH 6 was pre-heated for 10 minutes, before immersing the slides in the 
hot buffer and microwaving for a further 8 minutes. For both RORγt and T-bet  
PBS washes and 1% H2O2/MeOH incubations were performed as above. 
Before addition of RORγt or T-bet primary antibody a 5X casein solution 
(Vector laboratories) was added to the slides for 30 minutes at room 
temperature in a humid chamber. The casein was then removed and RORγt, 
antibody (eBioscience, AFKJS-9, 4µg/mL), T-bet  (abcam, EPR9301, 4.4 
µg/mL) or relevant isotype control antibody (4µg/mL, rat IgG2a, Biolegend) 
added to the relevant slide and incubated overnight at 4°C. After washing 
three times in PBS for a total of 5 minutes, sections stained with the RORγt 
antibody were incubated with rabbit anti-rat (Vector), washed three times in 
PBS then incubated with ImmPRESS anti-Rabbit for 30 minutes at room 
temperature. After further PBS washes sections were incubated with DAB for 
1 minute and 30 seconds. CD3 was then detected and sections were 
washed in dH2O and incubated with anti-CD3 antibodies (DAKO, 2µg/mL) 
followed by PBS washes, incubation with ImmPRESS anti-Rabbit, further 
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PBS washes and 3 minutes of contact with SG. Rabbit IgG was used as an 
isotype control. Slides were then dehydrated and mounted as described in 
the previous section (Section 2.2.1).     
2.2.2 Immunofluorescence 
In some cases PNAds and CD31 were stained simultaneously in paraffin 
sections using immunofluorescence. Formalin fixed paraffin embedded 
sections were hydrated and HIER was performed with 10 mmol/L Tris, 1 
mmol/ EDTA pH9 as described in section 2.2.1. Endogenous biotin was 
blocked by incubating sections with Avidin/Biotin Blocking Kit (Vector 
Laboratories) according to manufacturer’s instructions. Non-specific antibody 
binding was blocked by incubating sections with 2.5% horse serum (Vector 
Laboratories) for 30 minutes at room temperature. Sections were incubated 
simultaneously with CD31 (Rabbit polyclonal IgG, 2µg/mL) and biotinylated 
MECA-79 (rat IgM, 1 µg/mL) antibodies, diluted in 1% BSA/PBS, overnight at 
4°C. Sections were washed three times in PBS in the following day for a total 
of 5 minutes and then incubated simultaneously with Streptavidin-Alexa 
Fluor555® (Life technologies, 1µg/mL) and Alexa Fluor488® (Life 
technologies, 2µg/mL) secondary antibodies diluted in 1% BSA/PBS, for one 
hour at room temperature in the dark. After washing three times in PBS for a 
total of 5 minutes sections were incubated with 1% paraformaldehyde for 10 
minutes at room temperature. Slides were washed a further 2X in PBS 
before excess unreacted aldehydes were quenched with 0.3M glycine in 
PBS for 10 minutes. After a final wash in PBS sections were mounted using 
Vectashield mounting medium with DAPI (4, 6-diamidino-2-phenylindole, 
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Vector Laboratories) and glass coverslips. The cover slips were sealed with 
clear nail polish. A Zeiss LSM5 Pascal confocal microscope was used to 
image the sections.          
2.2.3 Cell Quantification  
 A NIKON microscope was used to count CD3+, CD4+ (CD3+CD8-), CD8+ 
and FoxP3+ labelled cells. 10 high power (600x) fields of view within the 
tumour mass (tumour centre) and at the tumour invasive margin were 
counted per section and the mean calculated. The counts at the tumour 
invasive margin were performed in the area between the tumour invasive 
margin line and the dashed line represented in Figure 2.1. The area 
represents a high power field of view of 600x.  
 
 
Figure 2.1 CD3+ T cells were enumerated per 10 high power fields of view and the 
mean calculated. Such counts were performed separately within the tumour centre and by 
the tumour invasive margin. 
 
 
A scanscope (Aperio technologies) was used to scan all the sections 
analysed in this study. The HEV and aggregate/ lymphocyte analysis was 
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then performed using the scanned images with the aid of the ImageScope 
viewer software (Aperio). HEV densities were enumerated in two different 
sites, the centre of the tumour and the extra-tumoural area represented in 
green (Figure 2.2).   
 
 
Figure 2.2 Formalin-fixed paraffin embedded colorectal tumour samples were stained 
with MECA-79, CD3- and CD20-specific antibodies. Grey represents HEVs, brown 
represents CD3+ cells and pink represents CD20+ cells. A/F, lymphoid aggregate/follicle. 
HEV, high endothelial venule. The area covered in green represents the extra-tumoural area. 
 
All HEVs were enumerated in both areas and divided by the corresponding 
area (in mm2) to give the HEV density. In addition, lymphocyte aggregates / 
follicles composed of B and T cells were also enumerated in both areas and 
the corresponding density obtained by dividing by the area (in mm2). Gut-
associated lymphoid tissue (GALT) as part of the normal bowel was 
excluded from the lymphocyte aggregate / follicle enumeration. 
2.0 mm 
Tumour stroma 
Tumour invasive margin 
Tumour epithelium     
A/F with HEVs 
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2.3 Testing for microsatellite instability (MSI) in colorectal 
cancer patients 
Tumour tissue from samples containing HEVs within the tumour centre and 
from samples with the highest HEV density within the extra-tumoural area 
(for both Dukes’ A and C) was collected. This was done by tissue 
macrodissection in which a scalpel blade was used to scrape off the tumour 
tissue from tumour sections adherent to glass slides. Approximately 15 x 5 
µm sections were used per tumour to extract DNA. The tumour samples 
were collected in 1.5 mL vials and 180 µL of ATL buffer (Qiagen) was added. 
The vials were then centrifuging at 13 500 RPM for 5 minutes and left 
incubating overnight at room temperature. 20 µL of proteinase k (Qiagen) 
was added to the mixture the following morning to remove any contaminating 
proteins/nucleases and samples were left in the thermo shaker for 1h 05m at 
56°C followed by 1h 05m at 90°C. 
The EZ1 DNA Tissue kit (QIAGEN) was used with the EZ1 Advanced XL 
robot (Qiagen) according to the manufacturer’s instructions to purify DNA. 
The principle is illustrated in Figure 2.3. Reagent cartridges with magnetic 
particles were loaded into the robot, followed by elution tubes, tip holders 
and opened samples tubes.    
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Figure 2.3 DNA from the lysates binds to the silica surface of the particles present in 
the reagent cartridges in the presence of a chaotropic salt. The particles bound to DNA 
bind to a magnet and all the remnant product is washed away. The DNA is then washed and 
eluted in elution buffer and ready to collect. This figure was obtained from the EZ1 DNA 
Tissue handbook (Qiagen). 
 
The DNA was collected and its concentration measured using a nanodrop 
(Thermo Scientific).  The microsatellite instability (MSI) Analysis System 
(Promega) was used to identify MSI samples according to the manufacturer’s 
instructions. Briefly, the nuclease-free water, gold ST*R 10X buffer, MSI 10X 
Primer Pair Mix (MSI analysis system, Promega) and AmpliTaq Gold® DNA 
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Polymerase (ThermoFisher Scientific, Applied Biosystems) was defrosted 
and vortexed prior to use.    
  
Table 2.3 Volumes of PCR reagents used per individual reaction. 
 
 
 
The total reagent volumes were calculated according to the number of 
samples used and 8 µL of the master mix aliquoted into each well (see table 
2.3). 2 µL of the template DNA purified using the EZ1 DNA Tissue kit were 
pipetted into each well. The MSI 10X Primer Pair Mix contains fluorescently 
tagged primers which are specific for the amplification of seven markers 
including five mononucleotide repeat markers (NR-21, NR-24, BAT-25, BAT-
26, and MONO-27) and two pentanucleotide repeat markers (Penta C and 
Penta D), included to control for sample contamination. This set of five loci 
was selected due to their sensitivity and specificity for the detection of MSI 
by detecting deletion or addition of units altering the length of the alleles in 
the DNA. K562 Genomic DNA was included as a positive amplification 
control and nuclease-free water was included as a negative amplification 
control. A thermal Cycler was used for the amplification step.  
 
 
Reagent Volume per reaction
Nuclease-Free Water 5.85 µl
Gold ST★R 10X Buffer 1.00 µl
MSI 10X Primer Pair Mix 1.00 µl
AmpliTaq Gold® DNA polymerase (5u/ µl) 0.15 µl
Total reaction volume 8.00 µl
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The cycle used was as follows: 
 
 
 
The PCR products were then removed from the thermal cycler and stored at 
4°C until further use.  
To detect amplified fragments using the 3730 DNA Analyzer (Applied 
Biosystems) a master mix of HiDi formamide (7.6 µL/test) and Internal Lane 
Standard 600 (0.4 µL/test) was prepared and 8 µL loaded into each well prior 
to addition of 2 µL of the PCR products. The samples were then denatured 
for 3 minutes at 95°C and immediately transferred to an ice block to stop the 
reaction before capillary electrophoresis using the 3730 DNA Analyzer 
(Applied Biosystems) was performed by a dedicated technician. Peak 
Scanner™ Software Version 1.0 (Applied Biosystems) was used to analyse 
the data generated from capillary electrophoresis (an example is shown in 
Figure 2.4).     
 
95°C for 11 minutes, then:
96° for 1 minute, then:
94°C for 30 seconds
ramp 68 seconds to 58°C, hold for 30 seconds
ramp 50 seconds to 70°C, hold for 1 minute
for 10 cycles, then:
90° for 30 seconds
ramp 60 seconds to 58°C, hold for 30 seconds
ramp 50 seconds to 70°C, hold for 1 minute
for 20 cycles, then:
60°C for 30 minutes
4° soak
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Figure 2.4 Microsatellite instability analysis. The top panel represents a normal sample 
which is microsatellite stable. The loci sizes associated with microsatellite stability are 
labelled with the different markers on the top panel. The bottom panel corresponds to a MSI 
tumour. Instability in each locus is represented by the arrows, which indicates a shortening 
or enlargement of the fragments. This figure was obtained from the Promega kit 
documentation for MSI Analysis handbook. 
 
For a sample to be considered microsatellite instable at least two out of the 
five microsatellite loci studied had to be unstable. 
2.4 Second cohort of colorectal cancer patients  
Colorectal cancer patients admitted to the University Hospital of Wales for 
tumour resection were consented during the morning before surgery in order 
to collect specimens of the tumour, healthy bowel and approximately 50 mL 
of blood into tubes containing heparin. See Appendix for a copy of the 
patient information sheet and consent form. Patients’ details are shown in 
Tables 2.4, 2.5 and 2.6. Some of the samples were used only for method 
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optimisation. Ethical approval was obtained from the South East Wales 
Ethics Board.  
 
 
Table 2.4 Details of CRC patients whose PBMCs used for the optimisation of IL-17A 
detection by ELISpot and FluoroSpot. Information was not available on the tumour 
location or stage for one male patient. 
   
Male Female
n 11 1
Age (Range) 72 (63-84) 48
Tumour Location (%) Ascending 2 (18) 0 (0)
Transverse 1 (9) 0 (0)
Descending 0 (0) 0 (0)
Sigmoid 2 (18) 0 (0)
Rectum 5 (45) 1 (100)
TNM Stage (%) T1 0 (0) 0 (0)
T2 2 (18) 0 (0)
T3 7 (64) 0 (0)
T4 1 (9) 1 100)
(Lymph Node Spread) N0 4 (36) 0 (0)
N1 4 (36) 1 (100)
N2 2 18) 0 (0)
Dukes' Stage (%) A 0 (0) 0
B 4 (36) 0
C1 6 (55) 1
C2 0 (0) 0
D 0 (0) 0
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Table 2.5 Details of CRC patients whose samples were used for the analysis of 
tumour-infiltrating lymphocytes (TIL) and colon-infiltrating lymphocytes (CIL). 
 
 
Male Female
n 7 6
Age (Range) 71 (54-85) 75 (56-87)
Tumour Location (%) Ascending 3 (43) 3 (50)
Transverse 0 (0) 1 (17)
Descending 0 (0) 0 (0)
Sigmoid 2 (29) 0 (0)
Rectum 2 (29) 2 (33)
TNM Stage (%) T1 0 (0) 0 (0)
T2 3 (43) 0 (0)
T3 3 (43) 5 (83)
T4 1 (14) 1 (17)
(Lymph Node Spread) N0 5 (71) 3 (50)
N1 2 (29) 2 (33)
N2 0 (0) 1 (17)
Dukes' Stage (%) A 2 (29) 0 (0)
B 3 (43) 3 (50)
C1 1 (14) 3 (50)
C2 1 (14) 0 (0)
D 0 0 (0)
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Table 2.6 Details of CRC patients who’s PBMCs were used for detection of cultured 
tumour-antigen responses. Information was not available on the tumour stage for one 
male and one female patient. Information on the location of the tumour was not available for 
two males and one female patient. 
Male Female
n 12 12
Age (Range) 68 (42-87) 73 (54-87)
Tumour Location (%) Ascending 2 (17) 4 (33)
Transverse 1 (8) 1 (8)
Descending 0 (0) 0 (0)
Sigmoid 3 (25) 1 (8)
Rectum 4 (33) 5 (42)
TNM Stage (%) T1 1 (8) 0 (0)
T2 1 (8) 1 (8)
T3 7 (58) 9 (75)
T4 2 (17) 1 (8)
(Lymph Node Spread) N0 7 (58) 8 (67)
N1 2 (17) 2 17)
N2 2 (17) 1 (8)
Dukes' Stage (%) A 2 (17) 1 (8)
B 5 (42) 7 (58)
C1 4 (33) 3 (25)
C2 0 (0) 0 (0)
D 1 (8) 1 (8)
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2.4.1 Collecting patient samples 
Pieces of the tumour and healthy bowel obtained from the pathologist were 
transferred to tumour infiltrating lymphocyte (TIL) extraction media containing 
warm RPMI 1640 medium (ThermoFisher Scientific), supplemented with 
2mM L-glutamine, 1mM sodium pyruvate, 50 µg/mL of penicillin, 
streptomycin and gentamicin (Life Technologies) and 2 µg/mL of Fungizone 
(Amphotericin B, Life technologies) and taken to the laboratory.  
2.4.2 Lymphocyte Isolation 
2.4.2.1 Preparation of single cell Suspensions from Tissues 
The tumour and colon samples were minced into a fine pulp on a Petri dish 
using a blade and filtered through a 70 µm cell strainer to isolate the 
infiltrating cells. At this point cells were centrifuged twice in TIL extraction 
media at 2000 rpm for 10 min at room temperature. Supernatants were 
discarded carefully and fresh media added to the samples. Only mechanic 
dissociation was used to obtain single cell suspension because the addition 
of enzymes such as collagenase or DNase greatly alters the expression of 
certain cell surface proteins (including chemokine receptors relevant to this 
study). Prior to detection of intracellular cytokines, cells were left in the 
incubator overnight in TIL/CIL resting media containing (RPMI 1640 
supplemented with 2mM L-glutamine, 1mM sodium pyruvate, 50 µg/mL of 
penicillin and streptomycin, 10 µg/mL of gentamicin (Life technologies), 1 
µg/mL of Fungizone (Amphotericin B, Life technologies) and 10% of AB 
serum).   
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2.4.2.2 Ficoll separations 
PBMCs were isolated from blood by layering on an equal volume of 
Lymphoprep (Axis-Shield) before spinning at 2000 RPM for 20 min at room 
temperature without break. A Pasteur pipette was subsequently used to 
aspirate the ring of PBMCs formed in the middle of the layers after 
centrifugation. PBMCs were transferred into a falcon tube and fresh 
complete RPMI (RPMI 1640 supplemented with 2mM L-glutamine, 1mM 
sodium pyruvate and 50 µg/mL of penicillin and streptomycin) was used to 
wash the PBMCs twice. Firstly by centrifugation at 2000 RPM for 10 min 
followed by centrifugation at 1600 RPM for 5 min both at room temperature. 
The cells were then enumerated; 20µL of cell suspension was mixed with 
20µL of Trypan blue and cells were counted using a haemocytometer under 
a light microscope.  
2.4.3 CD25+ Cell Depletion by MACS  
In order to deplete CD25hi T cells from PBMCs CD25 MicroBeads II (Miltenyi 
Biotec) were used. Cells were magnetically labelled by resuspending up to 
107 cells in 90 µL of cold MACS buffer (1x PBS, 0.5% BSA, 5 mM EDTA) 
and adding 10 µL of MicroBeads II (Miltenyi Biotec) before thorough 
resuspension and incubation at 4° for 15 min. Cells were washed twice in 
2mL of MACS buffer followed by resuspension in 500 µL of MACS buffer. To 
positively select the CD25hi T cell fraction a MS column was placed into a 
MACS separator and the magnetically labelled cells passed through the 
column. The column was washed three times with MACS buffer in order to 
collect the unlabelled fraction before removing the column from the MACS 
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separator and eluting the labelled cells with 500 µL of MACS buffer. Both 
CD25 replete and deplete fractions were washed twice in RPMI media prior 
to further use. The percentage of CD4+CD25+ Treg depletion was analysed 
by flow cytometry as shown in the results section.     
2.4.4 Antigens/Mitogens 
Tuberculin purified protein derivative (PPD) (Statens Serum Institut, 
Denmark) and haemagglutinin protein (HA) (kindly provided by Dr John 
Skehel, NIMR) were used routinely as control antigens to test for recall 
responses in all patients. Phytohaemagglutinin (PHA) was also used in all 
assays as a positive control. All of the aforementioned antigens were used at 
a concentration of 4 µg/mL. 
2.4.4.1 Candida Albicans 
C. Albicans was prepared by inoculating pieces of frozen yeast (SC5314) 
into a 5 mL yeast peptone dextrose broth (Dr Selinda Orr). The mixture was 
left incubating at 30°C for 16-24 hours with constant movement (150-
200RPM). The C. Albicans was washed three times in sterile PBS. Between 
each wash the cells were centrifuged at 300g for 5 mins at 4°C. Cells were 
resuspended in PBS and enumerated under a light microscope using a 
haemocytometer. In order to heat inactivate the C. Albicans, the cells were 
heated at 100°C for 45 min prior to two further washes in PBS. Cells were 
aliquoted into eppendorf vials and stored at -80°C until further use.  
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2.4.4.2 Carcinoembryonic antigen’s proteins 
Whole CEA proteins from two different sources and obtained by two different 
methods were used to assess the development of anti-CEA responses in 
CRC patients. CEA from Sigma Aldrich was obtained from human fluids 
whereas CEA from Merck Millipore Calbiochem® was derived from a human 
colon adenocarcinoma cell line.  
2.4.4.3 Carcinoembryonic antigen and 5T4 peptide pools 
The CEA protein sequence AAA51967.1 was used to design a set of seventy 
20 amino acid long peptides, each overlapping by 10 residues and covering 
the entire protein (Table 2.7). The peptides were obtained from GLBiochem, 
China and their purity was greater than 90%. Two super pools of CEA 
peptides were created. Peptide pool 1 (pp1) covered peptides 1 to 35 and 
peptide pool 2 (pp2) covered peptides 36 to 70. These were used at a final 
concentration of 1.5 µg/mL/peptide. Two super pools were also prepared 
with 5T4 peptides. 5T4 pp1 spanned from peptide 1 to peptide 20 and 5T4 
pp2 spanned from peptide 21 to peptide 41. 5T4 peptides were already 
available in the laboratory also from GLBiochem (China) (Table 2.8). 5T4 
peptide pools were also used at a final concentration of 1.5 µg/mL/peptide.  
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Table 2.7 CEA 20 mer peptide sequences. 
 
No Sequence No Sequence
1 MESPSAPPHR WCIPWQRLLL 36 NTTYLWWVNNQSLPVSPRLQ
2 WCIPWQRLLL TASLLTFWNP 37 QSLPVSPRLQLSNDNRTLTL
3 TASLLTFWNP PTTAKLTIES 38 LSNDNRTLTLLSVTRNDVGP
4 PTTAKLTIESTPFNVAEGKE 39 LSVTRNDVGPYECGIQNELS
5 TPFNVAEGKEVLLLVHNLPQ 40 YECGIQNELSVDHSDPVILN
6 VLLLVHNLPQHLFGYSWYKG 41 VDHSDPVILNVLYGPDDPTI
7 HLFGYSWYKGERVDGNRQII 42 VLYGPDDPTISPSYTYYRPG
8 ERVDGNRQIIGYVIGTQQAT 43 SPSYTYYRPGVNLSLSCHAA
9 GYVIGTQQATPGPAYSGREI 44 VNLSLSCHAASNPPAQYSWL
10 PGPAYSGREIIYPNASLLIQ 45 SNPPAQYSWLIDGNIQQHTQ
11 IYPNASLLIQNIIQNDTGFY 46 IDGNIQQHTQELFISNITEK
12 NIIQNDTGFYTLHVIKSDLV 47 ELFISNITEKNSGLYTCQAN
13 TLHVIKSDLVNEEATGQFRV 48 NSGLYTCQANNSASGHSRTT
14 NEEATGQFRVYPELPKPSIS 49 NSASGHSRTTVKTITVSAEL
15 YPELPKPSISSNNSKPVEDK 50 VKTITVSAELPKPSISSNNS
16 SNNSKPVEDKDAVAFTCEPE 51 PKPSISSNNSKPVEDKDAVA
17 DAVAFTCEPETQDATYLWWV 52 KPVEDKDAVAFTCEPEAQNT
18 TQDATYLWWVNNQSLPVSPR 53 FTCEPEAQNTTYLWWVNGQS
19 NNQSLPVSPRLQLSNGNRTL 54 TYLWWVNGQSLPVSPRLQLS
20 LQLSNGNRTLTLFNVTRNDT 55 LPVSPRLQLSNGNRTLTLFN
21 TLFNVTRNDTASYKCETQNP 56 NGNRTLTLFNVTRNDARAYV
22 ASYKCETQNPVSARRSDSVI 57 VTRNDARAYVCGIQNSVSAN
23 VSARRSDSVILNVLYGPDAP 58 CGIQNSVSANRSDPVTLDVL
24 LNVLYGPDAPTISPLNTSYR 59 RSDPVTLDVLYGPDTPIISP
25 TISPLNTSYRSGENLNLSCH 60 YGPDTPIISPPDSSYLSGAN
26 SGENLNLSCHAASNPPAQYS 61 PDSSYLSGANLNLSCHSASN
27 AASNPPAQYSWFVNGTFQQS 62 LNLSCHSASNPSPQYSWRIN
28 WFVNGTFQQSTQELFIPNIT 63 PSPQYSWRINGIPQQHTQVL
29 TQELFIPNITVNNSGSYTCQ 64 GIPQQHTQVLFIAKITPNNN
30 VNNSGSYTCQAHNSDTGLNR 65 FIAKITPNNNGTYACFVSNL
31 AHNSDTGLNRTTVTTITVYA 66 GTYACFVSNLATGRNNSIVK
32 TTVTTITVYAEPPKPFITSN 67 ATGRNNSIVKSITVSASGTS
33 EPPKPFITSNNSNPVEDEDA 68 SITVSASGTSPGLSAGATVG
34 NSNPVEDEDAVALTCEPEIQ 69 PGLSAGATVGIMIGVLVGVA
35 VALTCEPEIQNTTYLWWVNN 70 IMIGVLVGVALI
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Table 2.8 5T4 20 mer peptide sequences. 
No Sequence No Sequence
1 MPGGCSRGPAAGDGRLRLAR 22 GLRRLELASNHFLYLPRDVL
2 AGDGRLRLARLALVLLGWVS 23 HFLYLPRDVLAQLPSLRHLD
3 LALVLLGWVSSSSPTSSASS 24 AQLPSLRHLDLSNNSLVSLT
4 SSSPTSSASSFSSSAPFLAS 25 LSNNSLVSLTYVSFRNLTHL
5 FSSSAPFLASAVSAQPPLPD 26 YVSFRNLTHLESLHLEDNAL
6 AVSAQPPLPDQCPALCECSE 27 ESLHLEDNALKVLHNGTLAE
7 QCPALCECSEAARTVKCVNR 28 KVLHNGTLAELQGLPHIRVF
8 AARTVKCVNRNLTEVPTDLP 29 LQGLPHIRVFLDNNPWVCDC
9 NLTEVPTDLPAYVRNLFLTG 30 LDNNPWVCDCHMADMVTWLK
10 AYVRNLFLTGNQLAVLPAGA 31 HMADMVTWLKETEVVQGKDR
11 NQLAVLPAGAFARRPPLAEL 32 ETEVVQGKDRLTCAYPEKMR
12 FARRPPLAELAALNLSGSRL 33 LTCAYPEKMRNRVLLELNSA
13 AALNLSGSRLDEVRAGAFEH 34 NRVLLELNSADLDCDPILPP
14 DEVRAGAFEHLPSLRQLDLS 35 DLDCDPILPPSLQTSYVFLG
15 LPSLRQLDLSHNPLADLSPF 36 SLQTSYVFLGIVLALIGAIF
16 HNPLADLSPFAFSGSNASVS 37 IVLALIGAIFLLVLYLNRKG
17 AFSGSNASVSAPSPLVELIL 38 LLVLYLNRKGIKKWMHNIRD
18 APSPLVELILNHIVPPEDER 39 IKKWMHNIRDACRDHMEGYH
19 NHIVPPEDERQNRSFEGMVV 40 ACRDHMEGYHYRYEINADPR
20 QNRSFEGMVVAALLAGRALQ 41 YRYEINADPRLTNLSSNSDV
21 AALLAGRALQGLRRLELASN
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2.4.5 Primary cell Cultures 
Freshly isolated PBMCs from CRC patients were used to set up cell cultures 
in order to detect low frequency tumour-antigen specific responses. 13-14 
day cultures were used unless otherwise specified. During the optimisation 
stages different cell numbers were used and cells were grown for different 
periods of time. These variables are described in the first part of Chapter 4. 
After optimisation 0.5 x 106 PBMCs were seeded per well in a 96-well plate 
(Nunc) in 100 µL culture media (RPMI 1640 supplemented with 2mM L-
glutamine, 1mM sodium pyruvate, 50 µg/mL of penicillin, streptomycin and 
5% AB serum) as follows:   
 
 
Figure 2.5 Schematic of the 96-well plate used to culture PBMCs. HA; haemagglutinin, 
PPD; tetanus purified protein derivative, NS; non-stimulated. 
 
On day 0 HA and PPD were added at a final concentration of 4 µg/mL and all 
the peptide pools were added at a final concentration of 1.5 µg/mL/peptide. 
As a control no antigen was added to the NS (non-stimulated) well.  
10 µL of CellKine (CK) media (Helvetiva Healthcare) was added on day three 
and every three/four days 100 µL of culture media was replaced with fresh 
media supplemented with 40 U/mL of IL-2 resulting in a final concentration of 
20 U/ml of IL-2/well. The culture plate was kept in sterile conditions at all 
1 2 3 4 5 6 7 8 9 10 11 12
A PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS
B PBS HA NS HA NS HA NS HA NS PBS
C PBS PPD PPD PPD PPD PBS
D PBS CEA	pp1 CEA	pp1 CEA	pp1 CEA	pp1 PBS
E PBS CEA	pp2 CEA	pp2 CEA	pp2 CEA	pp2 PBS
F PBS 5T4	pp1 5T4	pp1 5T4	pp1 5T4	pp1 PBS
G PBS 5T4	pp2 5T4	pp2 5T4	pp2 5T4	pp2 PBS
H PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS
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times in an incubator (37°C, 5% CO2) for 13-14 days before re-stimulation. 
The wells at the edge of the plate were filled with PBS.    
2.4.6 IFN-γ  / IL-17A ELISpot Assays  
The IFN-γ and IL-17A ELISpot kits from Mabtech (Sweden) were used for all 
the ELISpot assays in combination with 96-well plates from Millipore (MAIP-
S-4510). To fully activate the membrane 50 µL of 70% ethanol were added 
to each well for 1 min. The plate was washed five times with sterile PBS (150 
µL/well) and coated with 50 µL of IFN-γ antibody (1-D1K, 15 µg/mL) or IL-
17A antibody (MT44.6, 10 µg/mL). Both antibodies were diluted in sterile 
PBS. Plates were left incubating overnight at 4°C. The following day the 
plate was washed five times with 150 µL/well of PBS prior to the addition of 
100 µL/well of culture media. The plate was then incubated at room 
temperature for at least 30 min to block the Fc receptors and diminish non-
specific binding. After the blocking step the culture media was removed and 
100 µL/well of culture media containing cells was aliquoted per well. 
Antigens were added to the culture media and plates left in the incubator 
(37°C, 5% CO2) for approximately 18 hours for the detection of IFN-γ or 42 
hours for the detection of IL-17A. 
Following 18 (IFN-γ) or 42 (IL-17A) hours incubation the cells were removed 
from the plates and the wells washed five times with 150 µL/well of PBS. 
50µL of the IFN-γ detection antibody (7-B6-1-biotin, 1µg/mL) or the IL-17A 
detection antibody (MT504-biotin, 0.5µg/mL) were added to each well and 
the plates incubated at room temperature for two hours. Following incubation 
the plates were washed five times with PBS and streptavidin-alkaline 
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phosphatase (1:1000) added to the wells (50 µL/well) and incubated for 1 
hour at room temperature. The wells were washed five times with PBS prior 
to addition of the substrate for approximately 15 minutes. The substrate 
consisted of 4% AP colour development, 1% substrate A, 1% substrate B in 
dH2O (Bio-Rad; Hercules, California). After 15 min the plate was washed 
under tap water to stop the reaction. The ELISpot plate reader (Autoimmun 
Diagnostika GMBH, A.I.D., Germany) and ELISpot 5.0 software was used to 
enumerate cytokine-producing T cells. The number of spots in each well was 
confirmed by eye.  
2.4.6.1 Ex vivo IFN-γ  / IL17A ELISpot Assay 
Ex vivo ELISpots were prepared on the day of blood collection. Ficoll purified 
PBMCs were enumerated and resuspended in culture media and added to 
the wells. 3.5 x 105 PBMCs were used per well for the detection of IFN-γ and 
5 x 105 PBMCs were used per well for the detection of IL-17A. Following 
incubation with a range of antigens the plates were developed as explained 
in section 2.4.6. 10 spots per 2 x 105 PBMCs post background subtraction 
and at least double the background were indicative of a positive ex vivo 
response. 
2.4.6.2 Cultured IFN-γ  / IL-17A ELISpot Assay 
For cultured IFN-γ or IL-17A ELISpot assays, PBMC lines kept in identical 
culture conditions as explained in section 2.4.5 were pooled from duplicate 
wells, washed and resuspended at 2 x 106/mL for IFN-γ detection and 5 x 
106/mL for IL-17A detection in 200 µL of culture media. 100 µL was added to 
two separate wells and one of them received antigen in order to compare 
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specific activation. An IFN-γ response was considered positive if for every 5 x 
105 cells seeded more than 50 peptide specific spots were present after 
subtraction of the background and there were double the number of 
background spots. An IL-17A response was considered positive if for every 5 
x 105 cells seeded more than 25 peptide specific spots were present after 
subtraction of the background and there were double the number of 
background spots. The number of cells initially seeded varied at times during 
the optimisation process as described in Chapter 4. 
2.4.7 IFN-γ  / IL-17A FluoroSpot Assays 
The human IFN-γ/ IL-17A FluoroSpot kit (MabTech) was used for all the 
FluoroSpot assays. 96-well IPFL plates specific for FluoroSpot (Millipore) 
were activated for 1 minute with 15 µL of 25% Ethanol. Following activation 
the plate was washed five times with PBS. A mix of coating antibodies was 
prepared by mixing anti-IFN-γ (1-D1K, 15 µg/mL) and anti-IL-17A (MT44.6 15 
µg/mL). 80 µl of the coating antibodies was added to the plates and 
incubated overnight at 4°C. The following day the plate was washed five 
times with PBS and incubated with 100 µL of culture media for at least 30 
minutes at room temperature. Culture media was removed and PBMCs in 
100 µL of culture media were added to each well. The plate was incubated 
for approximately 42 hours at 37°C with 5% CO2. The cells were removed 
from the plate and the wells washed five times with PBS. The detection 
antibodies were prepared by mixing anti-IFN-γ (7-B6-1-FS-FITC, 1:200) and 
anti-IL17A (MT504-biotin, 2 µg/mL) in PBS containing 0.1% of BSA before 
adding 100 µL to each well. The plate was incubated at room temperature for 
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two hours and washed five times with PBS. Anti-FITC-490 (1:200) and SA-
550 (1-200) were diluted in PBS containing 0.1% BSA and 80 µL of the 
solution added to each well. The plate was incubated in the dark for one hour 
at room temperature and washed again five times with PBS. 50 µL/well of 
Fluorescence enhancer (Mabtech) was added and the plate incubated for 15 
minutes at room temperature. The Fluorescence enhancer was removed 
from the wells by firmly tapping it onto paper towels before leaving the plate 
to dry in the dark at room temperature. Spots were detected and counted 
using an ImmunoSpot® Analyzer (C.T.L.) and ImmunoSpot 5.2 Analyzer 
(C.T.L.), respectively.     
2.4.7.1 Cultured IFN-γ  / IL-17A FluoroSpot Assays 
For the cultured IFN-γ/IL-17A FluoroSpot assays PBMC lines were grown in 
quadruplicate as shown in Figure 2.5. After 13-14 days of culture two 
identical lines were pooled together and washed at least twice with PBS (e.g. 
Lines in column 2 were pooled with lines in column 4 and lines in column 8 
were pooled with lines in column 10 (Figure 2.5)). After the last PBS wash, 
pooled cells in each well were resuspended in 200 µL of culture media and 
transferred to the FluoroSpot plate. Each pooled condition was split into two 
100 µL wells with 5 x 105 cells in each well. At this stage, if enough cells 
were available anti-DR (Biolegend, Clone L243, 10 µg/mL), anti-DQ 
(Biolegend, Clone Tu169, 10 µg/mL) and anti-HLA, A, B and C (Biolegend, 
Clone W6/32, 10 µg/mL) blocking antibodies were added to the wells and 
incubated at 37°C with 5% CO2 for 30-60 min before addition of the antigen. 
In order for a response to be considered positive it would have to be at least 
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double the background in addition to the following criteria: IFN-γ, IL-17A and 
IFN-γ/IL-17A responses were considered positive if a minimum of 50, 25 and 
10 spots, respectively, were present per 5 x 105 cells after subtraction of the 
background.  
2.4.8 Flow Cytometry 
2.4.8.1 Antibody staining 
0.2 – 1 x 106 PBMCs, colon infiltrating lymphocytes (CILs) and TILs were 
seeded in 96-well plates (Nunc) and washed twice in 200 µL PBS. 3µL of a 
1:10 dilution of aqua amine-reactive viability dye (Invitrogen) was added to 
the cell pellet to stain the dead cells. The cells were incubated with the dye 
for 15 min at room temperature in the dark. Cold flow cytometry buffer (PBS 
containing 2% foetal calf serum (FCS) and 5mM EDTA ) was used to wash 
the cells three times before addition of the surface antibodies. After the final 
wash the cells were resuspended in 50 µL of flow cytometry buffer containing 
anti-human antibodies to stain surface markers (Table 2.9). Cells were 
incubated with antibodies in the dark for 15 min at 4°C before being washed 
twice with flow cytometry buffer and incubated with 200 µL of 
fixation/permeabilization solution (eBioscience) overnight at 4°C. Cells were 
washed with 1x permeabilization buffer (eBioscience) and incubated with 30 
µL of 1x permeabilization buffer including 2% rat serum to block Fc receptors 
for 15 min at 4°C. Cells were resuspended in 50 µL 1x permeabilization 
buffer containing anti-human antibodies used to stain intracellular 
markers/cytokines (Table 2.10). Cells were incubated with the antibodies in 
the dark for 30 minutes at 4°C before washing three times in 1x 
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permeabilization buffer and fixed in flow cytometry buffer containing 2% 
paraformaldehyde (Sigma-Aldrich) prior to acquisition on a BD FACSCanto II.  
2.4.8.2 Activation for Intracellular Cytokine Analysis 
Cells were stimulated with phorbol myristate acetate (PMA,50 ng/mL) and 
Ionomycin (500 ng/mL) for five hours in combination with Brefeldin A (2 
µg/mL) before performing intracellular cytokine staining with the antibodies 
shown in Table 2.10. 
2.5 Statistical and graphical analyses 
Prism 5 (GraphPad) was used to perform all of the statistical analyses. The 
Mann-Whitney statistical test was used for comparison amongst groups. The 
Pearson method was used for correlation analyses and both P-value and 
Pearson correlation coefficients (r2) are shown. A P-value ≤ 0.05 was 
considered significant.  
Flow cytometry data was analysed using FlowJo version 10. 
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Table 2.9 Antibodies used for staining cell surface markers for flow cytometry. 
Dilutions or volumes per test are shown in cases where concentrations were not available. 
All the antibodies used were anti-human. 
 
         
Table 2.10 Antibodies used for intracellular staining and flow cytometry. Dilutions or 
volumes per test are shown in cases where concentrations were not available. All the 
antibodies used were anti-human. 
 
 
Marker Conjugate Clone Company
Final 
Concentration 
(µg/ml)
CD3 APC UCHT1 Biolegend 1.7 µg/ml
CD3 PE UCHT1 Biolegend 3.33 µg/ml
CD3 FITC UCHT1 Biolegend 3.33 µg/ml
CD3 PerCPCy5.5 UCHT1 Biolegend 5 µg/ml
CD4 Brilliant Violet 421 OKT4 Biolegend 5 µg/ml
CD4 APCh7 RPA-T4 BD 3 µg/test
CD4 PECy7 RPA-T4 Biolegend 10 µg/ml
CD4 APC-eFluor 780 SK3 eBioscience 0.4 µg/ml
CD8 PECy7 RPA-T8 BD 1:20
CD69 PECy7 FN50 Biolegend 6 µg/ml
CCR6 Brilliant Violet 421 G034E3 Biolegend 2.5 µg/ml
CCR6 PECy7 11A9 BD 1:20
CXCR3/CD183 PerCPCy5.5 1C6/CXCR3 BD 1:30
CXCR3/CD183 PerCPCy5.5 G025H7 Biolegend 5 µg/ml
LAG-3 PE 3DS223H eBioscience 0.8 µg/ml
Marker Conjugate Clone Company
Final 
Concentration 
(µg/ml)
ROR-γt PE Q21-559 BD 5 µl/test
T-bet eFluor 660 4B10 eBioscience 8 µg/ml
IL-10 PE JES3-19F1 Biolegend 1.7 µg/ml
IL-17A APC 64DEC17 eBioscience 0.8 µg/ml
IL-17A APC eFluor 780 64DEC17 eBioscience 1.7 µg/ml
IL-22 eFluor 660 22URTI eBioscience 2 µg/ml
IFN-γ FITC B27 BD 5 µg/ml
IFN-γ Brilliant Violet 421 4S.B3 Biolegend 1:30
IFN-γ APC eFluor 780 4S.B3 eBioscience 1 µg/ml
FoxP3 FITC PCH101 eBioscience 6.6 µg/ml
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3 High endothelial venules and lymphoid 
aggregates in the context of colorectal 
cancer 
3.1 Introduction 
HEVs are postcapillary venules specialised in lymphocytic extravasation from 
the blood into lymphoid organs. The presence of PNAds on the surface of 
their endothelial cells allows the specific binding of L-selectin+ cells. Cuboidal 
and plump endothelial cells form the lining of HEVs, which gives them their 
characteristic appearance and thus their “high endothelial venule” name. 
These structures are present in all secondary lymphoid organs within the 
body except from the spleen and support high levels of lymphocytic 
extravasation (Girard and Springer, 1995). A common feature of such 
vessels is the presence of lymphocytes within their walls. MECA-79 is a well-
characterised monoclonal antibody, which allows the detection of PNAds and 
therefore HEVs within LNs.   
Chronic inflammation and development of ectopic lymphoid structures or 
tertiary lymphoid organs has been reported in the context of autoimmune 
diseases such as rheumatoid arthritis amongst others. Often, the presence of 
HEVs is also associated with the presence of such structures (Girard and 
Springer, 1995; Stranford and Ruddle, 2012). Most recently, however, HEVs 
have also been described in the context of human and mouse tumours, 
namely breast, lung, colon and ovarian carcinomas and in melanomas 
(Avram et al., 2013; Martinet et al., 2012; 2011). More in-depth studies 
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carried on melanoma and breast cancer demonstrated a correlation between 
the number of HEVs detected, patient outcome and tumour and metastasis-
free survival (Martinet et al., 2011). The authors suggested that the formation 
of these new specialised blood vessels within the tumour aids infiltrating of 
effector T cells into the tumour site, thus promoting tumour control (Martinet 
et al., 2011). In support of such suggestion, previous studies in our own 
laboratory demonstrated that a high density of T cells within the tumour 
microenvironment is crucial for a successful control of methylcholanthrene 
(MCA)-induced tumours. Additionally, the presence of T cells was associated 
with the presence of HEVs, seen, in this model, only after depletion of Tregs 
(Hindley et al., 2012).        
Surgical removal of the tumour is often the route of treatment for CRC 
patients. However after colectomy around 40-50% of the patients suffer 
relapse. After resection, specimens are histologically classified from Dukes’ 
stage A to D according to the muscle bowel penetration and lymph node 
involvement, leaving patients diagnosed with Dukes’ A tumours at a better 
chance of survival than patients diagnosed with Dukes’ D which represents 
Dukes’ C tumours with distant metastasis. Nonetheless, such prognosis is 
not absolute and in the past years more and more evidence has suggested 
that the extent of T cell infiltration acts as an independent prognostic factor to 
histopathological staging (Galon, 2006; Pagès et al., 2005). It is likely that 
TILs may have an important role in limiting disease progression and also 
disease recurrence after resection of the primary tumour. Our group has 
performed detailed examination of the type of TILs infiltrating colorectal 
tumours at different disease stages (Betts et al., 2012; Scurr et al., 2014).   
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However, although the lymphocyte cellularity of tumours varies markedly, the 
mechanism of cell infiltration remains unclear. 
Based on the mouse studies performed in our lab (Hindley et al., 2012) and 
very initial published findings in human tumours (Martinet et al., 2011), I 
reanalysed the tissue sections from CRC patients to determine whether 
HEVs were present within the tumours and whether these were associated 
with an increased infiltration of T cells into the tumours. This chapter will 
focus on whether presence or absence of HEVs is associated with i) the 
formation of lymphoid structures at the site of the CRC; ii) type of T cell 
present within the tumour mass, iii) clinical stage of disease and iv) patient 
survival.  
3.2 Human colorectal cancers are associated with the 
development of extra-tumoural but rarely intra-tumoural 
HEVs 
In order to ascertain if HEVs were present within colorectal tumour mass 
and/or its adjacent area, formalin-fixed paraffin embedded tumours from 62 
patients were used for immunohistochemistry analysis. From the 62 patients, 
30 were female and 30 were male. There was no available information 
regarding gender for two patients. The mean recruiting age was 69.4 years. 
The cohort included twenty-four and thirty-eight patients diagnosed with early 
(Dukes’ A) and more advanced (Dukes’ C) disease, respectively.  
MECA-79 is a well-characterised antibody that binds to peripheral node 
addressins (PNAds) on HEVs. Thus, MECA-79 was used in 
immunohistochemistry along with the HEV characteristic cuboidal and plump 
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morphology and also the presence of lymphocytes in their vicinity to identify 
HEVs. In order to ascertain that MECA-79 staining was indeed indicatory of a 
blood vessel, sequential sections were also stained with the CD31 antibody 
(pan-endothelial cell marker). Thirteen samples of healthy bowel were also 
analysed for the presence of HEVs in order to compare the existence of 
HEVs in healthy and malignant colon. The MECA-79 antibody positively 
identified HEVs (grey staining in Figure 3.1A), which also stained for CD31 
(brown staining in Figure 3.1B) demonstrating the specificity of the antibody 
and the ability to identify HEVs within CRC through MECA-79 staining. The 
great majority of HEVs detected within CRC presented with the typical 
cuboidal and plump morphology of such structures found in LNs as can be 
observed from Figure 3.2. Figures A-C represent examples of 20x 
magnification images whereas figures 3.2 D-F represent images captured at 
a 40x magnification (examples are from different patients). A rat IgM 
antibody was used regularly as an isotype control to ascertain the MECA-79 
antibody specificity. As observed in Figure 3.3B, incubation of CRC sections 
with rat IgM does not generate any MECA-79-like staining. In order to 
understand if detection of HEVs was a trait only observed within colorectal 
tumours, thirteen samples of healthy bowel were also obtained and stained 
for HEVs. Due to the practical difficulty in obtaining healthy bowel from 
completely disease free donors, the samples were collected from a healthy 
portion of the bowel of CRC patients.  
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Figure 3.1 MECA-79 co-localises with CD31 staining and positively identifies High 
endothelial venules. Sequential formalin-fixed paraffin embedded colorectal tumour 
samples were stained with MECA-79 (A and C) and CD31 (B and D) antibodies. In figures A 
and C grey represents HEVs, brown represents CD3+ cells and pink represents CD20+ cells. 
In figures B and D dark brown represents CD31+ blood vessels. 
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Figure 3.2 HEVs identified within colorectal cancer have the characteristic plump and 
cuboidal shape typical of HEVs found in SLOs. Formalin-fixed paraffin embedded 
colorectal tumour samples were stained with MECA-79, CD3 and CD20 antibodies. A-C 
represent imagines of HEVs captured with a 20 x magnification whereas figures D – F 
represent imagines captured with 40 x magnification. Grey represents HEVs, brown 
represents CD3+ cells and pink represents CD20+ cells.  
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Figure 3.3 HEV staining is absent when staining is performed with isotype controls. 
Sequential sections were stained with CD3 (Brown), CD20 (Purple) and MECA-79 (Grey) 
and isotype controls. A) HEV staining in grey, T cell staining in brown and B cell staining in 
pink. B) Staining performed with isotype controls using exactly the same conditions as in A.
200 µm 
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MECA-79+ 
200 µm 
B 
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Such samples were collected the furthest away possible from the tumour. 
HEVs could only be detected within the healthy bowel in the context of gut-
associated lymphoid tissue (GALT) in close proximity to the crypts but in no 
other location (Figure 3.4 A-D). Antibody specificity is demonstrated on figure 
3.5 by the absence of staining in figure 3.5B when staining was performed 
with isotype control antibodies. The lack of HEVs within the healthy 
submucosa was strikingly different to what was observed in CRCs where 
HEVs were present within the extra-tumoural area, positioned ahead of the 
tumour invasive margin. The extra-tumoural area is considered to be the 
tissue directly adjacent to the tumour mass which could be perceived as part 
of the tumour microenvironment but not the tumour epithelium/stroma. In 
Figure 3.6A the superimposed green shape represents the extra-tumoural 
area. Under the microscope such distinction is easily made and the tumour 
invasive margin creates what could be perceived as a physical barrier, which 
separates the tumour epithelium and tumour stroma from the extra-tumoural 
area. HEVs were positively identified within the colorectal tumour 
environment but their presence was mostly confined to the extra-tumoural 
area. They were always detected in association with a concentration of CD3+ 
T and CD20+ B cells (Figure 3.6B). In 49 out of 62 patients HEVs were found 
within the tumour microenvironment, largely within the extra-tumoural area. 
In contrast to what has been reported for melanoma (Martinet et al., 2012) 
and breast cancer (Martinet et al., 2013), HEVs were rarely observed within 
the CRC tumour stroma or epithelium (tumour centre).  
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Figure 3.4 HEVs are only detected within the healthy bowel in the context of gut-
associated lymphoid organs (GALT). 13 samples from the healthy bowel of CRC patients 
were collected and analysed for the presence of HEVs. A) Overview picture of the 
localisation of GALT in relation to the crypts. B-D) Represent different examples of HEVs 
(Grey) detected in the context of GALT in association with crypts. B (Purple) and T (Brown) 
cells were also stained in combination with HEVs. 
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Figure 3.5 No T or B cells or HEVs can be detected in GALT with isotype control 
antibodies. A) Representative example of a GALT (gut associated lymphoid tissue) stained 
with CD3 (brown), CD20 (pink) and MECA-79 (grey). b) Sequential section stained with 
Rabbit IgG isotype control, mouse IgB2a isotype and Rat IgM isotype. 
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Figure 3.6 HEVs are identified within the extra-tumoural area of colorectal cancer in 
the context of lymphoid aggregates/follicles. Formalin-fixed paraffin embedded colorectal 
tumour samples were stained with MECA-79, CD3 and CD20 antibodies. Grey represents 
HEVs, brown represents CD3+ cells and pink represents CD20+ cells. A/F, lymphoid 
aggregate/follicle. HEV, high endothelial venule. In figure A the area covered in green 
represents the extra-tumoural area. In figure B the black line represents the tumour invasive 
margin.  
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In the aforementioned tumours, HEVs were described to be present within 
the tumour mass, directly influencing the amount of T cell infiltration 
occurring within the centre of the tumour. In the small number of tumours 
where HEVs were detected within the tumour centre (tumour stroma and/or 
tumour epithelium) (n=8), they did not exhibit typical HEV morphology 
(Figure 3.7A); phenotypic features linked to function. HEVs present within the 
tumour centre were formed by flat endothelial cells and in some cases 
absence of lymphocytic aggregates further supporting the atypical 
characteristics of such HEVs (Figure 3.7B).  
In some tumours binding of MECA-79 to the tumour epithelium was observed. 
This phenomenon only occurred in about one sixth of the tumours and even 
though the pattern of staining did not reflect the structure of HEVs further 
investigation was carried out in order to ascertain the absence of HEVs 
within the tumour mass. Sequential sections were incubated with either 
MECA-79 or CD31 and images were compared side by side at the same 
magnification (Figure 3.8). Alternatively, the exact same section was also 
stained with MECA-79 and CD31 by immunofluorescence which allowed the 
simultaneous use of both antibodies on the same section. Figure 3.9 and 
3.10 show that MECA-79 and CD31 positively identify HEVs through 
immunofluorescence regardless of autofluorescence known to occur with 
fluorescent staining on formalin fixed paraffin embedded sections of human 
tissue.   
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Figure 3.7 HEVs located within the colorectal tumour centre have a flat morphology. 
A) Example of an atypical HEV devoid of lymphoid tissue present within the centre of the 
tumour. B) Example of one of the few HEVs present within the tumour mass surrounded by 
B and T cells but composed of flat endothelial cells. Grey is indicative of MECA-79 staining, 
pink of B cell staining and brown of T cell staining.  
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Figure 3.8 MECA-79 unspecific staining within the tumour epithelium does not co-
localise with CD31 pan-endothelial staining. Consecutive sections were stained with CD3, 
CD20 and MECA-79 and CD31. A-C) Representative examples of MECA-79 unspecific 
staining within the centre of the tumour. D-F) Sequential sections stained with CD31.   
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Figure 3.9 MECA-79 immunofluorescence staining co-localises with CD31 staining. 
Formalin-fixed paraffin embedded tumours obtained from colorectal cancer patients were 
stained with anti-MECA-79 (red) and anti-CD31 (green). A) MECA-79, B) CD-31, C) DAPI 
(Nuclear stain) and D) A, B and C images superimposed. 
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Figure 3.10 Example of an HEV staining by immunofluorescence. Formalin-fixed 
paraffin embedded tumours obtained from colorectal cancer patients were stained with anti-
MECA-79 (red) and anti-CD31 (green). A) MECA-79, B) CD-31, C) DAPI (Nuclear stain) and 
D) A, B and C images superimposed. 
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Figure 3.8 and 3.11 demonstrate that the binding of MECA-79 within the 
tumour epithelium does not co-localise with CD31 staining thus indicating 
that that the MECA-79+ cells are not HEV. This can be observed in 
sequential sections (Figure 3.8) stained by immunohistochemistry or in 
sections stained with both antibodies at the same time by 
immunofluorescence (Figure 3.11). Furthermore, the morphology of the 
MECA-79+ cells within the tumour epithelium does not resemble the structure 
of typical high endothelial cells. 
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Figure 3.11 MECA-79 unspecific staining within the tumour epithelium does not co-
localise with CD31 pan-endothelial staining. Representative examples of MECA-79 (red) 
and CD31 (green) staining by immunofluorescence on colorectal cancer sections. Each row 
represents the staining on different tumours. The first column represents MECA-79 staining, 
the second represents CD31 staining and the third column represents MECA-79 and CD31 
staining superimposed.  
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3.3 HEVs are associated with lymphoid aggregates and 
lymphocyte numbers at the tumour invasive margin 
As mentioned in the previous sections HEVs were almost always identified in 
the presence of an agglomerate of T and B cells. These lymphocytic clusters 
were confined to the extra-tumoural area (represented in green in figure 
3.6A) and ranged from a disperse combination of sometimes only T cells to 
disorganised lymphoid aggregates (Figure 3.12 A-B) to extremely organised 
follicle-like structures (Figures 3.12 C-D), almost resembling ectopic 
lymphoid organs. The follicle-like structures contained distinguishable T and 
B cell areas (indicated by the dashed blue line in Figure 3.12 C-D) thus 
according to Professor Geraint Williams (retired Professor of Pathology, 
University of Wales) such structures are routinely referred to as lymphoid 
follicles. Cell agglomerates in which there is not a clear distinction between T 
and B cells are referred to as lymphoid aggregates.  
Amongst the 62 CRC samples studied a wide variety of lymphoid 
aggregate/follicles of different sizes and levels of organisation were observed. 
A possible relationship between the number of lymphoid aggregates/follicles 
and HEVs within the extra-tumoural area was explored and a highly 
significant correlation observed (Figure 3.13A: p < 0.0001, R2 = 0.442). Of 
note, all the HEVs found within the extra-tumoural area were surrounded by 
lymphocytes forming lymphoid aggregates/follicles. The reciprocal however, 
was not true as lymphoid aggregates/follicles with no detectable HEV were 
observed. This may simply be due to an inability to detect HEVs in all ectopic 
lymphoid structures due to the 2-dimensional nature of the 
immunohistochemical analysis. 
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Figure 3.12 Lymphoid aggregates/follicles arise in a variety of shapes and 
lymphocytic organisation. Formalin-fixed paraffin embedded colorectal tumour samples 
were stained with MECA-79 (Grey), CD3 (Brown) and CD20 (Pink) antibodies. A-B) 
represent lymphoid aggregates and C-D) represent lymphoid follicles found within the extra-
tumoural area. HEVs are present in B and D.  The blue dashed line represent a clear area of 
B cells. 
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The existence of HEVs within the tumour epithelium/stroma was extremely 
rare (8 out of 62 samples studied) and in contrast to the extra-tumoural area, 
no association was observed between these and lymphoid 
aggregates/follicles (Figure 3.13B: p=0.2889, R2 = 0.014873).  
3.4 HEVs are associated with lymphocyte numbers at the 
tumour invasive margin 
Even though HEVs were almost absent from the tumour centre (tumour 
epithelium/stroma) the question of whether the existence of HEVs and 
lymphoid aggregates/follicles in the vicinity of the tumour influenced T cell 
infiltration still remained.     
In order to determine the influence of HEVs on T cell infiltration, total CD3+ T 
cells were enumerated both by the tumour invasive margin and within the 
centre of the tumour (tumour epithelium/tumour stroma). In order to obtain a 
representative sample of the number of T cells within the tumour and 
invasive margin, ten high power fields of view were counted and averaged 
for both the invasive margin and centre of the tumour. The T cell counts by 
the tumour invasive margin were performed according to the dashed line in 
figure 3.14A. There was a highly significant association between the extra-
tumoural HEV density and CD3+ T cells within the tumour invasive margin 
(Figure 3.14B: p = 0.002, R2 = 0.148). However, this association was not so 
strong between the T cells located within the centre of the tumour and HEVs 
located within the extra-tumoural area (Figure 3.14B: p = 0.05, R2 = 0.065). 
Nevertheless, interestingly, such association between T cells and HEVs 
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located within the extra-tumoural area was only observed for more advanced 
disease (Figure 3.14C).  
It has been shown in other malignancies that HEV density correlates with T 
cell infiltration. Therefore CRC sections were stained with antibodies to CD3, 
CD8 and FoxP3 to determine if HEV density controls the number and 
composition of T cells by the tumour invasive margin where HEV density 
correlates with T cell infiltration. The median HEV density was used as a cut 
off point to divide samples into HEVhigh and HEVlow. (Figure 3.15A). 
The ratios of CD3+, CD4+ (CD3+CD8-) or CD8+ T cells to FoxP3+ T cells were 
then calculated according to HEV density both in patients that did (Figure 
3.15B) and did not (Figure 3.15C) survive five years post-surgery. As it can 
be observed in Figures 3.15B and C, HEV density at the extra-tumoural area 
has no influence on the type of T cells surrounding the tumour. Such pattern 
is observed regardless of patient survival time.  
3.5 Colorectal tumours with elevated numbers of HEVs are 
microsatellite stable 
Amongst all the diagnosed CRCs about 15% are microsatellite instable 
(Boland and Goel, 2010). Such instability arises as a consequence of 
mutations within the DNA repair machinery which results in the formation of 
longer or shorter microsatellite repeats. The length of such repeats allows for 
the detection of microsatellite instable (MSI) tumours. Patients with MSI 
tumours tend to have a better prognosis as they respond better to treatment 
and their tumours are often infiltrated with high numbers of T cells (Buckowitz 
et al., 2005).  
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Figure 3.13 Lymphoid aggregates/follicles within the extra-tumoural area correlate 
with the HEV density within the extra-tumoural area but not within the tumour centre. 
The number of lymphoid aggregates per mm2 was enumerated within the extra-tumoural 
area (A) or within the tumour centre (B) and correlated with the number of HEVs per mm2 
within the extra-tumoural area (A) or within the tumour centre (B). A/F, lymphoid 
aggregate/follicle. HEV, high endothelial venule. P < 0.05 was considered significant. 
Correlation analyses was performed using the Pearson method.     
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Figure 3.14 HEVs are associated with lymphocyte numbers at the tumour invasive 
margin. CD3+ T cells were enumerated per 10 high power fields of view and averaged. 
Such counts were performed separately within the tumour centre and by the tumour invasive 
margin as indicated in A. CD3+ T cells counts were associated with the number of HEVs 
found at the extra-tumoural area (B) and according to different disease stages (C). HEV, 
high endothelial venule. P < 0.05 was considered significant. Correlation analyses were 
performed using the Pearson method. The space between the solid and dashed black line in 
figure A corresponds to the area where the CD3+ T cells were enumerated for the tumour 
invasive margin counts. CD3+ cells were enumerated by Dr Emma Jones prior to my arrival.  
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Figure 3.15 HEV density has no influence on the type of T cells accumulating by the 
tumour invasive margin. HEV density at the extra-tumoural area was divided into high and 
low according to the geometric median (A). T cell ratios at the tumour invasive margin of 
HEV low and HEV high tumours in patients that survived more than five years  post 
colectomy (B) and patients that did not survive five years post surgery (C). Conventional T 
cells (Tcon) were considered to be CD4+ and CD8+ T cells combined but excluding FoxP3+ T 
cells. HEV, high endothelial venule. P < 0.05 was considered significant. The Mann-Whitney 
statistical test was used in B and C for comparison of HEV low and HEV high samples. T 
cells were enumerated by Dr Emma Jones prior to my arrival.  
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As HEV density correlates with T cell infiltration at the tumour invasive 
margin and MSI tumours are often enriched with T cells I examined whether 
the presence of elevated numbers of HEV was associated with microsatellite 
instability. In order to understand if elevated numbers of HEV were linked to 
the microsatellite status of the tumour, the samples with the highest HEV 
density within the extra-tumoural area and within the tumour centre for Dukes’ 
A and Dukes’ C were tested for microsatellite instability (For more details on 
how this analysis was performed please refer to the material and methods 
section). Only a small number of Dukes’ A and C tumour samples were 
tested due to the inability to extract usable DNA from most tumours. 
All the samples (including Dukes’ A and Dukes’ C stage tumours) tested 
negative for microsatellite instability (Table 3.1). This was observed in 
tumours that had elevated numbers of HEVs both within the extra-tumoural 
area and within the tumour centre.  
To ascertain that MSI does not drive neogenesis of HEV, four MSI+ tumours 
were subsequently obtained from the University Hospital of Wales archives 
and analysed for the presence of HEVs and lymphoid aggregates/follicles. 
After analysing the number of HEVs and lymphoid aggregates/follicles within 
MSI+ tumours, no striking differences were noted in comparison with the MSI- 
tumours. Non-HEV associated MECA-79 binding within the tumour glands 
was observed in 3 of the 4 MSI+ tumours, and no staining was observed in 
the fourth sample. No evidence of lymphoid aggregates/follicles or HEVs was 
found in 2 of the MSI+ samples (Figure 3.16A). 
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Table 3.1 Colorectal tumours with elevated numbers of HEVs are microsatellite stable. 
Microsatellite status for Dukes’ A and C in tumors with the highest density of HEVs in the 
extra-tumoral area and in tumors with HEVs within the tumor centre. Not all the samples 
tested were usable for MSI testing due to the poor DNA quality. MSS, microsatellite stable.  
 
 
The other two MSI+ tumours that contained lymphoid aggregates/follicles 
followed the pattern observed in MSI- tumours’ pattern i.e. they were located 
within the extra-tumoural area (Figure 3.16B). No HEVs were found within 
the tumour mass (tumour epithelium/stroma) as reported for MSI- tumours 
above suggesting that microsatellite instability is not associated with elevated 
HEV numbers. 
3.6 Lymphoid aggregates are associated with advanced 
disease 
HEVs within the tumour have been associated with a favourable prognosis in 
patients with breast cancer and the same has also been observed in 
fibrosarcoma models of tumour development. This positive association 
seems to be dependent on T cell infiltration into the tumour. 
 Dukes’ A Dukes’ C 
Microsatellite status in tumours 
with the highest HEV density within 
the extra-tumoural area 
MSS (n=3) MSS (n=4) 
Microsatellite status in tumours 
with HEVs within the tumour center 
MSS (n=2) MSS (n=3) 
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Figure 3.16 The location and pattern of expression of PNAds and lymphoid 
aggregates/follicles in MSI tumours is similar to MSS tumours. Four formalin-fixed 
paraffin embedded colorectal tumour samples known to be microsatellite instable were 
acquired from the NHS archives and stained with MECA-79, CD3 and CD20 antibodies. 
Grey represents HEVs, brown represents CD3+ cells and pink represents CD20+ cells. HEV, 
high endothelial venule. A and B represent examples of different microsatellite instable 
tumours.  
 
 
A 
B 
Lymphoid aggregates/
follicles 
Tumour centre 
Extra-tumoural area 
Extra-tumoural area 
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As an association between T cell infiltration and HEV density has been 
observed in more advanced disease (Figure 3.14C) the relationship between 
disease progression and HEV and/or lymphoid aggregates/follicles density 
was also determined. No significant difference between HEV density and 
disease progression or patient survival (Dukes’ A: tumour confined to the 
wall of the bowel, Dukes’ C: spread to adjacent lymph nodes) was observed 
(Figure 3.17A and B). Conversely, there was a significant increase in 
lymphoid aggregates/ follicles in more advanced disease (Figure 3.18A: 
Dukes’ A vs C, p = 0.015. Median number of lymphoid A/ F in Dukes’ A 
tumours: 0.025, interquartile range 0.006 - 0.098. Median number of 
lymphoid A/ F in Dukes’ C tumours: 0.085, interquartile range: 0.039 - 0.179). 
Even though more lymphoid aggregate/follicles are present in more 
advanced disease, their sizes do not reflect disease progression (Figure 
3.18B).    
3.7 Lymphocytic aggregates are not associated with patient 
prognosis 
A greater number of lymphocytic aggregates/follicles was detected in 
patients with more advanced disease, however their association with survival 
was still unknown. I next sought to determine if the presence of these 
structures were associated with a poor outcome. For the purpose of this 
analysis only patients with more advanced disease (Dukes’ C) were 
considered because the great majority of Dukes’ A patients survived five 
years post surgery.  
 121 
 
 
 
Figure 3.17 HEV density does not reflect disease progression or patient prognosis in 
colorectal cancer. HEV density was calculated by the extra-tumoural area and analysed 
according to disease progression (A) or five-year survival (B). P < 0.05 was considered 
significant. The Mann-Whitney statistical test was used to compare different groups.  
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Figure 3.18 Lymphoid aggregate/follicle density but not size reflect disease 
progression. Lymphoid aggregate/follicle density (A) or area (B) was calculated by the 
extra-tumoural area and analysed according to disease progression. P < 0.05 was 
considered significant. The Mann-Whitney statistical test was used to compare different 
groups.  
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Patients with more advanced disease were then divided into two groups 
according to their five year survival after colectomy and the density of 
lymphoid aggregates/follicles evaluated.    
When both survival groups were compared for lymphoid aggregates/follicles 
density, no significant difference was observed in the extra-tumoural area. 
These data suggest that presence or absence of HEVs and / or lymphoid 
aggregates/follicles is not associated with prognosis in patients with Dukes’ 
C tumours (Figure 3.17 and 3.19). 
3.8 Discussion 
This study focused on the identification of HEVs and their surrounding 
microenvironment in the context of CRC. HEVs were primarily identified 
within the extra-tumoural area but not in the tumour centre characterised by 
the tumour epithelium and stroma. Moreover, these venules were 
predominantly detected in association with T and B cells forming lymphocytic 
aggregates/follicles, in agreement with an active role for these structures in 
lymphocyte recruitment (Di Caro et al., 2014; Martinet et al., 2012). The 
density of these lymphoid follicles/aggregates in the extra-tumoural area is 
associated with a more advanced disease. Additionally, HEVs were found to 
correlate with T cell infiltration at the tumour invasive margin but only in more 
advanced stages of disease. TILs play an important role in controlling tumour 
development and growth and also development of metastasis. Numerous 
studies to date have shown a direct correlation between TILs and better 
clinical outcome (Galon, 2006; Pagès et al., 2005). Thus, as imperative 
players in tumour growth control the route of TILs entry into the tumour 
microenvironment is as important as density. 
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Figure 3.19 Lymphoid aggregate/follicle density/size does not predict patient survival 
in more advanced disease. Lymphoid aggregate/follicle density (A) or area (B) was 
calculated by the extra-tumoural area and analysed according to five year survival in Dukes’ 
C patients. P < 0.05 was considered significant. The Mann-Whitney statistical test was used 
to compare different groups.  
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HEVs express post-translational modified sialomucins which serve as ligands 
for L-selectin expressed on naïve and central memory T cells thus allowing 
their infiltration in SLO (Girard et al., 2012; Hayasaka et al., 2010). It was 
initially hypothesised that HEVs within the tumour microenvironment could 
play a similar role allowing the infiltration of more lymphocytes into the 
tumour. Therefore, the presence of HEVs in CRC was investigated to assess 
their role in this malignancy. 
The presence of HEVs in CRC does not appear to be associated with a 
longer survival. On the contrary, even though not significant, a trend for more 
HEVs is observed in patients that died within five years of tumour resection 
compared to patients that survived longer than five years post colectomy. 
Such tendency is not observed when comparing Dukes’ A and Dukes’ C 
patients, the two groups where most correlations were observed in this thesis.  
The findings described herein are different from those of Martinet et al. 
(Martinet et al., 2011). The latter studies of melanoma and breast cancer 
identified HEVs within the tumour epithelium and tumour stroma and their 
density correlated with T cell infiltration and tumour control. However, in the 
present study the great majority of HEVs were identified within the extra-
tumoural area which, albeit part of the tumour microenvironment, is not within 
the tumour centre where lymphocytes would most likely control tumour 
growth. Furthermore, as shown in Figure 3.14B, HEVs located within the 
extra-tumoural area appear to have little effect on the number of T cells 
infiltrating the centre of the tumour. Such observations suggest that HEVs 
located within the extra-tumoral area do not affect T cell infiltration and thus 
are not able to potentiate effective tumour growth control.   
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It could be the case that de novo formation of HEVs within the tumour mass 
is hindered by immunosuppressive mechanisms. This idea is supported by 
the fact that HEV formation in a mouse model of carcinogen-induced 
fibrosarcoma only occurs after depletion of Tregs (Hindley et al., 2012). This 
raises the interesting possibility that Tregs or perhaps other 
immunosuppressive mechanisms including myeloid derived suppressive 
cells present within CRCs actively inhibit HEV neogenesis limiting the extent 
of lymphocyte infiltration into the tumour.  
It is known that patients with inflammatory bowel diseases have a higher 
predisposition to CRC (Dyson, 2012; Karvellas et al., 2007) indicating that 
excessive inflammation may be disadvantageous for patient outcome. Th17 
cells appear to have a pathogenic role in colorectal cancer (Tosolini et al., 
2011), especially in advanced disease (Omrane et al., 2014). Tosolini et al. 
reported a poorer prognosis for patients with tumours exhibiting Th1-low 
Th17-high gene expression signatures (Tosolini et al., 2011). Even patients 
with tumours displaying Th1-high gene signature demonstrated a poor 
prognosis if this was accompanied by a Th17-high gene signature thereby 
demonstrating that the poor outcome associated with a Th17-high signature 
over-rides the beneficial effects of a Th1 high gene signature. Thus having 
elevated numbers of HEVs in colorectal cancer, allowing greater T cell 
infiltration could be detrimental for patient prognosis depending on the T cell 
subset being recruited. If the tumour antigen and cytokine milieu elicits a Th1 
response with increased production of Interferon-γ like observed by Martinet 
et al., having a greater number of HEVs would be beneficial for the patient. 
On the contrary, if a Th17 response is predominantly developed, IL-17A 
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could support cell survival, proliferation and promotion of VEGF formation by 
the tumour cells stimulating tumour growth. 
The present data suggests that HEVs may not be functional at the early 
stages of disease as no correlation is observed between CD3+ T cells and 
HEVs in Dukes’ A patients (Figure 3.14) possibly lacking enough stimuli to 
attract T cells. It was also noted that HEVs influence T cell infiltration in the 
extra tumoural area but not in the tumour centre implying that HEVs only 
have an effect in T cell infiltration in very close proximity but not at distant 
sites. For the exceptional cases where HEVs were found in the tumour mass, 
they did not exhibit their characteristic cuboidal shape implying poor function, 
hence explaining their lack of association with lymphocytic infiltration. Avram 
et al., have also reported cuboidal but not flat HEVs to be surrounded by 
lymphocytes (Avram et al., 2013). 
In a study carried out by Avram et al. an association between the level of 
HEV expression and lymphocytic infiltration was observed. The group 
enumerated HEVs in a similar manner to the present study and calculated 
the HEV density per mm2. They also divided HEVs into venules with a 
cuboidal and flat morphology and a stronger association with lymphocytes 
was observed in the venules with a cuboidal morphology (Avram et al., 2013). 
In the present study HEVs detected within the extra-tumoural area (the great 
majority of them) were always associated with a concentration of B and T 
cells. This pattern of HEV expression is similar to what is observed in 
melanoma metastases and lung cancer where HEVs were also identified 
surrounded by lymphocytes and never in other tumour sites (Cipponi et al., 
2012; de Chaisemartin et al., 2011).  
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In order to understand the relevance of this finding, normal colon was also 
stained for the presence of HEVs, B and T cells. In healthy colon HEVs were 
only found, as expected, in the well-organised gut associated lymphoid 
tissues (GALT), and not in the mucosa and submucosa part of the large 
intestine. In colonic homeostatic conditions lymphocytes aggregate at the 
bottom of the crypts forming a characteristic structure with B/T cells 
compartmentalisation also observed in this study (Bergomas et al., 2012).  
Lymphoid aggregates/follicles were not detected in normal colon in contrast 
to CRC. Such an observation suggests that the constant presence of tumour 
antigens drives the initiation of a local immune response and the de novo 
formation of these structures creating a local inflammatory microenvironment, 
which, as mentioned before, may promote tumour growth.  
Increased concentration of lymphoid aggregates/follicles within the extra-
tumoural area correlates with HEV density and CD3 infiltration at the tumour 
invasive margin increases with the presence of HEVs. Thus, suggesting that 
alongside the presence of lymphoid aggregates/follicles, HEVs may also play 
a role in the recruitment of T cells into the tumour microenvironment. 
However, in the present study, unlike HEVs, lymphoid aggregates/follicles 
appear to be associated with more advanced disease. This suggests that 
lymphoid aggregates/follicles density may be a better indicator of disease 
progression in CRC than HEVs density. In gastric biopsies lymphoid 
aggregates are detected in association with Helicobacter pylori infection and 
strikingly when the infection clears the lymphoid aggregates also dissolve 
reflecting the clearance of the infection (Genta and Hamner, 1994; Genta et 
al., 1993). 
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In the majority of cases formation of lymphoid aggregates/follicles in CRC 
does not produce follicles with clearly distinct B/T cell areas suggesting that 
ectopic lymphoid structures are at their initial stages, similar to what has 
been reported by Cipponi et al. (Cipponi et al., 2012). The presence of 
ectopic lymphoid structures has been reported in cases of chronic infection 
with Helicobacter pylori, chronic graft rejection, ulcerative colitis but also in 
several autoimmune conditions such as rheumatoid arthritis and Hashimoto’s 
thyroiditis (Aloisi and Pujol-Borrell, 2006; Thaunat et al., 2010). In a model of 
influenza infection Moyron-Quiroz and colleagues demonstrated that such 
structures can aid the development of humoural and cellular immune 
responses resembling the function of a secondary lymphoid organ (Moyron-
Quiroz et al., 2004).  
After analysing all the lymphoid aggregates/follicles it was clear that their 
neogenesis predisposes HEV formation as HEVs were always found within 
these structures but these structures were also present without HEVs. The 
organisational level of the lymphoid aggregate/follicle does not appear to be 
relevant for HEV formation, as HEVs appear to form in less well-organised 
aggregates but also in those that are well organised. 
Interestingly, de Chaisemartin et al. have previously shown that these 
lymphoid structures are functionally active in lung cancer. T cells in these 
structures express CD62L unlike the ones present anywhere else in the 
tumour. The expression of lymphoid chemoattractants like CCL19, CCL21 
and CXCL13 was also increased in these structures compared with tumour 
islets (de Chaisemartin et al., 2011). These findings are consistent with a role 
for these structures in actively recruiting naïve and central memory T cells 
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into the tumour microenvironment. The presence of newly formed ectopic 
structures within lung cancer is associated with a favourable prognosis 
(Dieu-Nosjean et al., 2008). A more detailed characterisation of the type of T 
cells populating these ectopic structures would be of utmost interest. 
Understanding the T cell receptor repertoire within these in comparison to 
TILs would also contribute to an understanding of the type of local response 
being generated within such tissues. This would allow us to understand if the 
specificity of the TILs overlaps in any way with the specificity of the T cells 
infiltrating/forming the follicles/aggregates. This information would help 
understand if clonal expansion of antigen-specific T cells is taking place 
within these T cell aggregates. 
Additionally, a key point to address is the state of activation of such 
structures aiming to understand if their development is promoting or 
hindering tumour development. Each individual follicle/aggregate could be 
studied by laser capture microdissection (LCM) allowing RNA extraction from 
individual structures. Analysing individual structures for exhaustion 
associated markers such as PD-1, LAG-3, CD122, TIM-3 and CTLA-4 
amongst others, in different disease stages would provide valuable clues on 
whether these structures are functionally active or not. Additionally, 
functional diversity could be assessed through analysis of transcription 
factors such as T-bet, RORγt and Foxp3, used to identify different T cell 
subsets e.g. Th1, Th17 and Treg, respectively. 
Interestingly, in a study performed by Di Caro et al. the presence of lymphoid 
aggregates was associated with a longer disease free survival for stage II 
CRCs, but this was only observed for tumours without any node involvement 
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(Di Caro et al., 2014). For stage III tumours however no association with 
disease free survival and ectopic structures was noted in agreement with the 
study described herein.  
Elevated levels of Crohn’s like reaction which can be perceived as a high 
level of lymphocytic infiltration has also been reported in less advanced 
disease and microsatellite instable tumours (Väyrynen et al., 2013).  
Collectively these data raise the interesting possibility that the composition of 
these lymphoid aggregates, and therefore their prognostic significance, alters 
with disease progression and according to the inherent immunogenicity of 
the tumour. With this in mind, studies to evaluate T cell activation signals and 
T cell signatures within these ectopic structures at different disease stages 
are necessary. 
In conclusion, this study of CRC-associated HEVs and lymphoid 
aggregate/follicle formation revealed that these ectopic structures rarely form 
in tumors, but accumulate in locations close to the tumor invasive margin. 
These structures form in association with more advanced tumors, suggesting 
they are a reaction to continuous tumor invasion. 
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4 Carcinoembryonic antigen (CEA)-
specific Th1 and Th17 responses in 
colorectal cancer patients 
4.1 Introduction 
Carcinoembryonic antigen (CEA) is a tumour associated antigen that is 
overexpressed on the surface of CRC but its presence, albeit at lower levels, 
is also detected on the surface of healthy bowel (Davidson et al., 1989). 
Thus CEA falls into the “overexpressed in cancer” category of tumour 
antigens. Tumour associated antigens (TAAs) can be degraded into peptides 
which are expressed on the surface of tumour cells in the context of MHCI or 
MHCII complexes.  
IFN-γ-producing T cells specific to TAA have been associated with a better 
prognosis in melanoma patients (Hunder et al., 2008). CD4+ T cell clones 
specific to the melanoma-associated cancer testis antigen (NY-ESO-1) were 
infused into a melanoma patient which completely cleared the disease within 
two months and continued a disease-free recovery for another twenty six 
months at the time of the latest follow-up (Hunder et al., 2008). Before 
infusion, the NY-ESO-1 specific CD4+ T cells were shown to produce IFN-γ 
and IL-2 in vitro (Hunder et al., 2008). In melanoma patients with distant 
metastasis the detection of a MAGE-3 and/or NY-ESO-1 IFN-γ specific 
response was associated with an overall better survival than patients without 
an IFN-γ response (Weide et al., 2012). 
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In order to understand the association between CEA-specific responses and 
patient survival, members of the laboratory in Cardiff previously measured 
the IFN-γ T-cell preoperative responses specific to CEA in peripheral blood 
of a cohort of ~60 colorectal cancer CRC patients. To their surprise, and 
considering the previous type of studies and results eluded to above, they 
observed a statistically significant superior risk of tumour recurrence in 
patients with pre-operative IFN-γ T-cell response to CEA (Figure 4.1A) but 
not to other antigens (oncofetal tumour antigen 5T4, haemagglutinin (HA), 
tuberculin purified protein derivative (PPD)) (Scurr et al., 2015). Even after 
patient stratification according to tumour stage, patients with early stage 
cancer (Dukes’ A), but demonstrating IFN-γ T cell responses to CEA were 
still at greater risk of tumour recurrence, than patients with late-stage disease 
where a CEA response was absent (Figure 4.1B).  
This unexpected observation led me to question why CEA-specific T-cells 
are associated with a detrimental outcome.  
 
Th17 cells are often observed in the tumour microenvironment and have 
been associated with a poor prognosis in CRC: the detrimental effects of 
Th17 cells were shown to overcome the benefit of an IFN-γ producing T cell 
response (Tosolini et al., 2011). One possible explanation is that IL-17A 
production occurs simultaneously with IFN-γ secretion by the same CEA-
specific T cells and neutralises the protective effects of IFN-γ expression, 
favouring tumour growth. IL-17A is thought to promote tumour growth by 
induction of angiogenic factors such as VEGF and PGE2 but also directly via 
STAT3 activation.  
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Figure 4.1 CRC patients that develop an IFN-γ  response specific to CEA are at a 
greater risk of tumour recurrence. PBMCs from CRC patients were obtained before 
surgery and T cell responses to CEA were measured by ex-vivo IFN-γ ELISpot and 
compared with tumour recurrence before (A) and after (B) stratifying the patients into tumour 
stage. CEA, Carcinoembryonic antigen. P < 0.05 was considered significant. All statistically 
tests were two-sided. These data was kindly provided by Dr Gareth Betts and analysed by 
Dr Martin Scurr (Scurr et al. 2015). 
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This Chapter describes the optimisation of IL-17A detection, and the 
transition from ELISpot to FluoroSpot methodology in our laboratory, 
enabling accurate measurements of the concurrent production of IFN-γ and 
IL-17A from the same CEA-specific T cell. Additionally, the prevalence of 
IFN-γ +/- IL-17A T-cell responses specific for CEA in the peripheral blood of 
a second cohort of CRC patients will be described. 
4.2 Enumeration of Th1 and Th17 cells in the tumour of CRC 
patients 
I gained access to five and seven blocks of formalin fixed paraffin embedded 
tumour samples from CEA responders and non-responders, respectively, 
and performed immunohistochemistry staining in order to assess the 
prevalence of Th17 cells. In order to enumerate Th1 and Th17 cells in the 
primary tumour I stained cells using CD3 (surface marker for T cells) and the 
transcription factors T-bet and RORγt (transcription factors for Th1 and Th17 
respectively). An example of Th1 and Th17 staining is shown in Figures 4.2 
A and B, respectively. In order to stain with RORγt and T-bet antibodies the 
sections were submitted to different antigen retrieval methods. Therefore it 
was not possible to enumerate Th1 and Th17 within the same section and 
sequential sections were used instead. In order to calculate the number of 
Th1 and Th17 infiltrating the tissues 10 high power fields of view were 
enumerated and the mean calculated. Most surprisingly I observed a much 
higher number of Th17 cells compared to Th1 cells in both CEA responders 
and non-responders (Figure 4.2). Even though not significant there were 
more Th17 cells in the CEA responders compared to non-responders, and 
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these preliminary data supported the testing of IL-17A-producing CEA-
specific T cells in the blood of CRC patients in a new cohort of patients. 
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Figure 4.2 Enumeration of Th1 and Th17 cells in the primary tumour of CEA 
responders and non-responders. Colorectal tumor sections were stained with anti-CD3, 
anti-T-bet and anti-ROR-γt antibodies. Representative images from (A) CD3+ (Grey) / T-bet+ 
(Brown), and (B) CD3+ (Grey) / RORγt+ (Brown) T cells, with examples of counted cells 
shown by blue arrows. Th1 (CD3+T-bet+) and Th17 (CD3+ROR-γt+) cells were enumerated in 
CEA responders (n=5) and non-responders (n=7) (C), and the Th17: Th1 ratio determined 
(D). (E) and (F) show the Th1 (E) and Th17 (F) cell numbers in CEA responders and non-
responders. One high power field of view is equivalent to 600x magnification. The result of 
an unpaired, two-sided t-test to compare the two groups is shown. NS, not significant. 
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4.3 Optimisation of Th17 cell culture and IL-17 detection 
4.3.1 Stimulation of PBMCs with Candida Albicans (CA), 
Phytohaemagglutinin (PHA) and tuberculin protein purified 
derivative (PPD) 
The ELISpot assay is routinely used in our laboratory to measure IFN-γ 
responses specific to tumour antigens, thus the initial cell number and 
appropriate cytokine concentration necessary to feed the cells for a period of 
12-14 days has been previously optimised. In order to establish a 
methodology for the consistent detection of IL-17A by ELISpot a set of 
parameters needed to be tested including 1) which antigen to use as a 
robust positive control 2) the minimum cell number to use in order to detect a 
consistent response and 3) the ideal cytokine combination necessary to 
expand the cells and support cell growth. 
Candida albicans (CA) is a human host pathogen that is recognised by the 
innate immune system via pattern recognition receptors (PRR) on APCs. 
This initial encounter leads to the secretion of cytokines such as IL-1β, IL-6 
and IL-23 by APCs, which are key cytokines for the development of Th17 
cells (Figure 1.2). Exposure to these cytokines in combination with TCR 
engagement promotes the commitment of a CD4+ T cell to a Th17 lineage 
which in turns secretes IL-17A, IL-17F and IL-22 (Hernández-Santos and 
Gaffen, 2012). Moreover, stimulation of PBMCs with heat-inactivated, but not 
live CA triggers the secretion of IL-17A (Hernández-Santos and Gaffen, 
2012). CA in its heat-inactivated format was then chosen as the ideal 
candidate to test IL-17A secretion from PBMCs. Zielinski et al. also used CA 
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and S. aureus to pulse autologous monocytes and observed the presence of 
antigen-specific proliferating T cells that secreted IL-17 and IL-22 after 12 
days of culture (Zielinski et al., 2012). These cells could not be detected 
when MHC antibodies class II blocking antibodies were included in the 
cultures suggesting the development of a class II-restricted CD4+ T cell 
response (Zielinski et al., 2012).  
In order to detect IL-17A secretion, it was necessary to expand the cells for 
11-14 days until their frequency was high enough to be detected by ELISpot.  
IL-2 is known to be essential for T cell differentiation, proliferation, expansion 
and survival. It is therefore regularly used to maintain T cell growth after 
antigen stimulation in combination with CellKine (CK) media in our laboratory.  
Even though T cell lines are routinely cultured in our laboratory for the 
detection of antigen-specific IFN-γ secreting T cells, the maintenance of cell 
lines to detect and support IL-17A secretion was new.  
IL-23 has initially been suggested as one of the necessary cytokines for 
Th17 development but it has been later understood that even though IL-23 
has a role in maintenance and expansion of already differentiated Th17 cells 
it is not capable of driving naïve T cells into a Th17 lineage commitment 
(Aggarwal et al., 2003; Stockinger and Veldhoen, 2007).  
In order to understand what optimal in vitro conditions should be used to 
generate and maintain a Th17 response after CA stimulation four different 
conditions including different combinations of IL-2, IL-23 and CK media were 
tested (Figure 4.3). 
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Figure 4.3 Combinations of CK media, IL-2 and IL-23 used to expand the cell lines for 
11 days. 2 x 105 PBMCs were used on day 0 to set up the cell lines. Numbers in the top row 
indicate days. R5, RPMI 1640 with 5% AB serum. CK media, CellKine. IL-2, interleukin-2 
(20U/mL). IL-23, interleukin-23 (20ng/mL). 
 
 
Freshly isolated PBMCs from the same donor were stimulated with PHA, 
PPD, two different concentrations of CA or left unstimulated. The cells were 
then expanded by addition of different growth factors as shown in Figure 4.3. 
IL-17A could be readily detected after addition of PHA under every condition 
but condition 4 generated a high response of 14 IL-17A spots per 105 
cultured PBMCs without antigen stimulation which indicated a possible non-
specific activation of the cells with such growth factors (Figure 4.4). Apart 
from PHA stimulation, no responses could be observed with condition 2 
which excluded IL-2 indicating that this cytokine is indispensible for cell 
growth and survival. Even though IL-17A could also be detected with CA 
stimulation in all the conditions except condition 2, the responses were weak. 
Moreover, although condition 4 supported the growth and maintenance of IL-
17A secreting cells the detection of such cells in absence of re-stimulation on 
day eleven indicated antigen-non-specific expansion of the cells.  
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Figure 4.4 IL-17A secretion can be detected after PBMCs stimulation with Candida 
albicans for 11 days. Freshly isolated PBMCs were assessed for their IL-17A production 
after stimulation with phytohaemagglutinin (PHA), tuberculin protein purified derivative 
(PPD) and different concentrations of Candida albicans, cultured for 11 days in condition 1 
(A), condition 2 (B), condition 3 (C) and condition 4 (D) as shown in figure 4.3 and re-
stimulated with the respective antigens.     
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The same experiment was repeated using a different donor. This time, the 
input number of cells was increased: 5 x 105 PBMCs/test were used instead 
of 2 x 105 PBMCs/test to set up the cell lines. The culture time was also 
prolonged to increase the chance of expanding the relevant cells as shown 
in Figure 4.5. 
  
 
Figure 4.5 Combinations of CK media, IL-2 and IL-23 used to expand the cell lines for 
13 days. 5 x 105 PBMCs were used on day 0 to set up the cell lines. Numbers in the top row 
indicate days. R5, RPMI 1640 with 5% AB serum. CK media, CellKine. IL-2, interleukin-2 
(20U/mL). IL-23, interleukin-23 (20ng/mL). 
 
 
Increasing the number of PBMCs used to set up the cell lines in addition to a 
longer culture period (13 days) led to the detection of more robust IL-17A 
responses (Figure 4.6). All conditions except 2 supported IL-17A-secreting 
cells expansion. Based on this observation and the fact that CA : PBMCs 1:4 
ratio was still producing some antigen-unspecific IL-17A secretion with 
conditions 3 and 4 it was decided to carry on further experiments with the 
ratio of 1 CA to 14 PBMCs. After comparison of IL-17A secretion by the lines 
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grown for 11 and 13 days it was also clear that condition 2 was not 
supporting a consistent cell growth. In order to ascertain that 11 days of cell 
expansion was not enough to generate a robust IL-17A secretion after 
stimulation with CA, a third donor was tested. Freshly isolated PBMCs were 
stimulated with CA : PBMCs on a ratio of 1:14 and detection of IL-17A was 
measured after 11 days of expansion (Figure 4.7). According to the previous 
results, IL-2 seemed to be absolutely necessary for cell survival; therefore 
conditions 2 and 4 were abandoned. Figure 4.7A and 4.7B represents the 
response observed after 11 days of expansion using R5 and IL-2 and R5+IL-
2+IL-23 to feed cells every 3 days, respectively. It was therefore clear that 
even though weak usage of IL-2 with or without IL-23 to expand the cells 
generated an IL-17A response. Such response was greater when IL-23 was 
absent from the culture (Figure 4.7).  
Therefore it was decided to expand cells for at least 13 days using condition 
1 (Figure 4.5) in order to be able to detect IL-17A responses. Besides, as 
quantification of IFN-γ secretion from the same cells would be the ultimate 
goal, condition 1 seemed ideal as it was routinely used in the laboratory to 
expand and maintain IFN-γ secreting cell lines.  
4.3.2 Detection of ex vivo and cultured IFN-γ  and IL-17A responses 
specific to CEA by ELISpot in CRC patients using two 
commercially available CEA proteins 
In order to test whether IL-17A responses specific to CEA could be detected 
in the blood of CRC patients I examined the frequency of antigen-specific IL-
17A secreting cells directly ex vivo and after culture.  
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Figure 4.6 IL-17A secretion can be readily and robustly detected after PBMCs 
stimulation with Candida albicans for 13 days. Freshly isolated PBMCs were assessed 
for their IL-17A production after stimulation with phytohaemagglutinin (PHA), tuberculin 
protein purified derivative (PPD) and different concentrations of Candida albicans (CA), 
cultured for 13 days in condition 1 (A), condition 2 (B), condition 3 (C) and condition 4 (D) 
and re-stimulated with the respective antigens. 
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Figure 4.7 Expansion of PBMCs for 11 days generates a weak IL-17A response after 
stimulation with C. albicans. 5 x 105 freshly isolated PBMCs were assessed for their IL-
17A production after stimulation with phytohaemagglutinin (PHA) and Candida albicans, 
cultured for 11 days in R5 with IL-2 (A) or R5 with IL-2 and IL-23 (B) and re-stimulated with 
the respective antigens.     
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Given the results obtained in the previous sections with CA, the expectation 
was that the frequency of IL-17A secreting cells would be too low for ex vivo 
detection. Moreover, because the main objective was to determine whether 
CEA-specific T cells secrete both IFN-γ and IL-17A, CEA-specific IFN-γ 
responses were also measured in parallel.  
Blood was collected from CRC patients on the day of surgery and PBMCs 
isolated immediately after collection. 
Two CEA proteins purchased from Calbiochem and Sigma were tested. 
Calbiochem CEA was derived from a human colon adenocarcinoma cell line; 
Sigma CEA derived from human fluids. 
Four patients were tested with these CEA proteins using both ex vivo and 
cultured assays. No IFN-γ and/or IL-17A response specific to CEA could be 
detected in these patients (representative results from one patient shown in 
Figure 4.8). IFN-γ and IL-17A could be detected in all the experiments either 
after stimulation with PHA or one of the recall antigens indicating that the 
inability to detect CEA-specific responses was not due to assay failure. As 
expected, the frequency of antigen-specific responses is greater after culture 
(Figures 4.8A vs 4.8B for IFN-γ; Figure 4.8C vs Fig 4D for IL-17A). An IL-17A 
response specific to PPD was detected in patient DCB12 after culture 
(Figure 4.9). No response was detected prior to culture indicating that even 
though cells specific to PPD were initially present, their frequency was too 
low to be measured by the assay. This shows that cycles of in vitro 
restimulation can successfully expand antigen-specific IL-17A secreting cells 
to a measurable number. 
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Figure 4.8 IFN-γ and IL-17A ex vivo and cultured responses specific to CEA and recall 
antigens in a representative patient. When possible, responses were measured in 
duplicate by ELISpot. (A) IFN-γ secreting cells per 105 PBMCs measured ex vivo or (B) after 
culture. (C) IL-17A secreting cells per 105 PBMCs measured ex vivo or (D) after culture. 
Data shown in A, C and D are means of duplicate measurements ± SEM. CEA C., 
carcinoembryonic antigen from Calbiochem. CEA S., carcinoembryonic antigen from Sigma-
Aldrich. TT, tetanus toxoid. HA, haemagglutinin. PPD, tuberculin purified protein derivative. 
PHA, phytohaemagglutinin. 
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Figure 4.9 The magnitude of IL-17A cultured responses is greater than ex vivo 
responses. Patient DCB12 IL-17A responses were measured in duplicate by ELISpot. (A) 
IL-17A secreting cells per 105 PBMCs measured ex vivo or (B) after culture. Data shown are 
means of duplicate measurements ± SEM. CEA C., carcinoembryonic antigen from 
Calbiochem. CEA S., carcinoembryonic antigen from Sigma-Aldrich. TT, tetanus toxoid. HA, 
haemagglutinin. PPD, tuberculin purified protein derivative. PHA, phytohaemagglutinin.               
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4.3.3 Detection of CEA-specific IL-17A and IFN-γ ex vivo responses by 
ELISpot before and after Treg depletion in CRC patients using a 
commercial available CEA protein 
Our group has previously described that Treg depletion can augment or 
unmask a tumour-antigen specific T cell response to 5T4, in CRC patients 
(Clarke et al., 2006). The same suppression, albeit to a lesser extent, was 
also observed for CEA-specific responses (Betts et al., 2012). The lack of 
detectable CEA-specific responses outlined above may be due to 
suppression by Tregs known to present at high numbers in the blood of CRC 
patients.  
In order to test if Treg cells were suppressing CEA-specific conventional 
responses, MACS CD25-microbeads were used to deplete the CD25hi 
population from PBMCs of six patients. Patient samples were analysed by 
flow cytometry before and after Treg depletion in order to ascertain the 
successful depletion of CD25hi cells (representative FACS plot Figure 4.10). 
As confirmed by flow cytometric analysis the proportion of CD25hi cells was 
significantly reduced after depletion of the CD25hi fraction by microbeads. In 
the example shown in Figure 4.10 the percentage of CD4+CD25hi cells 
changed from 8.25% to 0.51%. The expression of Foxp3 in the CD4+ T cell 
population confirmed that depletion of CD25hi cells was reflected by 
depletion of Foxp3+ cells. Removal of CD25hi cells resulted in a decrease in 
the percentage of CD4+Foxp3+ from 7.07% to 1.4%. 
 150 
 
Figure 4.10 Confirmation of Treg depletion by flow cytometry. The whole PBMC fraction 
was incubated with MACS CD25 microbeads followed by magnetic selection and depletion 
of CD25+ cells. (A) Gating strategy for identification of regulatory T cells. Lymphocytes were 
identified based on size (FSC) and granularity (SSC) followed by selection of live cells. From 
the live cells the CD4+ population was divided into CD25-, CD25int and CD25hi based on the 
maximum expression of CD25 on the CD4- population indicated by the dashed line. (B) 
Analysis of CD25 and FOXP3 expression on CD4+ cells before and Treg depletion. (C) 
Analysis of CD25 and FOXP3 expression on CD4+ cells after Treg depletion. SSC, side 
scatter. FSC, forward scatter. Treg, regulatory T cell. Hi, high. Int, intermediate.         
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The pattern of IFN-γ and IL-17A responses before and after Treg depletion is 
shown for a representative patient (DCB18, Figure 4.11). As shown in Figure 
4.11 and for all the six patients studied, IFN-γ and IL-17A responses specific 
to HA and PPD were observed before and after Treg depletion indicating that 
these responses were not completely suppressed by Tregs. The HA-specific 
IL-17A response did increase after Treg depletion, indicating that Tregs may 
limit this response, at least partially. Removal of Tregs did not however result 
in detection of either IFN-γ- nor IL-17A- producing CEA-specific T cells.  
4.3.4 Detection of CEA-specific IL-17A and IFN-γ cultured responses 
by ELISpot before and after Treg depletion in CRC patients 
comparing CEA proteins to CEA peptide pools 
The results using whole commercial CEA proteins had proven disappointing 
in my preliminary experiments.  
As well as the CEA proteins described above, I now also used two pools of 
overlapping (by 10 a.a.) 20-mer peptides spanning the entire CEA protein. 
CEA peptide pool 1 (CEA pp1) ranges from peptide 1 to peptide 35 and CEA 
pool 2 (CEA pp2) ranges from peptide 36 to peptide 70 (for detailed 
information, refer to Section 2.4.4.3). 
The frequency of IFN-γ and IL-17A secretion specific to CEA was examined 
in freshly isolated PBMCs from three CRC patients, tested after ≥13 days of 
culture. Responses were measured before and after depletion of CD25hi 
cells. The data shows that an IFN-γ response specific to CEA could be 
detected using CEA pp1 and CEA pp2 but not the whole proteins (Figure 
4.12A).  
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Figure 4.11 IFN-γ and IL-17A responses specific to CEA are absent before and after 
Treg depletion. IFN-γ and IL-17A responses specific to CEA and recall antigens were 
measured in patient DCB18 by ELISpot before and after depletion of regulatory T cells. (A) 
IFN-γ secreting cells per 106 PBMCs measured ex vivo (B) IL-17A secreting cells per 106 
PBMCs measured ex vivo. Data shown are means of duplicate measurements ± SEM. CEA 
C., carcinoembryonic antigen from Calbiochem. CEA S., carcinoembryonic antigen from 
Sigma-Aldrich. TT, tetanus toxoid. HA, haemagglutinin. PPD, tuberculin purified protein 
derivative. PHA, phytohaemagglutinin. Treg, regulatory T cell. 
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This response could be detected in the presence of CD25hi but not after their 
depletion (Figure 4.12B). Figure 4.12 and 4.13 shows a representative 
example out of the three CRC patients tested and in none of them could a 
response specific to whole CEA be detected. These results suggest that 
peptide pools are able to expand CEA-specific T cells more efficiently than 
whole protein. These CEA-specific responses were robust and detectable in 
the presence of CD25hi T cells indicating that in these cultured assays 
CD25hi T cells (e.g. Treg-rich population) do not appear to play a major role 
in suppression of CEA effector responses. Figure 4.12 C represents an 
example of an ELISpot well where an IFN-γ response specific to CEA pp2 
could be detected. A similar pattern, albeit to a less extent, was observed for 
IL-17A-producing CEA-specific T cells. IFN-γ responses to CEA pp2 were 
detected at a frequency of 925 IFN-γ spots/ 5 x 105 PBMCs compared to 265 
IL-17A spots detected per 5 x 105 PBMCs (Figure 4.13). This shows that 
even though an IL-17A response specific to CEA can be detected in the 
blood of CRC patients its cultured magnitude is much lower than the IFN-γ 
response. As this assay was performed in two separate ELISpot plates, it 
was not possible to determine whether IFN-γ and IL-17A CEA-specific 
responses were being produced by the same cells. 
The absence of an IFN-γ and IL-17A response specific to CEA using CEA 
pp1 and CEA pp2 could be a result of the depletion method used. Even 
though only CD25hi cells are being targeted during this essay some 
effector/activated CD25+ cells are also depleted thus possibly removing the 
CEA-specific population. Tregs can also transdifferentiate into different cell 
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subsets. It is also possible that the antigen-specific responses being 
detected by IFN-γ and IL-17A are a result of Tregs that have acquired a Th1 
and Th17-like phenotypes. Depletion of Tregs could therefore prevent the 
formation of antigen-specific Th1 and Th17 like cells capable of responding 
to the antigen. Nonetheless, the absence of Th17-related cytokines during 
expansion would not support such possibility.   
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Figure 4.12 IFN-γ responses specific to CEA can be detected by ELISpot after 13 days 
of culture using synthetic peptides spanning the entire protein. IFN-γ responses 
specific to CEA and recall antigens were measured in three patients by ELISpot before (A) 
and after (B) depletion of regulatory T cells. Representative example of IFN-γ secreting cells 
per 5 x 105 cultured PBMCs from patient DCB21. (C) ELISpot wells representing a IFN-γ 
CEA-specific response. Data shown are means of duplicate measurements ± SEM. CEA C., 
carcinoembryonic antigen from Calbiochem. CEA S., carcinoembryonic antigen from Sigma-
Aldrich. HA, haemagglutinin. PPD, tuberculin purified protein derivative. PHA, 
phytohaemagglutinin. Treg, regulatory T cell. PP, peptide pool.                
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Figure 4.13 IL-17A responses specific to CEA can be detected by ELISpot after 13 
days of culture using synthetic peptides spanning the entire protein. IL-17A responses 
specific to CEA and recall antigens were measured in three patients by ELISpot before (A) 
and after (B) depletion of regulatory T cells. (C) Representative example of IL-17A secreting 
cells per 5 x 105 cultured PBMCs from patient DCB21 showing a IL-17A CEA-specific 
response. CEA C., carcinoembryonic antigen from Calbiochem. CEA S., carcinoembryonic 
antigen from Sigma-Aldrich. HA, haemagglutinin. PPD, tuberculin purified protein derivative. 
PP1 and PP2, peptide pool 1 and 2. PHA, phytohaemagglutinin. Treg, regulatory T cell. 
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4.3.5 Detection of CEA-specific IL-17A and IFN-γ cultured responses 
by FluoroSpot in CRC patients using CEA proteins and CEA 
peptide pools 
ELISpot technology has been widely used to accurately and reliably measure 
the frequency of cytokine-secreting cells at the single-cell level. The 
FluoroSpot technology is an advance of the ELISpot assay as it allows the 
detection of up to three different cytokines in the same assay and from the 
same cell. This is made possible through use of fluorophore-labeled 
antibodies to differentiate and enumerate up to three analytes at the same 
time (for further information, see Section 2.4.7). I used this technology to 
determine whether T cells, specific for CEA, produced IFN-γ and IL-17A 
concurrently. 
Figures 4.14 – 4.16 show representative examples of patients that generated 
IFN-γ and/or IL-17A responses specific to CEA and 5T4 measured by 
FluoroSpot. Green spots indicate IFN-γ secretion, whereas red spots 
represent IL-17A secretion. Secretion of IFN-γ and IL-17A by the same cell is 
shown in yellow (Figures 4.14 – 4.16).  
Figure 4.17 represents the first patient in which a CEA-specific response 
could be detected. An IFN-γ response specific to CEA pp1 (but not CEA 
proteins) was observed (green spots). An IFN-γ but not IL-17A response 
specific to CEA could be detected in the blood of patient DCB27. In this 
patient, an IFN-γ response was not a surrogate marker for an IL-17A 
response. This was the first time I detected an antigen-specific response 
using the FluoroSpot technology; similarly to ELISpot, FluoroSpot was also 
able to determine the magnitude of low frequency responses.  
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Figure 4.14 Examples of IFN-γ and IL-17A secretion after stimulation with CEA peptide 
pools. 5 x 105 PBMCs were stimulated with the indicated peptides, expanded for ≥13 days 
and re-stimulated (+ antigen) or not (- antigen) with the same antigen before detection of 
IFN-γ and IL-17A release. The wells were incubated with 5 x 105 PBMCs. Green and red 
dots represent IFN-γ and IL-17A secretion, respectively. 
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Figure 4.15 Example of IFN-γ and IL-17A being produced by the same cell. 5 x 105 
PBMCs were stimulated with the CEA pp2, expanded for ≥13 days and re-stimulated (+ 
antigen) or not (- antigen) with the same antigen before detection of IFN-γ and IL-17A 
release. The wells were incubated with 5 x 105 PBMCs. Secretion of both cytokines by CEA-
specific cells is represented in yellow like indicated by the blue arrow. 
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Figure 4.16 Examples of IFN-γ and IL-17A secretion after stimulation with 5T4 peptide 
pools. 5 x 105 PBMCs were stimulated with the indicated peptides, expanded for ≥13 days 
and re-stimulated (+ antigen) or not (- antigen) with the same antigen before detection of 
IFN-γ and IL-17A release. (A) IFN-γ and IL-17A secretion specific to 5T4 after stimulation of 
PBMCs from DCB36 patient with 5T4 pp1. (B) IFN-γ (left-hand side) and IL-17A (right-hand 
side) secretion specific to 5T4 after stimulation of PBMCs from DCB42 patient with 5T4 pp2 
and 5T4 pp1, respectively. (C) Example of the same cell secreting IFN-γ and IL-17A specific 
to 5T4 pp2.The wells were incubated with 5 x 105 PBMCs. Green and red dots represent 
IFN-γ and IL-17A secretion, respectively. Cytokines produced by the same cells are shown 
in yellow/orange as indicated by the blue arrows. 
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Figure 4.17 IFN-γ responses specific to CEA can be detected by FluoroSpot after 14 
days of culture using synthetic peptides spanning the entire protein to stimulate 
PBMCs from DCB27. IFN-γ and IL-17A responses specific to CEA and recall antigens were 
measured by FluoroSpot after 14 days of culture. (A) IFN-γ secreting cells per 5 x 105 
cultured PBMCs. (B) IL-17A secreting cells per 5 x 105 cultured PBMCs. (C) FluoroSpot 
wells representing an IFN-γ response specific to CEA. The anti-IFN-γ antibody is labelled 
with FITC. Data shown are means of duplicate measurements ± SEM. CEA C., 
carcinoembryonic antigen from Calbiochem. CEA S., carcinoembryonic antigen from Sigma-
Aldrich. HA, haemagglutinin. PPD, tuberculin purified protein derivative. PP1 and PP2, 
peptide pool 1 and 2. PHA, phytohaemagglutinin. 
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As CD4+ T cells are not the only source of IL-17A (Passos et al., 2010; 
Rachitskaya et al., 2008; Sutton et al., 2009; Tajima et al., 2008), blocking 
antibodies against HLA class II -DR and -DQ molecules, and HLA class I -A, 
-B and C were used in the FluoroSpot assays when enough patient PBMCs 
were available. PBMCs were grown in exactly the same way as described 
before and on the day of re-stimulation cells were incubated with the blocking 
antibodies for 30 – 60 minutes before addition of the antigens/mitogens. As 
demonstrated in Figures 4.18 A and B, CEA pp1 and pp2 -specific responses 
detected by IFN-γ after stimulation are mainly -DR-restricted represented by 
the reduction/absence of response in the presence of -DR blocking 
antibodies. Similarly, CEA-specific cells secreting IL-17A alone or in 
combination with IFN-γ were at least partially -DR-restricted (Figure 4.18 C 
and D).   
4.4 CEA-specific IL-17A and IFN-γ  responses in CRC 
patients 
An initial hypothesis was that the association between tumour recurrence 
and the detection of CEA-specific T cell responses measured by IFN-γ 
secretion was due to secretion of tumour-promoting IL-17A by the same cells. 
In order to test this, I investigated IFN-γ/IL-17A producing cells in a new 
cohort of CRC patients (n=23). FluoroSpot assays were conducted as 
described above and IFN-γ and IL-17A responses specific to the tumour 
antigen 5T4 were also measured in order to determine whether responses to 
this antigen are similar or different to those against CEA.  
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Figure 4.18 IFN-γ and IL-17A responses specific to CEA are DR-restricted. 5 x 105 
PBMCs from donors DCB52 (A and D), DCB53 (B) and DCB46 (C) were stimulated on day 
0 with antigen, cultured for ≥13 days and re-stimulated or not before detection of IFN-γ (A 
and B), IL-17A (C) and IFN-γ/IL-17A (D) double producers. On the re-stimulation day cells 
were incubated with anti-DR, anti-DQ and anti-HLA A,B,C blocking antibodies for 
approximately 30 minutes before addition of antigen. After re-stimulation cells were 
incubated for approximately 48h before cytokine detection by FluoroSpot HA, 
haemagglutinin. C, CEA. Pp1, peptide pool 1. pp2, peptide pool 2. PHA, 
phytohaemagglutinin.   
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In agreement with a previous study from our laboratory, the percentage of 
patients demonstrating IFN-γ specific responses to CEA and 5T4 was 52% 
and 58%, respectively (Scurr et al., 2015) (Figure 4.19). This previous study 
also reported an association between CEA-specific IFN-γ responses and 
tumour recurrence which was even stronger when individuals making both 
CEA- and 5T4-specific responses were excluded from the analysis thereby 
supporting a protective role for 5T4-specific IFN-γ specific cells (Scurr et al., 
2015).  
The IFN-γ and IL-17A responses detected in this study specific to CEA and 
5T4 were then analysed in each patient. Figure 4.20A shows that from the 11 
patients secreting an IFN-γ response specific to 5T4 8 of them also secrete 
IFN-γ specific to CEA at a similar magnitude (Figure 4.20A and C). From the 
4 patients secreting IL-17A specific to CEA, half of them also secrete IL-17A 
specific to 5T4 at slighter higher levels suggesting that IL-17A could indeed 
be responsible for the worse prognosis observed in CEA-responsive patients 
when 5T4 protective role is subtracted from the analysis (Figure 4.20 B and 
D). However, even though the proportion of patients displaying IFN-γ specific 
responses to CEA and 5T4 is similar (Figure 4.21) the percentage of IL-17A 
responders is also similar, even slightly greater for 5T4 and IFN-γ/IL-17A 
double producers are more than twice as frequently observed in 5T4 specific 
responders than CEA responders. This suggests that CEA-responders are 
not more likely to generate IL-17A producing cells than 5T4 responders. 
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Figure 4.19 Percentage of patients secreting IFN-γ specific to CEA and 5T4 in the 
previous study published in the JNCI in 2015 (Scurr et al., 2005) and in the current 
study. Comparison of the percentage of CEA responders (A) and 5T4 responders (B) 
measured by the secretion of IFN-γ after ≥13 days of culture. In the current study CEA and 
5T4 responses were measured in 23 and 19 patients, respectively.  
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Figure 4.20 IFN-γ and IL-17A responses specific to CEA and 5T4 generated by the 
same patients. (A) Venn diagram representing the total number of patients producing an 
IFN-γ response to CEA (blue) that also generate an IFN-γ response specific to 5T4 (blue 
and pink combined) or that only generate an IFN-γ response specific to 5T4. (B) Like in A 
but for IL-17A responses. C and D represent the pattern of the magnitude of IFN-γ 
responses (C) or IL-17A responses (D) for both antigens. In C and D one individual line 
represents one patient. 
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Figure 4.21 A low percentage of CRC patients produce IFN-γ and IL-17A specific to 
CEA and 5T4 by the same cells. (A) The percentage of IFN-γ (n=23), IL-17A (n=24) and 
IFN-γ/IL-17A double producers (n=21) specific to CEA was measured in the blood of CRC 
patients after ≥13 days of culture. (B) Percentage of IFN-γ, IL-17A and IFN-γ/IL-17A double 
producers (n=19) specific to 5T4 detected in the blood of CRC patients after ≥13 days of 
culture. IFN-γ and IL-17A CEA and 5T4 responders represent cytokine secretion by different 
cells.   
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Also, the magnitude of IL-17A responses is lower than the IFN-γ specific 
responses both for CEA and 5T4 thus excluding the fact that maybe a 
greater IL-17A specific response to CEA could explain the tumour recurrence 
(Figure 4.22). The magnitude of the total responses detected by IFN-γ and 
IL-17A is similar for both tumour antigens (Figure 4.23) Taken together this 
suggests that IL-17A secreted by CEA-specific cells is not responsible for the 
tumour recurrence observed by patients secreting IFN-γ specific to CEA. No 
difference in the magnitude of responses was observed in different stages of 
disease both for CEA and/or 5T4 responses (Figure 4.24). Interestingly, 
however, is the fact that whenever an IL-17A response is detected for any of 
the antigens an IFN-γ specific response is also observed either from the 
same cells (double producers) or from distinct cells (Figure 4.25 and Tables 
4.1 and 4.2). IL-17A is therefore a surrogate marker for IFN-γ as whenever 
IL-17A is detected IFN-γ secretion specific to the same antigen is also 
detected.
 169 
 
 
 
 
Figure 4.22 IFN-γ responses specific to CEA and 5T4 are greater than IL-17A 
responses specific to the same antigens. The total magnitude of CEA (A and B) and 5T4 
(C and D) responses were calculated by combination of responses detected by peptide 
pools 1 and 2 and the mean and the SEM calculated (A and C). B and D represent IFN-γ, IL-
17A and IFN-γ/IL-17A secretion specific to CEA and 5T4 by each individual patient. One line 
represents one patient. IFN-γ CEA responses, n=23. IL-17A CEA responses, n=24. 5T4 
responses, n=19.  
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Figure 4.23 Total magnitude of IFN-γ and IL-17A responses specific to CEA and 5T4. 
The total magnitude of IFN-γ (A) and IL-17A(B) responses specific to CEA and 5T4 was 
calculated by combination of responses detected by peptide pools 1 and 2 and the mean 
and the SEM calculated. IFN-γ CEA responses, n=23. IFN-γ 5T4 responses, n=19. IL-17A 
CEA responses, n=24. 5T4 responses, n=19. Mann Whitney test was used to compare both 
groups. P ≤ 0.05 was considered significant. 
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Figure 4.24 Total magnitude of IFN-γ and IL-17A responses is not associated with 
disease stage for either CEA or 5T4 responders. Total magnitude of IFN-γ responses (A 
and B) and IL-17A responses (C and D) specific to CEA (A and C) and 5T4 (B and D) were 
calculated and grouped according to disease stage. Lines in the graphs represent the mean 
and SEM. Mann Whitney test was used to compare both groups. P ≤ 0.05 was considered 
significant   
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Figure 4.25 Cells secreting IL-17A specifically to CEA or 5T4 always secrete IFN-γ. (A) 
Venn diagram representing IL-17A (orange) or IFN-γ (green) secretion specific to CEA alone 
in orange and green, respectively, or in combination (orange and green superimposed). (B) 
As in A but for 5T4. 
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Table 4.1 Details of IFN-γ and IL-17A responses specific to CEA. PBMCs from CRC 
patients were tested for the presence of CEA responses by secretion of IFN-γ and/or IL-
17A. IFN-γ responses were measured in 23 patients, IL-17A responses were measured in 
the blood of 24 patients and IFN-γ/IL-17A double responses secreted by the same cells 
were measured in 21 patients. IFN-γ exclusive secretion represents cells that only secrete 
IFN-γ but no IL-17A. IL-17A exclusive indicates cells that only secrete IL-17A but no IFN-γ. 
IFN-γ/IL-17A double producers represent cells that secrete both cytokines. IFN-γ secretion 
by DCB23 could not be tested due to an infection in the plate. IFN-γ/IL-17A double 
producers could not be measured in DCB21, 23 and 26 because IFN-γ and IL-17A 
responses for these patients were measured by ELISpot. Background have been subtracted 
from the final responses represented here. Values represent number of spots detected per 5 
x 105 PBMCs.  pp1, peptide pool 1. pp2, peptide pool 2.  
 
Patient	ID pp1 pp2 pp1 pp2 pp1 pp2
DCB21 335 880 0 265 NT NT
DCB23 NT NT 37 222 NT NT
DCB26 0 0 0 0 NT NT
DCB27 49 0 0 0 0 0
DCB29 0 147 0 20 0 9
DCB32 0 0 0 0 0 0
DCB33 0 0 0 0 0 0
DCB35 0 0 0 0 0 0
DCB36 0 0 0 0 0 0
DCB37 0 0 0 0 0 0
DCB39 0 84 0 0 0 0
DCB41 0 224 20 0 0 0
DCB42 282 66 0 0 0 0
DCB44 0 0 0 0 0 0
DCB45 74 103 0 0 0 0
DCB46 0 0 0 16 0 6
DCB48 0 0 0 0 0 0
DCB50 0 0 0 0 0 0
DCB51 80 0 0 0 0 0
DCB52 115 317 0 22.5 0 25
DCB53 0 186 0 0 0 0
DCB54 306 448 17 0 0 0
DCB55 0 56 0 0 0 0
DCB56 0 0 0 0 0 0
IFN-γ	exclusive IL-17A	exclusive
IFN-γ/IL-17A	double	
producers
CEA responses 
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Table 4.2 Details of IFN-γ and IL-17A responses specific to 5T4. PBMCs from CRC 
patients were tested for the presence of 5T4 responses by secretion of IFN-γ and/or IL-17A. 
IFN-γ, IL-17A and IFN-γ/IL-17A double responses secreted by the same cells were 
measured in 19 patients. IFN-γ secretion represents cells that only secrete IFN-γ but no IL-
17A. IL-17A indicates cells that only secrete IL-17A but no IFN-γ. IFN-γ/IL-17A double 
producers represent cells that secrete both cytokines Background have been subtracted 
from the final responses represented here. Values represent number of spots detected per 5 
x 105 PBMCs. pp1, peptide pool 1. pp2, peptide pool 2.  
 
5T4 responses 
Patient	ID pp1 pp2 pp1 pp2 pp1 pp2
DCB32 0 0 0 0 0 0
DCB33 0 0 0 0 0 0
DCB35 0 0 0 0 0 0
DCB36 99 316 0 0 0 18
DCB37 0 0 0 0 0 0
DCB39 0 0 0 0 0 0
DCB41 0 298 0 0 0 0
DCB42 0 293 33 0 0 0
DCB44 0 0 0 0 0 0
DCB45 54 0 0 0 0 0
DCB46 0 0 0 0 0 0
DCB48 0 0 0 0 0 0
DCB50 23.5 342.5 0 88.5 0 14.5
DCB51 0 328 0 0 0 0
DCB52 65 345.5 18.5 113 0 25
DCB53 0 81.5 10 0 0 0
DCB54 29 982 0 39 0 13.5
DCB55 0 228 0 0 0 0
DCB56 354.5 118 12 0 6.5 0
IFN-γ IL-17A
IFN-γ/IL-17A	double	
producers
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4.5 Discussion 
CEA was first described in 1965 and since then it has been widely studied as 
a potential target for tumour treatment as it is overexpressed on 
adenocarcinomas, mainly of the breast, pancreas, lung and colon (Gold and 
Freedman, 1965; Hammarström, 1999). 
A number of studies using CEA transgenic mice (CEA.tg) have shown that 
vaccination with CEA-expressing recombinant viruses induces protective 
immune responses against CEA-expressing tumour cells (Greiner et al., 
2002; Kass et al., 1999).  
The ability to induce a CEA-specific T cell response after immunisation with a 
CEA-loaded vaccine has also been demonstrated in humans (Turriziani et al. 
2012). Zhue et al., detected an HLA class I restricted CEA response in 
patients vaccinated with a recombinant Avipox-CEA vaccine that was able to 
lyse CEA+ autologous tumour (Zhu et al., 2000). In a Taiwanese cohort of 
CRC patients Liu et al., observed a MHC class I restricted response after 
vaccination with dendritic cells loaded with CEA peptides. In this study a 70% 
increase in the number of responses specific to CEA after vaccination was 
reported (K.-J. Liu et al., 2004). All the studies aforementioned were capable 
of eliciting either a cellular or humoural response but what is less clear is the 
correlation between a T cell specific response and long-term patient survival.  
Our group has previously reported the existence of naturally occurring T cells 
specific to tumour antigens, namely CEA and 5T4 in the blood of CRC 
patients (Betts et al., 2012; Clarke et al., 2006) and recently we have also 
reported that detection of a CEA T cell response is associated with tumour 
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recurrence (Scurr et al., 2015); an effect that is even more striking when the 
5T4 responders are removed from analysis (Betts et al., 2012; Clarke et al., 
2006; Scurr et al., 2015).   
This chapter has focused on the investigation into the mechanisms involved 
in tumour recurrence in CRC patients developing a CEA T cell response. It 
was hypothesised that the presence of a CEA T-cell response by ex vivo 
IFN-γ detection by ELISpot could merely be a surrogate marker of an IL-17A 
response. IL-17A is the signature cytokine for Th17 cells and its high 
concentration in the blood and tumour of cancer patients has been 
associated with a poor outcome (He et al., 2011; Li et al., 2014; F. Zhang et 
al., 2008). VEGF and PGE are pro-angiogenic factors that promote tumour 
survival, expansion and vascularity. IL-17A mediates its tumorigenic effects 
by the induction of VEGF, PGE2 secretion and also via indirect activation of 
STAT3 via IL-6 (De Simone et al., 2013; L. Wang et al., 2009). 
In order to test for the concomitant secretion of CEA-specific IFN-γ and IL-
17A a series of experiments were conducted including detection of IFN-γ and 
IL-17A secretion directly ex vivo or after culture post stimulation with the 
whole CEA protein or two peptide pools spanning the entire protein. After 
optimising IL-17A detection by ELISpot using CA as a positive control it was 
observed that a culture of at least 13 days was necessary to detect a robust 
and measurable number of cytokine producing T cells. Zielinski et al. also 
stimulated CD4+ naïve T cells with monocytes pulsed with CA for 12 days in 
order to detect IL-17A secretion. Incubation in the presence of MHC class II 
blocking antibodies inhibited the secretion of IL-17A PBMCs showing this 
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response to be MHC class II specific (Zielinski et al., 2012). Similar findings 
are reported here. 
I found that both IFN-γ and IL-17A responses were more readily detected 
following a 13-day culture period (Figure 4.8 and 4.9). In an approach similar 
to ours, Shimato et al. measured cytokine release by ELISA in three 
glioblastoma patients on day 7 and 14 after PBMC culture. They reported 
that the magnitude of the response was markedly increased due to 
expansion of the cells during the culture period (Shimato et al., 2012). The 
Barker group also measured CEA-specific responses but in healthy donors 
and observed a peak proliferation of CEA-specific T cells around day seven 
(Pickford et al., 2007). 
In our system the detection of CEA-specific T cells was only possible when 
synthetic peptides covering the entire protein were used. This result was 
unexpected, as previously the laboratory had reported detection of CEA-
specific responses using whole CEA purchased from Calbiochem. A number 
of factors could account for this result: 1) as the previous study was 
performed between 2004 and 2007 the protein batch used at the time was 
somehow different from the batch used for the current study, 2) altered 
chemotherapy regime being currently administrated to the patients as 
compared to the 2004-2007 periods. In a phase I/II trial in 2005 Weihrauch et 
al. described that even though absolute CD4+ and CD8+ cell counts were not 
affected by the chemotherapy, three cycles of treatment decreased the 
Epstein-Barr Virus and Cytomegalovirus specific CTL response by 14% 
(Weihrauch, 2005). However this seems unlikely as I was able to detect 
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CEA-specific responses using peptide pools; this may reflect better efficiency 
of antigen presentation as peptides do not require extensive processing.  
The current study was undertaken to understand the impact of IL-17A-
producing CEA-specific T cells on tumour recurrence of CRC patients. To 
study the simultaneous production of IFN-γ and IL-17A by CEA-specific T 
cells cytokine release from the blood of twenty-three patients by ELISpot or 
FluoroSpot was measured after a short-term culture. The percentage of the 
CEA and 5T4 responses observed in this study was slightly higher but similar 
to the previous study (Figure 4.19).  
I report here for the first time the detection of IL-17A-producing CEA- and 
5T4-specific T cells in the blood of patients with CRC. Whilst on a single cell 
level, some T cells secreted IL-17A, IFN-γ-responses to CEA and/or 5T4 
were always detected in the same individual even if secreted by distinct cells. 
The only previous report of Th17 cells specific to a tumour antigen in the 
blood of cancer patients was published by Hamai et al. who screened the 
blood of 38 lung cancer patients and documented the detection of three 
MAGE-A3 Th1 specific responses and one MAGE-A3-specific Th17 
response (Hamai et al., 2012). Similarly to our findings they also described 
the secretion of IL-17A alone or in combination with IFN-γ. They were able to 
identify the same MAGE-A3-specific population in the CCR6+CCR4+ central 
memory and CCR6+CXCR3+ effector memory populations of one patient. 
CD4+ T cells were stimulated with a single peptide and expanded under 
clonal conditions. Molecular analysis of seven clones secreting either IL-17A 
alone and/or IFN-γ showed that all the clones used the TCR beta variable 
gene 20-1, the same complementary determining regions 3β and a unique 
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TCR beta joining gene. The clonotyping data in combination with the 
characterisation of the memory populations suggests that the MAGE-A3-
specific Th1/Th17 population is a transitory population that will later on 
during their developmental stage secrete solemly IFN-γ as the cells become 
Th1 effector cells. (Hamai et al., 2012). If this is true, it provides an 
explanation for why IL-17A secretion is always detected in association with 
IFN-γ whereas IFN-γ responses are often detected without IL-17A secretion. 
The data presented here also indicate that the association between tumour 
recurrence and IFN-γ-producing CEA-specific T cell responses cannot be 
accounted for by concomitant IL-17A-production by the same cells. I 
observed no difference in the pattern of IL-17A and IFN-γ-secretion amongst 
CEA vs 5T4-specific cells. This is important, as 5T4-specific responses were 
not associated with tumour recurrence. 
Tatsumi et al. reported a strongly skewed Th2 phenotype specific to MAGE-6 
epitopes in the blood of melanoma and renal cell carcinoma patients. The 
responses of healthy donors and patients with no remaining disease were 
mainly Th1 or a combination of Th1 and Th2 (Tatsumi et al., 2002). This 
suggests that even though the development of a Th1 response to tumour 
antigens is the dominant phenotype, other subsets of helper T cells can also 
recognise tumour antigens and impact on prognosis. Detection of IL-4 could 
therefore be included in the future analysis of CEA-specific responses. 
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5 Th1/ Th17 cells in the context of CRC 
5.1 Introduction 
Th17 cells were first described in mice in 2005 (Harrington et al., 2005; 
Iwakura and Ishigame, 2006; McKenzie et al., 2006; Park et al., 2005). Since 
then they have been widely studied in the context of human disease, with the 
discovery that these cells are associated with a number of autoimmune 
conditions, previously only linked to the activity of Th1 cells (Brucklacher-
Waldert et al., 2009; Lubberts et al., 2004). 
 Th17 cells have also been linked to tumour development, mainly 
CRC (Li et al., 2014). The colon is of special interest as it is populated by a 
vast number of microorganisms. Segmented filamentous bacteria (SFB) e.g. 
have been shown to induce the development of Th17 cells in the intestinal 
lamina propria of mice (Ivanov et al., 2009). Hyun et al. demonstrated that 
development of colitis associated cancer (CAC) was associated with IL-17A 
secretion as IL-17A KO mice presented less inflammation and less tumour 
development post-dextran sulphate sodium (DSS) treatment in comparison 
to WT animals (Hyun et al., 2012). Th17 cells appear not only to be related to 
the formation of CAC but also sporadic CRC. In a sporadic CRC model 
Grivennikov et al. depleted the APC gene which led to elevated levels of IL-
23 p19 and IL-17A within the tumour. Also, genetic deletion of Il-23, a crucial 
cytokine for the maintenance of the Th17 phenotype, resulted in the 
development of fewer and smaller tumours (Grivennikov et al., 2012).  
Thus, mouse studies indicate that Th17 cells promote disease progression. 
Studies in humans also point to a role for Th17 cells in the promotion of CRC. 
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It has been reported that frequencies of Th17 cells and their associated 
cytokines are elevated in the blood of CRC patients (Li et al., 2014; J. Wang 
et al., 2012). In a study by the Galon group published in 2011 analysing 
three CRC patient cohorts, Th17 cells were significantly associated with a 
poorer survival particularly when Th1 cell numbers were low (Tosolini et al., 
2011). Another characteristic feature of Th17 cells is transdifferentiation; the 
ability to secrete signature cytokines of other T helper subsets (e.g. IL-10 
and IFN-γ) (Gagliani et al., 2015; Zielinski et al., 2012). Current literature on 
CRC suggests that high prevalence of Th1 cells within the tumour correlates 
with a favourable prognosis, contrasting with Th17 cells which correlate with 
a poor prognosis. However it is not understood what role IFN-γ/IL-17A 
double-producing CD4+ T cells play in tumour development and progression. 
I also considered that by studying the chemokine receptors associated with 
each subset e.g. Th1, Th17 and IFN-γ/IL-17A producing cells I would gain a 
better understanding on the recruitment pattern of such cells and their role in 
CRC. 
Thus, this chapter focuses on i) evaluating the frequency and 
phenotype of Th1 and Th17 cells in blood, colon and CRC and ii) exploring if 
the ratios of Th1 : Th17 :Treg cells in these compartments reflect disease 
stage. 
5.2 Results 
In order to evaluate the frequency and phenotype of Th1 and Th17 T cells in 
the context of CRC, IFN-γ and IL-17A secretion from CD4+ T cells was 
determined in three compartments: PBMCs, colon infiltrating lymphocytes 
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(CILs) and TILs. For this purpose, intracellular cytokines as well as the 
percentage of CCR6 and CXCR3 expression, chemokine receptors 
associated with Th17 and Th1 cells, respectively, were measured. As 
PMA/Ionomycin stimulation might cause down regulation of chemokine 
receptor expression, CCR6 and CXCR3 were first assessed in unstimulated 
samples whilst cytokine secretion was assessed post-stimulation (cell 
number permitting) (Figure 5.1). Corroborating other reports, I observed a 
significant increase in the frequency of cells expressing CCR6 and IL-17A in 
the bowel (diseased or healthy) compared to PBMCs, with a trend for the 
highest frequencies of IL-17A-producing cells being within the TILs (Figure 
5.1 A and B) (Li et al., 2014). Similarly, the proportion of CD4+IFN-γ+ cells 
was also significantly increased in CILs and TILs compared to PBMC but this 
was not accompanied by an enrichment of CXCR3+ cells (Figure 5.1 C and 
D).  
Interestingly, for each given patient (represented by an individual line) 
proportions of CXCR3 and CCR6 expressing cells were roughly the same in 
PBMCs and CILs (Figure 5.2 A-B), whereas skewing in favour of CCR6+ 
cells was observed in TILs (Figure 5.2 C), due to a drop in the proportion of 
CXCR3+ cells. Collectively these data suggests that the balance between 
Th1 and Th17 cells is skewed in favour of Th17 cells in the tumour 
environment.
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Figure 5.1 Th17 associated markers are elevated within the bowel. Lymphocytes were 
isolated from the blood (PBMCs), healthy bowel (CILs) and tumour (TILs) of CRC patients 
as described in the Material and Methods section. Some cells were left unstimulated and the 
percentage of CD4+ cells expressing CCR6 and CXCR3 measured by flow cytometry (A and 
C). The remaining cells were stimulated for five hours with phorbol 12-myristate 13-acetate 
(PMA)/Ionomycin in the presence of Brefeldin A, fixed, permeabilised and stained for IL-17A 
and IFN-γ. Lines in the graphs represent the median and interquartile range. Mann Whitney 
test was used to compare groups. P ≤ 0.05 was considered significant. 
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Figure 5.2 Correlation of CD4+CXCR3/CCR6+ cells in PBMCs, CILs and TILs of CRC 
patients. Lymphocytes were isolated from PBMCs, CILs and TILs of CRC patients as 
described in Material and Methods. Cells were left unstimulated and the levels of CCR6 and 
CXCR3 expression measured by flow cytometry. The pattern of CXCR3 to CCR6 expression 
in CD4+ cells was analysed in PBMCs (A), CILs (B) and TILs (C). Every single line 
represents one individual patient. 
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To explore this further, I examined whether there was a correlation between 
CCR6 and IL-17A expression in T cells recovered from PBMC, CILs and 
TILs. Interestingly, whilst no correlation was observed in PBMCs or CILs 
(Figure 5.3 A and B) a positive correlation was observed in TILs suggesting 
that increased IL-17A expression in CRC is due to an enrichment of CCR6+ 
cells, possibly in response to local production of the chemokine CCL20 in the 
tumour microenvironment (Figure 5.3 C, p=0.0253, R2=0.4433). As CCR6-
specific antibodies were also included in the staining of stimulated cells for 
the majority of the patients’ samples, it was possible to analyse the levels of 
CCR6 expression in CD4+IL-17A+ retrospectively. First, levels of CCR6 
expression were evaluated in cells pre- and post-stimulation to determine the 
variation in CCR6 expression. Figure 5.4 represents the gating strategy used 
to identify CD3+CD4+ (Figure 5.4 A-D). Even though the levels of CCR6 do 
decrease upon stimulation, the decrease is minimal in PBMCs (Figure 5.4 E 
– H), CILs and TILs (Figure 5.5). Acknowledging the caveat that some down 
regulation of CCR6 occurred post-stimulation, these data indicate that 
CCR6+IL-17A+ cells are enriched in TILs but not CILs when compared to 
PBMCs (Figure 5.6A), supporting the premise that IL-17A-expressing T cells 
are enriched in CRC possibly due to local production of CCL20.  
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Figure 5.3 CCR6 expression in CD4+ cells correlates with IL-17A expression in TILs. 
Lymphocytes were isolated from PBMCs, CILs and TILs of CRC patients as described in 
Material and Methods. Some cells were left unstimulated and the expression levels of CCR6 
measured by flow cytometry in PBMCs (A), CILs (B) and TILs (C). The remaining cells were 
stimulated for five hours with PMA/Ionomycin in the presence of Brefeldin A, fixed, 
permeabilised and stained for IL-17A. P < 0.05 was considered significant. Correlation 
analyses were performed using the Pearson method. 
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Figure 5.4 Representative example of gating strategy used to analyse CD4+CCR6+ 
cells. PBMCs from patient DCB36 were isolated and stained using CD3, CD4 and CCR6 
antibodies amongst others. The lymphocytic population was isolated using the side scatter 
(SSC) and forward scatter (FSC) measurements representative of granularity and size, 
respectively (A). Single cells were then gated based on the FSC area and height (B) and live 
cells selected based on the inability to incorporate the Aqua dye (C). CD3+CD4+ single live 
lymphocytes were then selected prior to CCR6 analysis (D). E – H represent the expression 
levels of CCR6 on CD4+ cells when staining straight ex-vivo, without any prior manipulation 
(E), after resting overnight in medium containing serum (F), after resting overnight in 
medium containing serum and incubated for five hours with Brefeldin A (G) and after resting 
overnight in medium containing serum and stimulation for five hours with PMA/Ionomycin in 
the presence of Brefeldin A (H). Fluorescence minus one (FMOs) were used in the majority 
of the gating strategies when enough cells were available. 
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Figure 5.5 Representative example of gating strategy used to analyse CD4+CCR6+ 
cells in CILs and TILs. Healthy colon infiltrating lymphocytes (CILs) and TILs from patient 
DCB36 were isolated and stained using CD3, CD4 and CCR6 antibodies amongst others. 
CD3+CD4+ single live lymphocytes were then selected prior to CCR6 analysis like shown in 
figure 5.5. A and C represent the expression levels of CCR6 on CD4+ cells when staining 
straight ex-vivo, without any prior manipulation. B and E represent staining after resting 
overnight in medium containing serum and stimulation for five hours with PMA/Ionomycin in 
the presence of Brefeldin A. D represents staining after resting overnight in medium 
containing serum. A and B represent staining in CILs and C – E represent staining in TILs. 
Fluorescence minus one (FMOs) were used in the majority of the gating strategies when 
enough cells were available. 
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IFN-γ/IL-17A double producing cells have been documented in the context of 
CRC but no detailed studies on such population within PBMCs, CILs and 
TILs have been published. Furthermore, CD4+IL-17A+ cells can acquire the 
ability to also express IFN-γ which could theoretically alter their fate in CRC 
development. CD4+IL-17A+ cells within PBMCs are mainly IFN-γ-, however a 
higher percentage of CD4+IL-17A+ cells in the bowel (healthy or diseased) 
secrete IFN-γ suggesting that factors present within the bowel 
microenvironment may contribute to the formation of cell expressing both 
IFN-γ and IL-17A (Figure 5.6B). Given the fact that approximately half of the 
CD4+IL-17A+ cells within the bowel express IFN-γ the proportion of CD4+ 
cells expressing IL-17A+/IFN-γ+ was also assessed in PBMCs, CILs and TILs. 
T cells secreting both cytokines are more prevalent within the bowel and this 
phenotype is even more frequent within TILs (Figure 5.7 A and B). 
 
One of the objectives of this study was to assess the differences in T cell 
populations within the blood, healthy bowel and the tumour in order to 
identify patterns of T cell activity unique to CRC and to determine how well 
relative proportions and phenotype of T cell subsets in blood, reflects the 
tumour microenvironment. For this purpose, ratios of Th1, Th17 and Treg 
were determined within PBMCs, CILs and TILs by examining proportions of 
T cells expressing IFN-γ, IL-17A and FoxP3, respectively.  
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Figure 5.6 Th17 cells within the bowel express a high percentage of CCR6. 
Lymphocytes were isolated from PBMCs, CILs and TILs of CRC patients as described in 
Material and Methods. Cells were stimulated for five hours with PMA/Ionomycin in the 
presence of Brefeldin A, fixed, permeabilised and stained for CCR6, CXCR3, IL-17A and 
IFN-γ amongst others. The percentage of CD4+IL-17A+ cells expressing CCR6 (A) or IFN-γ 
(B) was measured in PBMCs, CILs and TILs of CRC patients. Lines in the graphs represent 
the median and interquartile range. Mann Whitney test was used to compare groups. P ≤ 
0.05 was considered significant. 
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Figure 5.7 CD4+ IFN-γ/IL-17A double producing cells are more prevalent within the 
bowel, especially within the tumour. Lymphocytes were isolated from PBMCs, CILs and 
TILs of CRC patients as described in Material and Methods. Cells were stimulated for five 
hours with PMA/Ionomycin in the presence of Brefeldin A, fixed, permeabilised and stained 
for IL-17A and IFN-γ amongst others. The percentage of CD4+IL-17A+IFN-γ+ was measured 
in PBMCs, CILs and TILs of CRC patients. Lines in A represent the median and interquartile 
range whereas every individual line in B represents one single patient and the pattern of 
CD4+IL-17A+IFN-γ+ existence in the blood, healthy bowel and tumour. Mann Whitney test 
was used to compare groups. P ≤ 0.05 was considered significant.  
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As expected for sites of immune activation, the percentages of all 
differentiated T cells increased in CILs and particularly TILs (Figure 5.8A). 
The ratios are dramatically altered especially in TILs where the enrichment in 
Th17 cells reported above reduced the ratios of Th1:Th17 cells and 
Treg:Th17 cells indicating that CIL and TIL populations are Th17-rich 
compared to blood (Figure 5.8B). Irrespective of the low numbers the same 
pattern was observed for every disease stage (Figure 5.9). 
5.3 CEA responders have fewer IFN-γ-producing cells and 
Tregs within their TILs 
As outlined above CEA-specific T cell responses, measured in blood, were 
associated with a poorer prognosis. I examined whether CEA-responders 
could be distinguished from non-responders by the proportion of Tregs, IFN-γ 
and/or IL-17A-producing cells within TILs. This analysis revealed that CEA-
responders had significantly lower proportions of Th1 cells (IFN-γ+ T cells, 
Figure 5.10E) and Foxp3+ T cells in TILs (Figure 5.10K) compared to non-
responders. No difference was observed in proportions of IL-17A-producing 
cells (Figure 5.10Q) or between 5T4 responders and non-responders (Figure 
5.10 right column).    
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Figure 5.8 The tumour of CRC patients is enriched with Th17 cells. Lymphocytes were 
isolated from PBMCs, CILs and TILs of CRC patients as described in Material and Methods. 
Cells were stimulated for five hours with PMA/Ionomycin in the presence of Brefeldin A, 
fixed, permeabilised and stained for IL-17A and IFN-γ amongst others. The percentage of 
Th1 cells was determined by the percentage of CD4+ cells expressing IFN-γ and Th17 cells 
were determined by the percentage of CD4+ cells expressing IL-17A. Treg cells were 
identified by the expression of Foxp3. The percentage (A) or ratios (B) of Th1, Th17 and 
Tregs were determined in PBMCs, CILs and TILs of CRC patients. The bars represent mean. 
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Figure 5.9 No difference in the percentage of Th1, Th17 and Treg cells or ratios is 
observed in different disease stages. Lymphocytes were isolated from PBMCs, CILs and 
TILs of CRC patients as described in Material and Methods. Cells were stimulated for five 
hours with PMA/Ionomycin in the presence of Brefeldin A, fixed, permeabilised and stained 
for IL-17A and IFN-γ amongst others. The percentage of Th1 cells was determined by the 
percentage of CD4+ cells expressing IFN-γ and Th17 cells were determined by the 
percentage of CD4+ cells expressing IL-17A. Treg cells were identified by the expression of 
Foxp3. The percentage (A-C) or ratios (D-F) of Th1, Th17 and Tregs were determined in 
PBMCs (A and D), CILs (B and E) and TILs (C and F) of CRC patients. The bars represent 
means.    
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Figure 5.10 Analysis of cytokine secretion and transcription factor expression in 
PBMCs, CILs and TILs of CEA and 5T4 responders and non-responders. Patients were 
divided into responders (R) or non-responders (NR) according to their secretion of IFN-γ 
upon CEA or 5T4 stimulation as described in the previous chapter. The levels of IFN-γ, IL-
17A and Foxp3 expression in CD4+ cells in PBMCs (top two graphs), CILs (middle graphs) 
and TILs (bottom graphs) amongst others was analysed for CEA (left column) and 5T4 (right 
column) responders and non-responders.   
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5.4 Discussion 
Inflammation has long been linked to the development of CRC, the 
most obvious example being the increase in CRC cases seen in patients 
suffering from extensive IBD (Munkholm, 2003).  In the past two decades, 
the dual role of lymphocytes in both the development and prevention of 
tumorigenesis has been examined. Tosolini et al. reported in three cohorts of 
CRC patients that not only is the level of intra-tumoural T cell infiltration 
important for patient prognosis but also T cell phenotype: high levels of Th17 
cells in combination with low levels of Th1 cells were associated with a 
shorter disease free survival (Tosolini et al., 2011). Thus, characterising the 
phenotype of infiltrating cells may help understand how different groups of T 
cells impinge on disease progression. The Galon group came to this 
conclusion by analysing the gene expression levels of Th1 and Th17 related 
genes such as IFNG, TAP1, GZMB, and IL17A and RORc, respectively. This 
was validated by tissue microarray using anti-Foxp3, anti-Tbet and anti-IL17 
antibodies (Tosolini et al., 2011). Even though Tosolini et al. studied the 
gene expression of Th1, Th17 and Treg related markers and characterised 
the levels of IL-17A and T-bet in situ, the group did not analyse cytokine-
producing cells. In order to gain a better understanding on the type of T cells 
infiltrating CRC I examined and compared cytokine production and 
chemokine receptor expression by T cell subsets in PBMCs, CILs and TILs.  
The data obtained here revealed that CCR6+IL17-producing T cells were 
enriched in the gut compared to PBMCs, particularly in CRC. Similar findings 
have been reported by others. Wang et al. observed an increase in the 
percentage of Th17 cells in TILs of CRC patients in advanced disease and 
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other groups have reported that more Th17 cells are found within the intra-
tumoural regions than non-tumour regions (Amicarella et al., 2015; Li et al., 
2014; J. Wang et al., 2012). 
  Since the majority of Th17 cells in CRC express CCR6, it is possible 
that the cells migrate and are retained in CRC in response to CCL20, the 
only known ligand for CCR6 (Baba et al., 1997; Greaves et al., 1997; Liao et 
al., 1997; Power et al., 1997). In support of this hypothesis, previous reports 
indicate that CCL20 is highly prevalent within the bowel and is constitutively 
expressed in mucosa-associated lymphatic tissue (MALT) (Schutyser et al., 
2003). Even though expressed at low levels during homeostasis, CCL20 is 
upregulated upon inflammation through TNF-α and IL-1β signalling (Fujiie et 
al., 2001). Indeed, CCL20 is highly expressed by CRC tumour cells in 
comparison to healthy mucosa (Brand et al., 2006). Given the fact that 
CCL20 is the only CCR6 ligand described to date, local blockade of CCL20 
could potentially prevent further pathogenic Th17 cells infiltration into the 
tumour averting tumour progression. Caution should however be taken as 
CCL20 is also important for mucosal immunity and CCL20-/- mice do not yet 
exist to study ablation of such signalling pathway. The CCR6-CCL20 
pathway may also be relevant for other tumours. Yu and colleagues reported 
the recruitment of Th17 cells to cervical cancer via this pathway. They 
observed an increase in CCL20 levels measured by real-time PCR in tumour 
compared to non-tumour tissues, which correlated, with the percentage of 
Th17 cells infiltrating the tumour. Using recombinant chemokines and 
supernatant from cervical cell lines the group also observed the recruitment 
of Th17 cells by CCL20 in a transwell system (Yu et al., 2015).  
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In contrast to Th17 cells, I observed no evidence for selective 
enrichment of CD4+IFNγ+ or CD4+CXCR3+ cells, in TILs compared to CILs. 
As described previously, it is known that Th1 cells are associated with a 
good prognosis in CRC unless Th17 cells are also present (Galon, 2006; 
Tosolini et al., 2011). It is notable therefore that the Th1/Th17 and Treg/Th17 
ratios in CILs and particularly TILs were strikingly different to those observed 
in PBMCs. In a homeostatic setting e.g. healthy bowel, the ratio of Th1 cells 
to Th17 cells is approximately 8:1. In tumours however, this ratio is 
approximately 3:1, reflecting the enrichment of Th17 cells.  
Th17 cells are mainly characterised by secretion of IL-17A which 
signals through the ubiquitously expressed IL-17 receptor A. Engagement of 
IL-17A with its receptor on epithelial cells promotes activation of NFκB and 
the mitogen activated protein kinase (MAPK) pathways leading to epithelial 
cell proliferation and production of pro-inflammatory cytokines such IL-6, IL-
23 and TNF-α (B. Yang et al., 2014). IL-17A also plays a role in shaping the 
tumour vasculature promoting angiogenesis via VEGF stimulation and PGE2 
production as shown by Liu and colleagues (J. Liu et al., 2011). Moreover, 
IL-17A also attracts myeloid derived suppressor cells (MDSCs) into the 
tumour microenvironment promoting an immunosuppressive niche. Th17 
cells also secrete IL-21 and IL-22 albeit to a lesser extent. Engagement of 
the IL-21 and IL-22 receptors on epithelial cells activates STAT3, stimulating 
epithelial cell proliferation and secretion of IL-6 and IL-17A by IL-21R+ 
monocytes (Jiang et al., 2013; Stolfi et al., 2011). Continuous cell 
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proliferation contributes to the generation of additional mutations potentiating 
a synergistic tumorigenic effect.  
The relationship between Tregs and Th17 cells in CRC is unknown. 
There is however evidence to suggest that Tregs may suppress the activity 
of Th17 cells. Rudensky’s group demonstrated that Treg-specific ablation of 
STAT3 caused fatal Th17-driven colitis driven by Th17 cells highlighting the 
regulatory effects Tregs have on Th17 cells (Chaudhry et al., 2009). This 
suppression was later on shown to occur via IL-10 signalling (Chaudhry et al., 
2011). 
Gut microbiota promotes background inflammation and Th17 
differentiation (Goto et al., 2014; Ivanov et al., 2009; van Beelen et al., 2007; 
Y. Yang et al., 2014). Therefore the Th17 population present within CRC 
may be driven to a degree by bacteria mediating tumour progression. 
Another possibility, which may occur along side the above, is that a 
population of tumour antigen-specific Th17 cells expand specifically in 
response to CRC. Indeed a trend for higher prevalence of double IFN-γ/IL-
17A secretors in TILs was observed in this study. Th17 cells specific for C. 
albicans secreted IL-17A and IFN-γ, whilst Th17 cells specific for 
Staphylococcus aureus secrete IL-17A and IL-10 (Zielinski et al., 2012).  
 
As previously described, we have observed that an IFN-γ T cell 
response specific to CEA measured in the blood is associated with a bad 
prognosis in CRC patients. I therefore examined whether the pattern of 
cytokine production by TILs bore any relationship with CEA-responses 
measured in blood as described in Chapter 4. Interestingly two markers 
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showed a significant difference between CEA responders and non-
responders, namely decreased proportions of IFN-γ+ and Foxp3+ cells in the 
TILs of CEA responders. 
However debatable levels of CEA in the serum of patients has been 
associated with a worse prognosis post tumour resection, although there is 
some debate over this (Duffy, 2001; Saito et al., 2016). It could be 
hypothesised that tumours from CEA-responders are more aggressive thus 
the link with a poor outcome. Such aggressiveness could be related to a) 
lack of tumour immunogenicity, b) metastatic potential, c) loss of epithelial 
barrier function or a combination of all three. The findings described herein 
are compatible with the hypothesis that the tumours of CEA-responders are 
poorly immunogenic compared to non-responders. Furthermore, Lee et al. 
recently reported that CEA-overexpressing tumour cells diminish T cell 
activation and proliferation thus further supporting this hypothesis (K.-A. Lee 
et al., 2015). Overexpression of CEA on certain tumours could make the 
tumour less immunogenic by down regulating T cell responses (i.e. Th1 and 
Tregs). Such CEA overexpression would also result on a higher level of CEA 
protein being shed into circulation that could be captured by APCs and 
presented to naïve T cells leading to the expansion of CEA-specific T cells. 
Such scenario would explain the presence of less Th1 and Treg cells in the 
tumours of patients mounting a specific response to CEA.  
As CEA is a glycoprotein involved in cell-cell adhesion and 
agglomeration, its excessive expression may contribute to abnormal 
intercellular bonds and irregular cell contacts which could aid metastases 
formation. Studies performed in athymic nude mice showed that a systemic 
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CEA protein increase coincided with a greater percentage of liver 
metastases (Hostetter et al., 1990). This may suggest that CEA-
responsiveness is a reflection of high CEA serum levels indicative of micro-
metastasis not detectable at the time of diagnosis. It would be extremely 
interesting to fully understand whether detection of CEA-specific responses 
in the blood of CRC patients correlates with high CEA levels in the serum 
and if both phenomena are associated with tumour recurrence. Alternatively, 
CEA-specific T cells secreting IFN-γ could target CEA expression on 
epithelial junctions leading to deregulation of the epithelial barrier 
potentiating microbial translocation into the lamina propria. Commensal 
microbiota sensing by TLRs on myeloid cells could lead to the secretion of 
IL-23 which would in turn promote a Th17-rich environment implicated in 
tumorigenesis as mentioned above (Grivennikov et al., 2012). This 
hypothesis is currently under investigation in our laboratory. 
The small cohort of patients analysed here suggests that tumour 
development is associated with an extensive accumulation of Th17 cells, 
however a higher numbers of patients would need to be assessed if order to 
verify this and also to determine the significance of a Th17 response to 
cancer progression.  
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6 Final Discussion 
CRC is the second and third most diagnosed cancer amongst women and 
men worldwide and it accounts for approximately 600 000 deaths per year. 
Even though curative tumour resection is performed in the majority of 
patients, 40 - 50 % of those still relapse. Therefore, it is imperative to 
develop new therapies capable of successfully treating CRC patients. CRC 
poses specific challenges because of its position within the gut 
microenvironment. The gastrointestinal tract is populated by a vast number 
of bacteria which needs to be taken into account for the creation of future 
therapies. Thus, understanding the relationship between the immune system 
and cancer in the context of this unique environment is of most importance. 
6.1 High endothelial venules, ectopic lymphoid structures 
and Th17 involvement in tumour development 
To begin to understand features of the immune response to CRC, the studies 
described here first focussed on examining CRCs for ectopic HEVs, recently 
shown to be associated with a good prognosis in breast cancer and 
melanoma (Martinet et al., 2012; 2011). In the case of CRC, HEVs could 
barely be detected within the tumour epithelium/stroma. They could however 
be detected in the tumour vicinity, namely extra-tumoural/peritumoural area 
in the context of lymphoid aggregates/follicles which were more prevalent in 
more advanced disease (Dukes’ C) suggesting that these structures develop 
as a consequence of constant exposure to tumour antigen. Important 
questions emerge from these observations. Do CRC associated lymphoid 
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aggregates a) mediate tumour growth by priming pathogenic T cell 
development such as Th17 cells, b) mediate tumour growth by aiding Treg 
cell development and suppression of tumour antigens specific effector 
responses, c) mediate tumour growth by forming a microniche that supports 
the growth and expansion of tumour progenitor cells, d) limit tumour growth 
by priming Th1 and CTLs which may travel to the tumour and elicit anti-
tumour effects or e) develop as a result of disease progression but have no 
impact on disease progression? 
 
Finkin et al. recently showed that hepatocellular carcinoma progenitor 
cells concentrate within ELS prior to independent tumour formation (Finkin et 
al., 2015). The group showed by histology that small clusters of tumour 
progenitor cells agglomerated within ELS prior to their egression from these 
structures. They propose that ELS contain all the survival and growth factors 
necessary to support the expansion of tumour progenitor cells which later 
become self-sufficient, exit the ELS and form a full-blown tumour (Finkin et 
al., 2015).    
 
Tregs can dampen cytotoxic anti-tumour responses in tumour-draining 
LNs (Boissonnas et al., 2010), therefore it is plausible that a similar 
mechanism is taking place in cancer-associated ELS. In an attempt to further 
characterise the role of ELS in tumour development Joshi et al. used a 
mouse model of lung adenocarcinoma in which development of tumour 
associated ELS was observed. Fibroblastic reticular cells (FRCs), follicular 
dendritic cells (FDC), high endothelial venules (HEVs), B and T cells, namely 
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activated Tregs within the T cell zone were all detected within ELS which 
was indicative of a fully functional TLO. Furthermore, in vitro activated 
memory T cells specific to the OVA antigen expressed on the tumour were 
adoptively transferred into the mice and homed to the ELS where they 
interacted with DCs. Systemic depletion of Tregs led to upregulation of co-
stimulatory molecules such as B7.1 and B7.2 on DCs and increased 
lymphocytic proliferation (Joshi et al., 2015). The combined data suggests an 
active role for Tregs in the suppression of anti-tumour responses in ELS 
which could be indicative of what is happening in CRC. 
 
Bacteria such as SFB have been implicated in Th17 differentiation 
(Goto et al., 2014; Ivanov et al., 2009; Y. Yang et al., 2014). In a study 
performed by Lécuyer et al. IL-17A secretion by mesenteric LN cells could be 
detected upon CD3/CD28 activation in mice colonised with SFB even if 
Peyer’s Patches and isolated lymphoid follicles were absent but not in the 
absence of ELS implicating ELS in the development of a local Th17 antigen-
specific response (Lécuyer et al., 2014). 
 
It is therefore reasonable to propose a pathogenic role for the Th17 
cell/axis on two fronts: 1) bacteria such as SFB are detected by APCs which 
drain to the mesenteric LNs via the lymphatics where they present SFB 
antigens in the context of MHC. pMHC interaction with naïve T cells in 
combination with cytokines such as IL-6 promote Th17 differentiation which 
then extravasate into the tissue secreting IL-17A and IL-22 upon a second 
encounter with SFB. IL-17A and IL-22 receptor binding leads to STAT3 
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activation within epithelial cells promoting uncontrolled epithelial cell division 
and tumour growth (L. Wang et al., 2009) (Figure 6.1). 2) Other bacteria, 
such as gram-negative bacteria also interact with epithelial cells promoting 
CCL20 secretion (Bouskra et al., 2008). Elevated levels of CCL20 within the 
inflamed tissue may a) attract more CCR6-expressing cells e.g. Th17 cells 
into the gut and b) bind to the CCR6 receptor on the surface of lymphoid 
tissue inducer cells (LTi). The role of lymphotoxin signalling in the formation 
of cancer-associated ELS is still not clear however studies have shown that 
IL-17A and IL-23 are important for the formation of ELS in the lungs (Rangel-
Moreno et al., 2006). In agreement with this hypothesis the study described 
here indicated a tendency for elevated levels of Th17 cells amongst TILs.  
  
IL-22 has also been implicated in the early development of ELS. 
Barone and colleagues injected replication-deficient adenovirus into the 
salivary glands of mice and studied the formation of ELS in WT and Il-22 
deficient mice. They observed that reduced levels of CXCL12 and CXCL13 
in Il-22-/- mice led to the formation of abnormal ELS in relation to B cell 
organisation and accumulation (Barone et al., 2015).  
 
Laser capture microdissection is a technique that would allow for the 
individual dissection of specific groups of cells. A similar approach could be 
used to determine the inflammatory/regulatory signature of the extra-
tumoural ELS and also to examine the TCR repertoires of ELS-resident 
versus TILs. Such information would be of great value in understanding if T 
cells present within the ELS are travelling to the tumour and possibly 
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influencing tumour growth. Another avenue for future work would be to 
compare the microbiomes in individuals with tumours exhibiting low vs high 
numbers of ELS in order to gain insight into whether certain gut bacteria 
promote an inflammatory environment, driving the formation of ELS and 
tumorigenesis.  
 
Thus far, based on the data obtained on ELS in CRC, it is tempting to 
speculate that therapeutic intervention to prevent lymphoid/aggregate 
formation would be beneficial in the context of CRC. Nonetheless, additional 
information on the exact role of such structures in the tumour development is 
necessary as these could develop as a consequence of tumourigenesis and 
have no impact on disease progression.  
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Figure 6.1 Hypothetical model explaining the involvement of Th17 cells in the formation of ectopic lymphoid structures and CRC progression. 1) 
Microbial flora such as segmented filamentous bacteria (SFB) can be detected in the gut by APC which travel to mesenteric lymph nodes and present SFB 
antigens to naïve T cells (Tn). pMHC:TCR interaction in the presence of IL-6 lead to differentiation and expansion of Th17 cells which a) secrete IL-17A and 
IL-22 upon a second antigen encounter and promote uncontrolled epithelial proliferation via activation of STAT3 and/or b) migrate towards local 
chemoattractants such as CCL19 and CCL21 promoting the formation of ectopic lymphoid structures. 2) Engagement of CCL20 expressed by epithelial cells 
with its receptor on lymphoid tissue inducer (LTi) cells could led to upregulation of lymphotoxinα1β2 which upon engagement with its receptor on lymphoid 
tissue organiser (LTo) cells promotes their activation and expression of RANKL and IL-7 creating a feedback loop through binding to receptors on LTi cells. 
ELS / TLOs may further mature through interactions between FDCs and IL-17A-driven secretion of CXCL13 and CCL19 serving to attract B and T cells.. 
Growth factors not yet understood in cancer promote development of HEVs within ELS which promote further infiltration with naïve and central memory T 
cells. Such T cells may comprise both Th1 and Th17 cells that could be specific to tumour antigens such as CEA or bacterial antigens. Figure created by the 
author based on (Bouskra et al., 2008; Gallimore and Godkin, 2013; Ghadjar et al., 2009; Ivanov et al., 2009; G. W. Jones and S. A. Jones, 2016; Pitzalis et 
al., 2014; Zhou et al., 2007).    
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6.2 CEA and 5T4 specific T cell responses in CRC patients 
Our own group has shown a positive correlation between 5T4-specific IFN-γ 
secreting cells and patient survival supporting the important role of IFN-γ in 
tumour growth control (Betts et al., 2012). Nonetheless, a study performed 
by the lab revealed a correlation between tumour recurrence and the 
detection of IFN-γ-producing CEA-specific T cells in the blood of CRC 
patients (Scurr et al., 2015). This finding was unexpected; therefore this 
study set to investigate whether the release of IFN-γ by CEA-specific T cells 
was merely a surrogate for IL-17A and whether the negative outcome 
observed in CEA-responsive patients was as a result of IL-17A secretion by 
CEA-specific T cells. 
 
The data described in Chapter 4 indicates however that even though 
detected in the blood of CRC patients, IL-17A secretion by CEA-specific IFN-
γ secreting cells is not the main factor influencing the patients’ poor outcome. 
Furthermore, even though IFN-γ is not a surrogate marker for IL-17A, IL-17A 
is a surrogate marker for IFN-γ as the former cytokine is always secreted in 
association with the latter. Moreover, the percentage of IL-17A expressing T 
cells, measured by FACS is similar in the blood, CILs and TILs of CEA 
responders and non-responders, thus neither IL-17A-secretion by CEA-
specific T cells nor the proportion of all T cells expressing IL-17A 
discriminated between CEA responders and non-responders. Other 
explanations must therefore account for why CEA-responders are more likely 
to experience tumour recurrence compared to non-responders. Perhaps 
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tumours from CEA responsive patients are less immunogenic than tumours 
from CEA non-responsive patients. The significant decrease in Treg and Th1 
cells in the tumour of CEA responsive vs non-responsive patients supports 
this hypothesis whereas no difference is observed between 5T4 responsive 
and non-responsive patients. A new cohort of CRC patients should be set up 
to examine whether CEA+ tumours are associated with poorer immune 
responses. It has recently been reported that CEA, mainly the membrane 
bound form, impinges on CD4+ T cell proliferation. Co-culturing of CD4+ T 
cells with mice and human adenocarcinoma cell lines expressing CEA 
decreases T cell activation as shown by decreased expression of IL-2 and 
CD69 (K.-A. Lee et al., 2015). CEA expression also increases during 
transformation of epithelium into adenocarcinoma and is also upregulated in 
liver metastasis (Rao et al., 2013). It is thought to regulate a number of inter 
and intra-cellular functions including polarisation, intercellular matrix 
adhesions, signal transduction and migration of cancer cells (Bajenova et al., 
2014; Blumenthal et al., 2005; Ordoñez et al., 2000). CEA has been directly 
implicated in influencing metastatic potential (Hostetter et al., 1990). Injecting 
CEA directly into mice prior to injection of cancer cells, or up regulating its 
expression on cancer cell lines increases metastasis (P. Thomas et al., 
1995; S. N. Thomas et al., 2008). CEA+ CRCs may therefore metastasise 
more efficiently to other organs whilst also suppressing the anti-tumour T cell 
response through direct immune modulating effects of CEA on T cells. A 
recent study reported that even though serum levels of CEA do not correlate 
with protein expression at the time of initial surgery, they do correlate with 
CEA expression on metastatic tissue (Saito et al., 2016); observations which 
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support the above hypothesis (K.-A. Lee et al., 2015) (Figure 6.2). Moreover, 
Pickford et al. measured CEA-specific responses in the blood of healthy 
donors and reported that after CEA stimulation, T cells from 46% of the 
healthy donors secreted IL-10 resulting in suppression of T cell responses 
(Pickford et al., 2007). IL-10 secretion in response to CEA stimulation 
supports an immunosuppressive role for CEA. 
 
Future therapeutic approaches could include a combination of CEA-
blocking antibodies that would only bind to the shed forms of the protein in 
combination with blockade of immune checkpoints e.g. PD-1/PDL1 signalling 
pathway. This multi-step approach may prevent formation of metastasis by 
inactivating CEA activity whilst simultaneously boosting tumour 
immunogenicity in CEA-responsive patients.  
 
 
Figure 6.2 Model explaining aggressiveness of CEA+ tumours. 
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6.3 Concluding Remarks 
In conclusion, I have shown here that intra-tumoural HEVs are scarce in 
CRC and are not associated with disease progression. HEVs are however 
present within extra-tumoural structures resembling TLOs. Such structures 
appear as a result of T and B cell clustering and are associated with disease 
progression. A more in depth characterisation of such ectopic structures is 
necessary in order to understand the signals which drive their formation and 
their influence on the immune response to CRC. If such structures form as a 
result of tumour progression and act as a site of priming for anti-tumour T 
cells, promoting their formation may be beneficial for patient survival. 
However, if their formation promotes tumour growth, it is extremely important 
to understand how TLO-development can be prevented as part of a 
therapeutic regime.  
 
Furthermore, I show here for the first time the presence of IL-17A 
secreting cells specific for CEA and 5T4 in the blood of CRC patients. The 
IL-17A responses detected in this study specific for tumour antigens were 
always generated in parallel with IFN-γ responses. CEA-responsiveness 
could be used in the future as a biomarker of disease progression as patients 
responsive to CEA may have less immunogenic tumours, thus impinging on 
tumour recurrence.  
 
Overall the data presented herein identify TLOs, IL-17 producing T 
cells and CEA-specific T cells as key features of CRC progression. Future 
work is however required to determine whether TLO formation is associated 
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with a detrimental patient prognosis or merely a consequence of 
tumourigenesis having no impact on disease progression.  
IL-17 producing cells are enhanced in CRC. It is critical that signals 
driving accumulation and proliferation of these cells in CRC are identified in 
order that therapies that inhibit their disease-promoting activities can be 
developed. CEA clearly represents a potential therapeutic target on two 
fronts as blocking CEA may prevent both metastasis and CEA-mediated 
immune-suppression whilst development of CEA vaccines should be 
discouraged.  
 
Current novel immunotherapies have proven disappointing for the 
treatment of CRC. It is clear from the data presented herein that for immune 
interventions for CRC to be successful, the gut microenvironment, which 
profoundly shapes the type of immune response that develops, must be 
taken into account.  
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Figure A Representative example of gating strategy based on fluorescence minus one 
(FMO) and addition of Brefeldin A. The lymphocytic population was isolated using the side 
scatter (SSC) and forward scatter (FSC) measurements representative of granularity and 
size, respectively. Single cells were then gated based on the FSC area and height and live 
cells selected based on the inability to incorporate the Aqua dye. CD4+ single live 
lymphocytes were then selected prior to CCR6 and CXCR3 analysis which was based on 
the FMO gating (top four graphs (A-B)). In order to control for intracellular cytokine staining 
PBMCs were also incubated with Brefeldin A without any other stimuli (bottom two graphs 
(C). 
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Figure B Representative example of gating strategy based on fluorescence minus one 
(FMO) after stimulation with PMA and Ionomycin and addition of Brefeldin A. The 
lymphocytic population was isolated using the side scatter (SSC) and forward scatter (FSC) 
measurements representative of granularity and size, respectively. Single cells were then 
gated based on the FSC area and height and live cells selected based on the inability to 
incorporate the Aqua dye. FMOs represented for CD4-BV421 (A), CCR6-PE-Cy7 (B), IFN-γ-
APC-Cy7 (C), IL-17A-APC (D) and Foxp3-FITC (E).  
CD4 – BV421 
S
S
C
 
S
S
C
 
PMA/ Ionomycin stimulated 
PBMCs 
FMO + Antibody 
C
C
R
6 
- P
E
-C
y7
  
IF
N
-γ
 –
 A
P
C
-C
y7
 
IF
N
-γ
 –
 A
P
C
-C
y7
 
IL
-1
7A
 - 
A
P
C
 
IL
-1
7A
 - 
A
P
C
 
Fo
xp
3 
- F
IT
C
 
Fo
xp
3 
- F
IT
C
 
FMO + Antibody 
CD4 – BV421 CD4 – BV421 CD4 – BV421 
CD4 – BV421 CD4 – BV421 CD4 – BV421 CD4 – BV421 
CD4 – BV421 CD4 – BV421 
C
C
R
6 
- P
E
-C
y7
  
A
B
C
D
E
 219 
 
 
 
 
 
 
 
 
 
 
 
Figure C Representative example of gating strategy for CILs and TILs for IFN-γ and IL-
17A based on the absence of staining following 5 hour incubation with Brefeldin A. 
CILs and TILs were often not extracted in enough quantity to perform FMOs post-stimulation 
therefore incubation with Brefeldin A for 5 hours was used to control for cytokine staining.   
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Figure D Representative example of gating strategy based on fluorescence minus one 
(FMO) post PMA/ Ionomycin stimulation and incubation with Brefeldin A. The 
lymphocytic population was isolated using the side scatter (SSC) and forward scatter (FSC) 
measurements representative of granularity and size, respectively. Single cells were then 
gated based on the FSC area and height and live cells selected based on the inability to 
incorporate the Aqua dye. CD4+ (A) and CCR6+ (B) cells were then selected based on the 
FMO gating. 
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Participant Information Sheet (09/09/2015 version 1.3) 
 
PART 1 
1. Study title  
The role of leukocytes in the colon and blood 
 
2. Invitation paragraph  
We would like to invite you to take part in a research study. Before you 
decide you need to understand why the research is being done and what it 
would involve for you. Please take time to read the following information 
carefully. Talk to others about the study if you wish. Take time to decide 
whether or not you wish to take part. The person running this study is 
Professor Andrew Godkin who looks after patients with diseases of the colon 
in Cardiff and Vale University Health Board and undertakes research with 
scientific colleagues from Cardiff University.  
 
3. What is the purpose of the study?  
The purpose of the study is to study the role of white blood cells (leucocytes) 
and the way they work in differing diseases of the colon and in people 
without disease of the colon. 
We request samples from four different groups, one of which you fall into: 
 
Group 1 – Samples of blood from healthy people without diseases of the 
colon 
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Group 2 – Samples of blood and normal colon from patients undergoing 
surgery of the colon 
Group 3 – Samples of blood, normal colon and tumour from patients 
undergoing surgery for cancer of the colon 
Group 4 – Samples of blood and bowel from patients undergoing 
gastointestinal endoscopy for clinical reasons 
 
4. Why have I been invited?  
You have been invited to take part as a member of Group [insert 
group]…………….. 
 
5. Do I have to take part?  
It is up to you to decide. We will describe the study and go through this 
information sheet, which we will then give to you. We will then ask you to 
sign a consent form to show you have agreed to take part. You are free to 
withdraw at any time, without giving a reason. This will not affect the 
standard of care you receive. 
 
6. What will happen to me if I take part? 
For all Groups – You will be told by the surgeon or physician who is looking 
after your clinical care about the study and asked if you are interested in 
taking part. If you are interested and agree to take part in the study, samples 
will be taken by staff involved in your clinical care and will be passed to the 
research team at Cardiff University. When the research group get your 
sample, it will have no details that can identify you with it, only a code 
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number. The master copy with your identification details will stay with the 
chief investigator in a locked office, and will not be disclosed to the 
researchers. Where useful to understand the pathology, clinical outcomes 
may be recorded. We will allocate a code number to each person so that the 
clinicians can provide this additional information (e.g. on the outcome of your 
surgery if you are having an operation) at a later date. The data on each 
subject will be retained for 10 years. 
Group 1 - If you agree to participate, we will take a sample of your blood (3-5 
teaspoonfuls) and use it to identify white blood cells and to perform studies in 
the laboratory on how they work. 
 Group 2 - If you agree to participate, we will take a sample from the normal 
part of your colon or bowel when it is removed during surgery and look at 
how the wall of the bowel works. This material would normally be disposed of 
after surgery. We would also like to take a sample of your blood (3-5 
teaspoonfuls), both the bowel and the blood sample will be used to look at 
how the white cells work.  
Group 3 - If you agree to participate, we will take a sample from part of the 
tumour in your colon and the normal part of colon when it is removed during 
surgery. This material would normally be disposed of after surgery. We 
would also take a sample of your blood (3-5 teaspoonfuls), both the normal 
bowel/tumour and the blood sample will be used to look at how the white 
cells work.  
Group 4 - If you agree to take part, we will take two or three additional 
biopsies when you undergo your routine clinical endoscopy. We would also 
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like to take a sample of your blood (3-5 teaspoonfuls), both the bowel and 
the blood sample will be used to look at how the white cells work.  
It is possible you may be approached for an additional blood sample after 4-
8 weeks; you would be asked for repeat consent. 
 
7. What are the possible disadvantages and risks of taking part? 
For Groups 1-3 there are no disadvantages or risks in taking part (other than 
a small bruise from the blood test) 
For Group 4 there is a risk in having additional biopsy samples taken for 
research. In the course of over 25 years of performing endoscopies, in over 
10 000 patients, and taking 1000s of biopsies, the chief investigator is yet to 
witness a significant problem. Guidelines from the British Society of 
Gastroenterology in 2006 stated that an endoscopic biopsy is rarely 
complicated by significant bleeding. In theory, bleeding may occur. 
 
8. What are the possible benefits of taking part? 
Taking part in this study will not help you but the information we get from this 
study will help to improve our understanding of the role of white blood cells in 
the body, and how they react to different diseases. 
 
Part 2 
 
1. Will my taking part in the study be kept confidential?   
Yes. We will follow ethical and legal practice and all information about you 
will be handled in confidence. The data that is sent outside the clinical team 
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will be anonymised so that the research team will not have access to your 
information 
 
2. What will happen to my samples? 
The samples are transferred to the laboratory where they are prepared for 
experiments. These include looking at how white blood cells and other cells, 
and compounds such as proteins function in different tissues. 
 
3. What will happen if I don’t want to carry on with the study?  
You can decide to withdraw from the study at any point. If you want to 
withdraw you can contact the research team and make that request. If any 
samplesare stored they can destroyed at your request. If the results from 
experiments with your sample have been included in an analysis, it will not 
be possible to withdraw it retrospectively. 
 
4. What if there is a problem?  
If you have any concerns about the conduct of this study, you should ask to 
speak to the Chief Investigator who will do his best to answer your questions 
(029 20687129). If you remain unhappy and wish to raise a formal concern 
then you should contact Cardiff University Research and Innovation Service 
via the governance officer (029 20879131). 
If you have a concern about the clinical care you have received, you can do 
this through the Cardiff and Vale Concerns Team (029 21847391).  
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5. Future research  
With your consent, we might store the sample/s you have given us for use in 
future research, we do not yet know what the research might involve but it 
may include collaborators abroad or working for a commercial company. The 
stored samples may include serum and cells including the genetic material in 
the cell i.e. DNA. This will be done in accordance with the Human Tissue Act 
which lays down requirements for the storage and use of all samples. No 
identifiable personal information will be stored with the sample. If you wish, 
you can agree for the sample to be used for the current project but not for 
future research. If so, you should not sign this part of the consent form. 
 
6. Will any genetic tests be done?  
No familial genetic testing will be done on these samples during the current 
study, but genetic material may be stored for future analysis. 
 
7. What will happen to the results of the research study?   
It is intended to submit the results of this study for publication in medical 
journals and to present the results at national and international meetings. 
You will not be identified in any report/publication. 
 
8. Who is organising and funding the research?  
This study is being funded by charitable trusts and scientific grant giving 
bodies. The funding will pay for the salaries of some of the participating 
researchers, for purchasing the reagents required for carrying out these 
studies, and for disseminating the new knowledge gained by these studies. 
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9. Who has reviewed the study?  
All research in the NHS is looked at by an independent group of people, 
called a Research Ethics Committee to protect your safety, rights, wellbeing 
and dignity. This study has been reviewed and given favourable opinion by 
the Research Ethics Committee. 
 
Contact details of the Researcher for further information: 
 
Professor Andrew Godkin 
Henry Wellcome Building, 
Cardiff University 
Heath Park, 
Cardiff. CF14 4XW. 
Tel 029 20687129 
Email: godkinaj@cf.ac.uk 
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Please 
initial 
CONSENT FORM 
The role of leukocytes in the colon and blood 
Chief Investigator Prof Andrew Godkin (Consultant Gastroenterologist and 
Hepatologist) 
1. I confirm that I have read and understand the information sheet 
Version 1.3 for the above study and have had the opportunity to 
ask questions. 
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
3. I understand that relevant sections of my medical notes and data 
collected during the study, may be looked at by responsible 
individuals from regulatory bodies, Cardiff University or the 
Cardiff and Vale University Health Board. I give permission to these 
individuals to have access to my records. All information will remain 
confidential. 
4. I agree for blood and/or clinical waste samples to be collected 
and used for the purposes of this study (Groups 1-3) 
5. I agree for additional biopsies and a blood sample to be collected 
and used for the purposes of this study (Group 4 only) 
6. I consent for my anonymised results of this study to be published 
in scientific / medical journals. 
7. I consent for obtained samples to be stored for future research in 
the UK and abroad, I understand the research may involve DNA 
analysis and use by the commercial sector (Please cross out if 
you do not wish your samples to stored) 
8. I agree to take part in the above study 
 
Name of Patient                    Signature       
Date 
Name of Person taking consent                        Signature   
Date 
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When completed make two copies: 1 offered to participant; 1 to be kept in 
medical notes. Original kept and filed by CI. 
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